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 The key signaling mechanism(s) of phosphatase of regenerating liver 3 (PRL-3) has 
been a subject of tremendous interest, largely due to the pleiotropic effects this elusive 
phosphatase has on cancer progression. Here, I provide evidence for the PRL-3 induced 
ligand-independent activation of the epidermal growth factor receptor (EGFR) and its 
downstream signaling cascades in multiple cancer cell lines, including the mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) 
pathway. PRL-3-induced phosphoactivation of EGFR was associated with the transcriptional 
downregulation of protein tyrosine phosphatase 1B (PTP1B), an EGFR inhibitory 
phosphatase. Significantly, PRL-3-induced phosphoactivation of EGFR correlated with an 
increase in cell proliferation and motility, and induced dependency on the oncogenic signaling 
of this protein as evidenced by the dramatic decrease in biochemical activity of MAPK and 
AKT phosphorylation upon EGFR inhibition, in corollary suggesting a novel mechanism to 
retard dual PRL-3- and EGFR-positive tumors. In the second part of my study, I report the 
PRL-3 driven downregulation of β-catenin, an adherens junction component, in human 
ovarian cancer cells. The downregulation of β-catenin corresponded with reduced homotypic 
cell-cell adhesion and, unexpectedly, increased cell proliferation as reflected from an MTT 
assay. β-catenin downregulation by PRL-3 required a functional Axin/APC degradation 
complex, components of which were also found to be regulated by PRL-3. Significantly, a 
negative correlation between PRL-3 and β-catenin was also observed in several human 
cancers, suggesting a clinical significance of this result. Finally, I present data evidencing a 
novel role for PRL-3 as an EGFR-interacting protein in vivo. Interestingly, PRL-3 
phosphorylation, particularly on tyrosine residues, was detectable upon EGF stimulation or 
Src overexpression in two different cancer cell lines. Using a prenylation mutant, I showed 
that this phenomenon was dependent on membrane association, which also regulated the 
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ability of PRL-3 to interact with EGFR. Significantly, phosphorylation of PRL-3 appeared to 
correlate negatively with its ability to interact with the EGFR complex. Taken together with 
my earlier results on EGFR activation, the phosphorylation of PRL-3 might constitute a 
potential feedback loop on EGFR regulation.  Ultimately, the better understanding of the 
pathways and regulatory mechanisms of PRL-3 presented here will facilitate development of 
better, more focused therapy and diagnosis for tumors overexpressing this phosphatase.  
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CHAPTER 1: INTRODUCTION 
1.1. The PRL Family of Protein Tyrosine Phosphatases 
 Protein phosphorylation is major reversible regulatory mechanism controlling many 
basic processes, estimated to affect approximately 30% of cellular proteins [1]. Reversible 
tyrosine phosphorylation is governed by the balanced action of protein tyrosine kinases and 
protein-tyrosine phosphatases (PTPs). PTPs constitutes a large family of enzymes (>100) 
which play crucial roles in positive and negative regulation of key signaling pathways 
involved in the control of cell proliferation, adhesion, migration, differentiation and survival 
[2]. Dysregulation of PTP activity results in aberrant tyrosine phosphorylation frequently 
implicated in the progression of various diseases including diabetes, rheumatoid arthritis, and 
cancer [1,3]. 
The phosphatase of regenerating liver (PRL) family of PTPs comprises three members, PRL-
1, PRL-2, and PRL-3. The PRLs were named after the founding member of this group, PRL-
1, that was first identified as an immediate-early upregulated gene during rat liver 
regeneration [4,5]. Subsequently, two other PRLs, PRL-2 and PRL-3, were identified in a 
database screen for PRL-1 homologues in mice [6]. In an independent study, human PRL-1 
and PRL-2 were discovered using an in vitro screen for prenylated proteins [7]. In humans, 
PRLs are encoded on different chromosomes, with PRL-1 (PTP4A1), PRL-2 (PTP4A2) and 
PRL-3 (PTP4A3) mapped to chromosomal loci 6q12, 1p35 and 8q24, respectively. Alignment 
of their sequences reveal that PRL family members share significant amino acid identity – 
highest being 87% between PRL-1 and PRL-2, followed by 79% between PRL-1 and PRL-3, 
and lowest being 76% between PRL-2 and PRL-3 in humans (Fig. 1).  PRLs are remarkably 
conserved across different species, suggesting an important evolutionary role for these 
phosphatases in development [8]. Interestingly, Drosophila melanogaster contains only a 
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single PRL member, suggesting that the requirement for PRL activity during the development 
of multicellular metazoans is more complex in mammals with the evolution of 3 functional 
members. 
 
Figure 1: Sequence alignment of PRLs of different species and structurally related 
phosphatases. The secondary structure elements refer to PRL-3. Key functional motifs of 
human PRL-1, PRL-2 and PRL-3 are labeled and boxed in red. This alignment map was 




Based on the conserved amino acid sequences of their catalytic domain, PRLs have been 
classified as a unique subgroup of VH1-like PTPs with dual-specificity [2]. Overall, PRLs are 
most closely related in sequence to PTEN and Cdc14, members of the dual-specificity 
phosphatase (DSP) family [6]. PRLs have a conserved core PTP domain with the signature 
C(X)5R (single-letter codes for amino acids) active site motif [10]. Notably, PRLs are the only 
PTPs known to bear the membrane-targeting CAAX prenylation motif at their COOH-
terminus, a moiety which targets them for farnesylation in vitro and in vivo [7,11]. In PRLs, a 
conserved polybasic region immediately precedes the CAAX motif, providing a cluster of 
positive charges which, for PRL-1, have been shown to also play a crucial role in lipid 
binding, presumably via electrostatic interactions [12]. Despite low sequence identity (< 
30%), structural studies have revealed that PRLs share similar secondary structures and 
teritary folding to several members of the DSP family including PTEN, VHR and KAP (PRL-
1 and PRL-3), and Cdc14 and MKP (PRL-1) (Fig. 1) [9,13,14]. Unlike other DSPs, PRLs 
posses unusually shallow and wide active site clefts surrounded by few protruding loops [9]. 
Such a layout might allow PRLs to accommodate both the short and long side chains of 
phosphorylated Ser/Thr and phosphorylated Tyr residues, respectively. Interestingly, in 
agreement with the potential of this active site layout to also accommodate phosphoinositol 
headgroups, a lipid phosphatase activity of PRLs has recently been described [15]. 
Collectively, these features establish PRLs as a unique subclass of PTPs with a diverse and 
potentially redundant substrate repertoire. 
The catalytic activity of PTPs harboring an active site C(X)5R motif (or P-loop) occurs via a 
two-step mechanism and, like Ser/Thr protein phosphatases, is independent of metal ions 
[16]. The PTP dephosphorylation cycle begins with the insertion of the substrate 
phosphoaminoacid into a pocket within the active site, where it lies in close proximity to the 
essential catalytic cysteine of the C(X)5R motif located at the base of the pocket. This cysteine 
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initiates catalysis via a nucleophilic attack on the substrate phosphate thioester, creating a 
covalent cysteinyl-phosphate intermediate, while the conserved Arg of the C(X)5R motif 
binds and positions this group. In PRLs, these essential catalytic residues are Cys104 and 
Arg110 (PRL-1 and PRL-3) and Cys101 and Arg107 (PRL-2). In agreement with an essential 
role in catalysis, substitution of the catalytic cysteine has been shown to abrogate PRL-
mediated biological responses [17-19]. In the second step of catalysis, enzyme 
dephosphorylation is achieved via hydrolysis facilitated by a distal Asp residue located within 
the WPD loop (another conserved feature within the PTP superfamily) of the enzyme (Fig. 1). 
This Asp residue (Asp72 in PRL-1 and PRL-3; Asp69 in PRL-2) functions both as a general 
acid, by transferring a proton to the leaving substrate tyrosine group during phosphoenzyme 
intermediate formation, and as a general base, by removing a proton from an essential water 
molecule thus allowing it to act as a nucleophile for regenerating the free enzyme. The 
detailed biochemistry of the PTPase catalytic cycle summarized here has been reviewed 
elsewhere [16,20]. 
PRLs have notoriously low protein phosphatase activity in vitro, as assayed using the 
unnatural substrates 3-O-methylfluorescein phosphate, p-Nitrophenyl phosphate, and 6,8-
Difluoro-4-methylumbelliferyl phosphate [9,14]. Surprisingly, the dephosphorylation of 
synthetic phosphopeptides corresponding to several published PRL-3 substrates was also 
equally inefficient in vitro [15]. A possible explanation for this is the Ser to Ala substitution 
located C-terminus to the essential Arg of the C(X)5R motif in PRLs. The hydroxyl group 
provided by this Ser normally participates in hydrolysis of the phosphoenzyme intermediate 
during catalysis [21]. Indeed, PRL-1 reconstituted with a Ser at this position (A111S) 
demonstrated much higher catalytic efficiency in in vitro and tumorigenic activity in vivo 
[12]. The lack of this hydroxyl group in PRLs suggests that additional factors, or substrate 
themselves, might supply it in trans for normal catalysis in vivo. Interestingly, PRL-1 has 
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been reported to be less efficient at forming trimers in vitro than in vivo [13,14]. Assuming 
that trimerization might provide this hydroxyl group in trans, it could also provide 
mechanistic explanation for the poor catalytic efficiency of PRL-1 in vitro [13]. Notably, in a 
recent study, a similar substitution of Ala to Ser at this site (A111S) resulted in the 
abolishment of PRL-3 phosphoinositide-directed phosphatase activity in vitro [15]. These 
reports collectively suggest that PRLs might be carefully regulated to operate as a dual 
protein and lipid phosphatase by carefully tuned intrinsic features within their structures. 
As mentioned earlier, the CAAX motif of PRLs subjects them to farnesylation in vivo. 
Indeed, multiple reports have demonstrated the unambiguous association of PRLs to the 
plasma membrane and early endosome [11,17,22,23]. Interestingly, although predominantly 
reported to be localized to the cytomembrane and cytosol in multiple cancer cell lines, human 
colon cancer and endometriosis tissues [24,25], the nuclear localization of PRL-1 and PRL-3 
have also been reported [5,26]. This contrasting result was partially explained by recent work 
in myeloma cells, where PRL-3 was found to shuttle between the nucleus and cytoplasm 
during S-G2M and G0/G1 phases respectively [26]. Recently, the possibility for the C-
terminus polybasic sequence of PRL-3 to serve as a nuclear localization signal was 
invalidated [27], suggesting that nuclear import might occur via passive diffusion or 
alternative active processes. In support of the latter, deletion of the C-terminus prenylation 
motif of PRLs has been shown to promote their nuclear accumulation [11,28], suggesting that 
the regulation of PRL nucleo-cytoplasmic distribution might be via the reversible prenylation 
of such proteins [29]. Finally, besides cytomembranous and nuclear localization, PRL-1 has 
also been found to cycle between the endoplasmic reticulum and the centrosome in mitotic 
cells in a farnesylation-independent manner [30].  
PRL members have distinct expression profiles. PRL-1, unlike the almost ubiquitously 
expressed PRL-2, has a somewhat more restricted pattern of expression, with an overall lower 
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expression level than PRL-2 in the same tissue or cell types [31,32]. Unlike PRL-1 and PRL-
2, prominent PRL-3 mRNA expression has been described in the heart, skeletal muscle and 
pancreas, although it is found at lower levels in other organs [5,6,33-35]. Interestingly, PRL-3 
protein has been detected in fetal heart, developing blood vessels, and developing 
erythrocytes, but not in their mature counterparts [36]. This observation, taken together with 
other reports describing the expression and function of PRL-3 in endothelial cells [37,38], 
suggest important roles for PRL-3 during the early development of the cardiovascular system 
and angiogenesis.  
Today, PRLs are best known for their involvement in cancer. The deregulated expression of 
members of the PRL family, particularly PRL-3, has been implicated in the metastatic 
progression of multiple cancer types (reviewed in [39]). To keep in line with the nature of this 
thesis subject matter and word limit constraints, the following sections will briefly review 
only the association of PRL-3 with different cancers and focus on discussing the molecular 
mechanisms that have been proposed to contribute to PRL-3’s role in tumor malignancy. 
1.2. PRL-3 and Cancer Metastasis 
 Cancer is the uncontrolled growth of abnormal cells in the body. It has a reputation as a 
highly deadly disease, and the statistics are staggering: in 2011 in the United States alone, an 
estimated 1.6 million people were diagnosed with cancer, and 570,000 are predicted to have 
succumbed to cancer-related deaths [40]. Metastasis is the primary cause of these cancer-
related deaths. In fact, invasive cancers are the leading cause of death in developed countries, 
and the second leading cause of death in the developing world [41]. Metastasis encompasses 
the stepwise process in which malignant cells spread from the primary tumor or origin to 
colonize distant organs. Initially, cells are first transformed by acquisition of tumor-initiating 
alterations that promote unlimited proliferation, genomic instability, resistance to apoptosis, 
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attraction of a blood supply, cell motility and the maintenance of an undifferentiated state 
[42]. Subsequently, transformed cells acquire additional alterations or mutations conferring 
the ability to penetrate blood or lymph vessels, survive in the circulation, infiltrate distant 
organs, and eventually colonize the new microenvironments they encounter.  
Mounting evidence over the past 10 years implicates the PRL family in the metastatic 
progression of multiple human cancers. The first PRL associated with metastasis was PRL-3, 
when it was found to be expressed at high levels in all of 18 human colorectal cancer (CRC) 
liver metastases examined, but at lower levels in the corresponding primary tumors and 
normal epithelium [43]. This was a truly remarkable finding, as the authors specifically 
identified PRL-3 as a consistently upregulated gene from an unbiased global gene expression 
profiling approach involving thousands of gene transcripts. In a more recent study analyzing 
global gene expression patterns between uveal melanoma patients who developed liver 
metastases within 3 years or fail to do so, PRL-3 was again identified as strong predictor of 
metastatic recurrence using from an unbiased analysis using gene expression microarrays and 
comparative genomic hybridization microarrays [44]. These reports constitute the most 
significant indicators of the role PRL-3 in cancer metastasis, particularly to the liver. 
Supporting these reports, many groups have confirmed the significance of PRL-3 in multiple 
cancer types. Using in situ hybridization and/or immunohistochemistry, tumor-specific 
upregulation of PRL-3 has been reported not just in CRC-derived metastatic lesions, but also 
in primary tumor samples as well [24,34,45-47]. Significantly, several of these studies 
showed that high levels of PRL-3 expression in CRC primary tumors were an independent 
predictor of metastasis, and associated with poor outcome or shorter survival time [45,47]. 
Besides CRC, elevated PRL-3 expression has also been correlated to the metastatic potential 
and poor prognosis of multiple cancer types including gastric cancer [48-54], breast cancer 
[55-57], ovarian cancer [58,59], brain cancer [60], non-small cell lung cancer [61,62], liver 
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cancer [63,64], cervical cancer [65], esophageal squamous cell carcinoma [66,67], 
nasopharyngeal carcinoma [68], oral squamous cell carcinoma [69], endometriosis [25], and 
uveal melanoma [44]. Remarkably, in all these studies, PRL-3 expression was found to be 
higher in the primary tumors compared to matched non-cancerous tissues. For this reason, 
PRL-3 has been rightfully proposed as a potential biomarker for assessing tumor 
aggressiveness and, in many cases, a promising predictor of distant metastasis [39]. 
Interestingly, independent non-biased high-throughput insertional mutagenesis screens have 
also identified PTP4A3 as a retrovirally tagged cancer gene ([70]; database accessible online 
at http://variation.osu.edu/rtcgd). In such screens, retroviruses induce hematopoietic tumors in 
mice by randomly integrating into the genome and deregulating the expression of proto-
oncogenes or inactivating the expression of tumor suppressor genes [71]. The subsequent 
development of hematopoietic tumors based on the retroviral insertion site (RIS) then 
facilitates the identification of candidate proto-oncogenes or tumor suppressors: tumors 
arising from proto-oncogene activation would contain RIS upstream of a gene to drive 
expression, whereas tumors arising from tumor suppressor inactivation posses RIS within a 
gene sequence thus disrupting its expression. Remarkably, out of six mice that were found to 
have an RIS in the PTP4A3 locus, all of them had RIS upstream of the PTP4A3 coding 
sequence. This unbiased screen thus strongly suggests that the involvement of PRL-3 in 
tumorigenesis is conserved in mice. Interestingly, PRL-3 was recently reported to confer 
therapeutic resistance in human acute myeloid leukemia cells, suggesting that a role for PRL-
3 mediated leukemogenesis in humans might exist [72]. 
Given the remarkable association of PRL-3 with cancer, much interest has been focused on 
elucidating the involvement of PRL-3 in metastatic progression. Although sparse, several 
PRL-3 interacting proteins have been identified and some of these are postulated to be PRL-3 
substrates (Table 1). Importantly, several molecular mechanisms have been proposed, and 
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these, together with the biological roles of PRL-3 in the fundamental steps of the metastatic 
process – namely cellular proliferation, invasion, motility, angiogenesis and survival – will be 
reviewed here. 
TABLE 1. Binding partnersa and putative substrates of PRL-3 
Protein name Gene name Outcome of interaction Cell line 
Validation 
method(s) Refs. 
Cadherin-22 CDH22 N.d. SW480 IP, PD, Y2H [73] 
Ezrin EZR Ezrin dephosphorylation in vitro (indirect) and in vivo HCT116 - [74,75] 
Elongation factor 2 EF-2 N.d. HCT116 - [75] 
FK506-binding 
protein 38 FKBP38 PRL-3 degradation in vivo HEK293 IP [76] 
Integrin α1 ITGA1 N.d. COS-7 IP, PD, Y2H [77] 
Keratin 8 KRT8 KRT8 dephosphorylation in vivo SW480 IP [78] 
Nucleolin NCL NCL dephosphorylation in vivo SW480 IP [79] 
PRL-3 PTP4A3 Oligomer formation in vitro HEK293 IP [12,27] 
Stathmin STMN1 N.d. SW480 IP  [80] 
aIn a high-throughput study employing ESI-MS/MS, 36 other PRL-3 interactors (not listed here) were identified, 
but lacked further validation [81]. IP, immunoprecipitation; PD, GST pull-down; Y2H, yeast 2-hybrid assay; N.d., 
not determined. 
 
1.2.1. PRL-3 Signaling in Cell Proliferation 
Progression towards metastasis typically starts with the oncogenic transformation of cells, 
giving them an unlimited proliferative advantage. Cell proliferation is regulated via several 
key signaling cascades including the MDM2/p53 pathway, the phosphatidylinositol-3-
kinase/protein kinase B (PI3K/AKT), and the mitogen-activated protein kinase (MAPK) 
pathway [82-84]. Surprisingly, PRL-3 has been documented to regulate all these pathways to 
promote proliferation in a variety of cell lines [18,33,85-87]. However, several reports 
indicate otherwise [23,26,68,88]. The results from these studies are discussed below. 
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p53 is a transcription factor that activates and represses various target genes which participate 
in cell cycle arrest, including the cyclin-dependent kinase (CDK) inhibitor p21 [82]. In 
HCT116 colon cancer cells, PRL-3 has been reported to enhance the ubiquitination and 
proteosome-mediated degradation of p53, an event mediated by a synergistic increase in 
PIRH2 transcription and MDM2 phosphorylation, both negative regulators of p53 stability 
[89]. This downregulation of p53 required both catalytic function and proper prenylation of 
PRL-3. Surprisingly, PRL-3 has also been identified as a p53 upregulated gene [23], 
suggesting that cancer cells may circumvent this negative feedback loop by activation of 
alternative p53-independent pathways. Supporting this possibility, PRL-3 has been reported 
to activate the pro-proliferative and pro-survival PI3K/AKT pathway in many cancer cells 
[83]. In DLD-1 colorectal cancer cells, forced expression of PRL-3 resulted in AKT 
activation, a phenomenon that could be abolished by treatment of these cells with the PI3K 
inhibitor LY294002 [90]. The DSP phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) is the most important negative regulator of the PI3K/AKT pathway 
[91]. Significantly, PTEN was found to be downregulated in these cells, suggesting a 
mechanism for PRL-3 mediated PI3K/AKT activation. The third proliferative pathway 
potentially abused by PRL-3 in cancer cells is the MAPK pathway. MAPK signaling, 
particularly via the extracellular signal-regulated kinase (ERK) pathway, is commonly 
dysregulated in cancer [92]. In A549 lung cancer cells depleted of PRL-3, a reduction in ERK 
activity and cellular proliferative ability has been reported [61]. Interestingly, ERK activation 
was also observed upon the forced expression of PRL-3 in HEK293 human embryonic kidney 
cells [18]. In this study, PRL-3 induced ERK phosphorylation was potently inhibited by 
inhibitors against Src family kinases, suggesting an upstream role for members of this kinase 
family in promoting proliferation. 
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In apparent contrast to these reports, several groups have noted a lack of PRL-3 involvement 
in cell proliferation. In INA-6 human myeloma cells and 5-8F and HONE1 nasopharyngeal 
carcinoma cells, depletion of PRL-3 failed to have any effect on proliferative ability of the 
cells, despite a reduction in migratory abilities [26,68]. Even more surprisingly, in contrast to 
the results in all the aforementioned transformed cells, overexpression of PRL-3 was found to 
induce a late G1 cell-cycle arrest in mouse embryonic fibroblasts via a p53-independent 
phenomenon [23]. This involved the PI3K/AKT mediated upregulation of p21 expression, 
and was dependent on cyclin-dependent kinase 2 (CDK2). Surprisingly, ablation of PRL-3 in 
MEFs also elicited a potent arrest response, a phenomenon dependent on p53 [23]. The 
authors noted different observations in cancer cells: in RKO colon carcinoma cells, no arrest 
was seen upon PRL-3 overexpression, whereas in U2OS osteosarcoma cells, PRL-3 
overexpression dramatically enhanced G1/S cell cycle progression. Collectively, because all 
these studies were conducted in different systems, the results suggest that PRL-3 may regulate 
proliferation in different ways and may reflect cell-type specific responses. 
1.2.2. PRL-3 Signaling in Cell Invasion and Motility 
 To enter the circulation and infiltrate distant organs, transformed epithelial cancer cells 
must acquire additional abilities to invade the surrounding mesenchyme. This involves at least 
two key events: basement membrane degradation, and increased cell motility. The 
contributions of PRL-3 to both these mechanisms are discussed below. 
Focal adhesions are dynamic structures regulated by complex signaling pathways emanating 
from the clustering and interactions of cell-surface integrins with a variety of extracellular 
matrix (ECM) components [93]. PRL-3 has been implicated in the regulation of cell-matrix 
adhesion. In B16 murine melanoma cells, PRL-3 increased cell spreading on fibronectin and 
lamin, but decreased cell spreading on collagen type I [86]. These three ECM components 
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constitute integrin ligands, and in agreement with an involvement of PRL-3 in regulation of 
integrins, no difference was observed on the nonintegrin ligands polylysine or concanavalin 
A. Interestingly, recent evidence suggests that this might be a feature of PRLs in general [87]. 
Integrin engagement regulates the activity of members of the Rho family of small GTPases – 
key regulators of actin cytoskeletal dynamics associated with cell motility and invasion [94]. 
Members of the Src family of tyrosine kinases also localize in cell-matrix adhesions; by 
partnering with focal adhesion kinase (FAK), FAK-Src complexes regulate guanine-exchange 
factors and GTPase-activating proteins that act on Rho-GTPases. Thus, integrin signaling 
through FAK-Src complexes can regulate the localization and activity of these GTPases to 
coordinate membrane protrusion, focal adhesion turnover and cell motility [93]. PRL-3 has 
been implicated in integrin/Src signaling by regulating the activities of various focal adhesion 
components. Integrin-β1 has been reported to be necessary for PRL-3 mediated activation of 
ERK1/2 in LoVo colorectal carcinoma cells, as well as for the consequent increase in 
motility, invasion and metastasis of PRL-3 overexpressing LoVo cells [95]. Importantly, 
treatment of these cells with an ERK inhibitor impaired PRL-3-induced invasion. In separate 
studies in HEK293 cells, PRL-3 was found to downregulate c-Src kinase (Csk) translation, 
thereby relieving the inhibitory phosphorylation of this kinase on Tyr527 of Src and 
promoting the latter’s activity in activating ERK [18,96]. Collectively, these studies indicate 
ERK1/2 activation as a key node in PRL-3-induced invasiveness and motility of cancer cells. 
With regards to Rho GTPases in PRL-3 induced motility, disparate results have been 
reported. In SW480 colorectal carcinoma cells, PRL-3 overexpression was found to increase 
cell motility and RhoA and RhoC activity by 4- to 7- fold, both of which was essentially 
abrogated by inhibition of the Rho kinase (ROCK), a key Rho effector [97]. In agreement 
with this, PRL-3 depletion in A549 cells led to an inhibition of RhoA and RhoC expression 
and reduced migration [61]. In contrast, both RhoA and Rac1 activity was found to be 
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reduced in PRL-3-overexpressing Chinese hamster ovary (CHO) and DLD-1 colorectal 
carcinoma cells, although no motility assays were reported [90]. These contradictory results 
might be explained by the dynamic focal adhesion turnover during different stages of cell 
adhesion and spreading, which involves spatiotemporal oscillations in the activities of RhoA, 
Rac1 and Cdc42 [93]. Ezrin, a member of the Ezrin-Radixin-Moesin family, was recently 
reported as a PRL-3 substrate in HCT116 and human umbilical vascular endothelial cells 
(HUVEC) [74]. Interestingly, ezrin phosphorylation at Thr567, the reported PRL-3 targeted 
site, results in its recruitment of negative Rho regulators of motility [98], thereby suggesting a 
mechanism to explain the increase in activities of Rho GTPase family proteins earlier 
described. 
In CHO and DLD-1 cells, PRL-3 overexpression caused a pronounced decrease in expression 
and phosphorylation of focal adhesion adaptors paxillin and vinculin [90]. Vinculin promotes 
focal adhesion assembly and cell spreading by promoting assembly of stress fibres [99]. 
Concomitant with the downregulation of vinculin, less filamentous actin and reduced stress 
fiber formation were observed in PRL-3 overexpressing cells [90]. These results imply that 
PRL-3 either (1) reduced the number of focal adhesions and/or (2) increased focal adhesion 
turnover in these cells, thereby inhibiting stress fiber formation and promoting cell migration. 
Interestingly, the proteosome-mediated degradation of PTEN has been shown to be regulated 
by vinculin and adherens junctions as a whole [100], suggesting that the PRL-3-induced 
downregulation of PTEN previously reported [90] may reflect a PRL-3-mediated disruption 
of adherens junctions through an as yet unknown mechanism.  
The degradation of the extracellular matrix is an important aspect in tumor invasion. Matrix 
metalloproteinases (MMPs) are major hydrolytic enzymes targeting ECM during metastasis 
and there is a clear connection between MMPs, ECM degradation and cancer cell invasion 
[101]. Interestingly, the expression of PRL-3 correlates significantly with that of MMP2 and 
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MMP9 in human glioma and hepatocellular carcinoma (HCC) patient samples [60,96]. In a 
more direct study, PRL-3 overexpression in DLD-1 cells resulted in a PI3K/AKT and ERK 
dependent 3- to 10-fold increase in the expression of multiple MMPs [102]. Notably, MMP7 
depletion completely abrogated PRL-3-induced migration and invasion of these cells. 
It is noteworthy that PRL-3 has been separately shown to negatively regulate keratin8 
phosphorylation and cadherin-22 expression [73,78]. Furthermore, PRL-3 overexpression in 
DLD-1 cells was also shown to result in downregulation of various epithelial markers 
including E-cadherin, plakoglobin and integrin β3, a phenomenon characteristic of epithelial-
mesenchymal transition [90,103]. Unfortunately, no correlation between changes in these 
adhesion proteins to PRL-3-induced invasiveness or motility was attempted in these studies. 
1.2.3. PRL-3 Signaling in Angiogenesis 
 Concomitant with increasing tumor invasiveness, PRL-3 also promotes tumor 
angiogenesis, an important step metastasis in promoting the dissemination of motile cancer 
cells as well as sustaining the growth of the solid tumor mass. In an in vitro angiogenesis 
model system, both CHO and DLD-1 cells overexpressing PRL-3, but not its catalytically 
dead mutant (C104S), could dramatically enhance HUVEC tube formation [36]. Importantly, 
the subcutanous injection of PRL-3 overexpressing CHO cells led to increased recruitment of 
host endothelial cells within the tumor mass in vivo. This phenomenon was partially attributed 
to PRL-3 mediated downregulation of the angiogenesis inhibitor, interleukin-4 [36]. More 
recently, the pro-angiogenic cytokines vascular endothelial growth factor (VEGF), and its 
isoform VEGF-C, have been reported to be upregulated in PRL-3-positive non-small cell lung 
cancers (NSCLC) [61]. Immunohistochemical analysis of PRL-3 expression in NSCLC 
revealed a significant association between PRL-3 expression and VEGF and VEGF-C 
expression, microvessel density and lymphatic vessel density. In addition, treatment of A549 
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lung cancer cells with an anti-PRL-3 antibody resulted in a decrease in VEGF and VEGF-C 
expression, concomitant with a decrease in invasive and migratory abilities [61]. Finally, in 
LoVo cells, PRL-3 has been reported to decrease expression of tissue metalloproteinase 
inhibitor 2 (TIMP2), a potent angiogenesis inhibitor [95,104]. 
1.2.4. PRL-3 Signaling in Cell Survival 
 Without the ability to escape apoptosis and survive in harsh foreign conditions, cancer 
cells would fail to reach, extravasate, and establish micrometastasis at distant sites. PRL-3 
facilitates these final steps of tumor metastasis in several ways. Firstly, PRL-3 overexpression 
in non-metastatic CHO cells imparted profound metastatic capabilities to these cells, as 
assayed using a tail-vein metastasis assay [17]. Because this assay bypasses the need for 
intravasation, this result hinted strongly at a specific role for PRL-3 in cell survival and/or 
extravasation into the mesenchyme. Remarkably, PRL-3 overexpressing CHO cells could also 
form solid tumor emboli within blood vessels and survive within this intravascular location 
[105], alluding to a dominant pro-survival effect of PRL-3 for circulating tumor cells, in 
addition to promoting tumor extravasation. In line with promoting survival and reducing cell 
death, PRL-3 has also been reported to promote resistance to p53-induced apoptosis by 
targeting this potent tumor-suppressor for degradation [89]. Thus, by simultaneously 
promoting extravasation and increasing cell survival, PRL-3 employs a potent dual-pronged 
approach to drive tumor dispersion in late metastasis. 
1.3. The Regulation of PRL-3 Expression and Function 
 Despite much headway in the analysis of PRL-3 expression patterns in normal and 
neoplastic tissues, the regulation of PRL-3 expression is relatively underexplored.  
Nonetheless, several reports have documented important regulators of PRL-3 expression at 




Figure 2: Proposed regulatory network and signaling pathways downstream of PRL-3 
culminating in metastatic progression. Figure adapted from Al-aidaroos and Zeng [8]. 
 
1.3.1. PRL-3 regulation at gene expression level 
 PRL-3 has been found to be amplified in 25% (3/12) of liver metastasis of CRCs [43].  
Indeed, a statistically significant difference in PRL-3 gene copy number between liver 
metastasis and primary lesions of CRCs has also been reported [34]. Increased gene copy 
numbers of PRL-3 have also been found in primary CRC with liver metastasis compared to 
those without liver metastasis [106], as well as in several myeloma cell lines [26].  c-myc is a 
well-characterized oncogene located on 8q24.12-q24.23, a locus just upstream of PRL-3, and 
is commonly amplified and over-expressed in metastasizing colorectal cancers [106]. Due to 
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the physical proximity of these 2 gene loci, it is not yet clear if PRL-3 gene amplification is 
specifically selected in synthesis with c-myc amplification, or an indirect consequence of c-
myc locus amplification. 
However, several reports have discounted gene amplification as the primary means of PRL-3 
overexpression. For instance, in CRC, ovarian cancer and myeloma cells, no correlation was 
reported between PRL-3 gene copy number and the high mRNA expression levels observed 
in these malignancies [26,43,58]. These observations suggested that PRL-3 expression must 
be tightly regulated at transcriptional and/or post-transcriptional levels. Several reports 
support this notion. Firstly, the increase in PRL-3 mRNA expression upon direct mitogenic 
stimulation [26,38] and exposure to conditioned medium from carcinoma-associated 
fibroblasts [107] suggests that extracellular stimuli transduced via growth factor signaling 
networks are involved in transcriptional regulation of PRL-3. In addition, functional promoter 
binding sites for myocyte enhancer factor 2C (MEF2C) [108], Snail [109] and p53 [23]  have 
been identified in sequences within and upstream of the PRL-3 gene, and implicated in 
driving PRL-3 expression. In contrast, transforming growth factor beta (TGFβ) stimulation 
has been shown to suppress PRL-3 expression by inducing binding of Smad transcription 
factors to PRL-3 promoter sequences [110]. It is worth highlighting that bioinformatics 
prediction tools (CONSITE, TRED) have identified PRL-3 to possess binding sequences for 
several other transcription factors, including that for n-MYC, STAT3 and NF-kB. 
Interestingly, two recent studies have implicated STAT activity in regulating PRL-3 mRNA 




1.3.2. PRL-3 regulation at post-transcriptional level 
 Although the upregulation of PRL-3 mRNA has been commonly reported in many tumor 
samples and cancer cell lines, PRL-3 protein expression levels do not always correlate well 
with them [112]. Poly(C)-binding protein 1 (PCBP1) is a member of the hnRNP family of 
RNA- and/or DNA-binding proteins, with described roles in the regulation of RNA 
transcription, pre-mRNA processing, maturation, and mRNA export [113]. Overexpression or 
ablation of PCPB1 resulted in suppression or increase in PRL-3 protein levels respectively, 
without any change in PRL-3 transcript levels [112]. The mechanism behind this was 
attributed to PCBP1-induced binding to triple GCCCAG motifs within the 5’-untraslated 
region (5’-UTR) of PRL-3 mRNA, thereby retarding its incorporation into polyribosomes and 
subsequently downregulating PRL-3 protein translation. Significantly, immunoblotting and 
immunohistochemical analysis revealed an inverse correlation between PRL-3 and PCBP1 in 
multiple tumor types, thereby establishing a clinical relevance of this finding [112]. 
1.3.3. PRL-3 regulation at post-translational level 
 Protein post-translational modifications (PTMs) constitute a large family of covalent 
modifications of proteins which serve to regulate their biological activity, molecular 
interactions, and dynamic stability [29]. To date, the only two PTMs characterized for PRL-3 
are oxidation and prenylation, and some evidence suggests they may be related. Due to 
participation of the catalytic cysteine in disulfide bond formation, oxidized PTPs lose 
catalytic function and require reduction by cellular reducing agents to regain activity [114]. 
Two oxidative inactivation mechanisms of PRL-3 have been proposed. The first involves the 
formation of an intradisulfide bond between the catalytic Cys104 and a proximally-located 
Cys49 residue in PRL-3 structure, whereas the other involves the novel oxidation of Cys104 
to catalytically-dead glycine [9,115]. Biochemical analysis of PRL-1 has found it to have a 
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reduction potential of approximately -365mV at pH7.5 [116], a value much lower than the 
reduction potential in most cellular compartments. This suggests that PRL-1, and possibly 
PRL-3, is largely kept inactive by catalytic cysteine oxidation intracellularly and may require 
activation by some post-translational modification or binding partner. Interestingly, mutation 
of Cys170 of PRL-1, which is the cysteine residue targeted for farnesylation in the PRL-1 
CAAX motif, makes it less prone to inactivation [116]. This implies that farnesylation, in 
addition to proper localization for enzyme-substrate interaction, could serve to regulate both 
localization and enzymatic activity by promoting reduction of catalytic cysteine and provide 
basis for previous reports describing the requirement of prenylation for the biological 
activities of PRL-3 in vivo [27,97,117].  
PRL-3 has the propensity to form oligomers in vitro and in vivo [12,27]. In PRL-1, mutation 
of resides at its trimerization interface resulted in an abrogation of PRL-1 driven cell 
proliferation and migration [12]. Interestingly, Thr13, a critical residue reported to be 
involved in PRL-1 trimerization, is substituted by a Ser in PRL-3 (Fig. 1). The contribution of 
Ser13 to PRL-3 oligomerization is as yet unknown. Recently, the peptidyl prolyl cis/trans 
isomerase FK506-binding protein 38 (FKBP38) was identified as a PRL-3 interacting protein 
which promotes the proteosome-mediated degradation of both exogenous and endogenous 
PRL-3 [76]. In agreement with this, FKBP38 could suppress PRL-3-mediated cell 
proliferation. However, the reliability of these observations requires further validation in 
different cellular systems. 
1.4. PRL-3 as a Therapeutic Target 
 With the establishment of key PRL functions in metastatic progression, the mechanisms 
underlying regulation of PRL expression and function have attracted both basic science and 
pharmaceutical researchers. Since an excess of PRL phosphatase activity is clearly a key 
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alteration contributing to the acquisition of metastatic properties in tumor cells, much focus 
has been placed on exploring and understanding the regulation of PRLs, particularly PRL-3 
(Fig. 2). Numerous anti-PRL-3 agents have been reported in recent years [111,118-124], and 
they can be generally classified into small molecule inhibitors (SMIs) or immunotherapy. 
Several SMIs have been reported to inhibit PRL family members. These included SMIs 
specific to all three PRLs [118,120], PRL-3 alone [111,122], or with unexplored specificities 
to non-PRL-3 members of the family [119,121,123]. The most best characterized and most 
promising SMI amongst this list is thienopyridone, or 7-amino-2-phenyl-5H-thieno[3,2-
c]pyridin-4-one. This drug was shown to selectively inhibit all three PRL members, but not 
11 other tyrosine and dual-specificity phosphatases of different classes, in vitro [120]. 
Inhibition of PRLs by thienopyridone resulted in the inhibition of tumor cell anchorage-
independent growth and the induction of anoikis (a type of apoptosis). Thienopyridone 
treatment also inhibited mitogen-induced endothelial cell migration. These effects were 
shown to occur through a novel p53-independent mechanism involving the inhibitory 
cleavage of p130Cas [120]. Modern high-throughput screening methods have also unveiled 
new classes of PRL-3 small molecule inhibitors, including rhodamine with an IC50 value of 
0.9 μM [119]. In an alternative study employing structural-based virtual docking of PRL-3, 12 
novel and structurally diverse compounds were identified to bind and inhibit PRL-3, with 
IC50 values as low as 10 μM [121]. Notably, these compounds had binding activity to both 
active and peripheral sites of PRL-3, increasing the likelihood for specific target inhibition. 
However, the value and specificity of these newly identified small molecule PRL-3 inhibitors 
will require further characterization before preclinical testing and drug development. 
An emerging alternative therapeutic option against PRL-3, and potentially PRL-1, is the use 
of immunotherapy. Unexpectedly, intravenous administration of PRL-3 specific antibodies 
resulted in the ablation of lung metastasis of cells expressing exogenous or endogenous PRL-
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3 in a tail vein mouse metastasis model [122]. Remarkably, these PRL-3 specific antibodies 
specifically inhibited the development of PRL-3-mediated metastatic tumors, but not PRL-1-
mediated metastatic tumors, suggesting a high degree of specificity. The mechanism for this 
is still unknown, although the presence of functional B-cells in vivo was shown to be 
necessary for an efficient response in such an intracellular antibody targeting approach [125]. 
Ultimately, in view of the differences in the expression profiles between PRLs, particularly 
PRL-2, specific antibody targeting of individual PRL members constitutes an important 
consideration in minimizing unwanted side effects in anti-PRL cancer therapy. 
1.5. Rationale and Hypothesis 
 Despite its implication in cancer a decade ago, the molecular signaling pathway(s) of 
PRL-3 is still not well understood. Notably, there seems to be apparent cell-specific effects 
for PRL-3 in several of the signaling pathways reported, such as the activation of Src 
restricted in HEK293 [18], the downregulation of PTEN only in DLD-1 [90], the opposing 
result of ezrin phosphorylation in HCT116 and SW480 cells [74,78], as well as the lack of 
consistency in the downregulation of the epithelial marker plakoglobin in DLD-1 and SW480 
cells [73,90]. Conveniently, none of the conflicting studies comment on their inability to 
reproduce preceding data reported by other groups, leaving much to the interpretation of the 
investigators in the field.  
Early research with overexpression of PRL-3 in cell systems revealed that PRL-3 could 
promote metastasis-associated characteristics both in cancerous and non-cancerous cells 
[17,86]. To date, MAPK/ERK activation seems to be the conserved consequence of PRL-3 
overexpression across several different cellular systems, suggesting it indeed plays an 
important role in PRL-3-mediated oncogenesis. Interestingly, many of the signaling pathways 
reported to be perturbed by PRL-3, particularly MAPK/ERK and PI3K/AKT, lie downstream 
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of growth factor receptor signaling [1]. Since the activation of growth factor receptors, 
particularly receptor tyrosine kinases (RTKs), are consistent with the pathways perturbed by 
PRL-3 in different cell systems, it led to the formation of my initial hypothesis: 
PRL-3 signals via a common receptor-proximal node of multiple signaling pathways 
that control cell processes key to the progression and metastasis of human cancers.  
To investigate this hypothesis, I set the following aims: 
1.  To develop PRL-3 overexpressing systems in various cancer cell lines to investigate 
the activation of RTKs by PRL-3. 
2.  To study the alterations in cell signaling pathways upon PRL-3 overexpression. 
3.  To study the relationship between alterations in signaling pathways regulated by 
PRL-3 and any consequential biological activity contributing to cancer progression. 
In ovarian cancer, PRL-3 expression has been shown to correlate with disease progression 
and is predictor of poor outcome [58,59]. In a recent screen for PRL-3 regulated proteins in 
ovarian cancer cells, we unexpectedly identified β-catenin expression to be potently 
downregulated upon forced expression of PRL-3. Interestingly, the loss of β-catenin has been 
reported to correlate with increased invasiveness and poorer prognosis in ovarian cancer 
[126,127]. Because PRL-3 might negatively regulate β-catenin in this cancer type, I 
developed my second hypothesis: 
The downregulation of β-catenin is involved in PRL-3-mediated ovarian cancer 
progression. 
To investigate this hypothesis, I set the following aims: 
1.  To study the biological effects of PRL-3 expression in ovarian cancer cells. 
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2.  To study the relationship between the β-catenin expression and the biological effects 
of PRL-3 expression in ovarian cancer cells.  
3. To study the relationship between β-catenin and PRL-3 expression in human cancer 
samples. 
While reviewing PRL-3 literature, it became apparent that the ‘cell-type specific’ effects of 
PRL-3 might be explained by the differential post-translational modification (PTM) of this 
oncogene in the genetically different biological systems used. Indeed, besides prenylation and 
oxidation, there is a dearth of reports documenting alternative post-translational regulation of 
PRL-3.  challenging. Interestingly, protein phosphorylation is a highly prevalent PTM, 
reversibly affecting approximately 30% of the proteome [1]. Since many phosphatases 
themselves have been described to undergo dysregulated phosphorylation during malignancy 
[128-130], it led to the next key hypothesis of my study: 
PRL-3 is regulated by post-translational mechanisms that govern its function in cancer 
cells. 
To investigate this hypothesis, I set the following aims: 
1.  To study the phosphorylatability of PRL-3 in various cancer cells. 
2.  To study the effects of PRL-3 phosphorylation on its biological interactions. 
 
The results from my experiments investigating all three hypotheses above constitute the 
primary body of this thesis. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Reagents 
The complete list of reagents, according to the specific Method section in which they are first 
mentioned, is detailed in Appendix I. A complete list of antibodies used in this study is 
detailed in Appendix II. 
2.2. Plasmids 
2.2.1. Generation of EGFP-tagged wild-type and mutant PRL-3 constructs 
cDNA corresponding to human PRL-3 (PTP4A3; CCDS ID 6382) was cloned into the 
pEGFP-C1 vector (Clontech, USA) using forward and reverse primers containing EcoRI and 
BamHI restriction sites (see Table 2 for primer sequences), respectively, to generate the 
pEGFP-PRL-3 plasmid. The PCR cycling parameters used in the HotStarTaq amplification 
reaction was as follows: initial denaturation – 95°C (15 min); amplification – 30 cycles of 
94°C (30 sec), 53°C (30 sec), 72°C (60 sec); final extension – 72°C (10 min). The gel-
purified PCR amplicon and pEGFP-C1 vector were sequentially digested with high fidelity 
EcoRI (EcoRI-HF) and BamHI (BamHI-HF) restriction enzymes and subsequently ligated 
together in a 20 uL reaction for 1 h using 1 uL of T4 DNA ligase at room temperature (RT) to 
obtain pEGFP-PRL-3.  Half the ligation mixture was incubated with 80 uL of DH5-alpha 
bacteria cells on ice for 30 min, followed by a heat shock at 42°C for 45 sec. Following 
recovery on ice (2 min), cells were supplemented with 0.5 mL antibiotic-free Luria Broth 
(LB), allowed to grow for 1 h at 37°C in a shaking incubator (New Brunswick Scientific, 
USA), and 0.2 mL of the cell suspension was spread on home-made agar plates containing 
kanamycin (50 μg/mL) as a positive selection. After overnight incubation, growing colonies 
were picked, expanded overnight in LB supplemented with kanamycin (50 μg/mL), and 
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plasmids purified using a commercial plasmid spin-purification kit according to the 
manufacturer’s instructions (Qiagen, USA). Plasmids were validated by sequencing using the 
Big Dye terminator cycling method (Applied Biosystems, USA) using the forward and 
reverse primers against the amino- and carboxy-terminal ends of PRL-3 sequence (fwd: 5’-
ATGGCTCGGATGAACC-3’; rev: 5’-CTACATAACGCAGCACCG-3’). The following 
parameters were used in the sequencing cycle: initial denaturation – 96°C, 3 min; 
amplification – 30 cycles of 96°C, 60 sec, 56°C, 30 sec, 60°C, 4 min; final extension – 60°C, 
1 min. Sequencing data was subsequently collected in an ABI Prism 377 DNA Sequencer 
(Applied Biosystems, USA) by the DNA Sequencing Unit of the Institute of Molecular and 
Cell Biology, Singapore. 
For site-directed mutagenesis using pEGFP-PRL-3 as a template, high performance liquid 
chromatography (HPLC)-purified overlapping oligonucleotide primers containing the desired 
mutations were first synthesized (1st Base, Singapore). Each primer pair was designed to have 
a 13-16 bp stretch flanking each side of the point mutation(s) and were calculated a priori to 
possess a melting temperature (Tm) of at least 78°C, in accordance with the recommendation 
of the Quikchange Lightning site-directed mutagenesis kit employed (Stratagene, USA). The 
detailed list of primers used for obtaining various PRL-3 mutants is provided in Table 2. The 
PCR cycling parameters used for all mutagenesis reactions were as follows: initial 
denaturation – 95°C (2 min); amplification – 18 cycles of 95°C (20 sec), 60°C (10 sec), 68°C, 
(5 min); final extension – 68°C (5 min). PCR products were subsequently digested with DpnI 
enzyme, which specifically digests the methylated and hemi-methylated parental template, 
and 2 μL of the mixture was used to transform XL-10 ultracompetent cells (Stratagene, USA) 
at 42°C for 30 sec. Following heat-shock, bacteria were recovered, positive clones expanded, 
and plasmids purified as described earlier. 
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For generation of pEGFP-PRL-3-C170S, I amplified the PRL-3 coding sequence from 
pEGFP-PRL- with a forward primer harboring an EcoRI site and a reverse primer encoding a 
T-to-A missense mutation coding for Cys170 to Ser together with a BamHI restriction site 
(sequence details in Table 2). The gel-purified PCR amplicon and pEGFP-C1 vector were 
digested and ligated as before to obtain pEGFP-PRL-3-C170S. All plasmids were sequenced 
and verified before use in any experiment. 
TABLE 2. List of DNA constructs made for this study, and the primers involved. 
Plasmid name Vector Insert Primers used (5’->3’) Purpose in this study 
pEGFP-PRL-3 pEGFP-C1 human PRL-3 (wt) F: TAA GAATTC TATG GCT CGG ATG 
AAC CGC CCG G 
R: TAA GGATCC CTA CAT AAC GCA 
GCA CCG GGT CTT 
Expression of the N-terminal 
EGFP tagged PRL-3-wt fusion 
protein in mammalian cells. 
pEGFP-PRL-3-
C104S 




F: TGG CTG TGC ACA GCG TGG CGG GC 
R: GCC CGC CAC GCT GTG CAC AGC CA 
Expression of the N-terminal 
EGFP tagged PRL-3-C104S 








F: GGC GGG CCT GGG CAG TGC TCC 
AGT CCT TG 
R: CAA GGA CTG GAG CAC TGC CCA 
GGC CCG CC 
Expression of the N-terminal 
EGFP tagged PRL-3-R110S 








F: TAA GAATTC TATG GCT CGG ATG 
AAC CGC CCG G 
R: TAA GGATCC CTA CAT AAC GCA 
GCT CCG GGT CTT 
Expression of the N-terminal 
EGFP tagged PRL-3-C170S 




pEGFP-C1 human  
PRL-3 (Y14F) 
F: CGG TGG AGG TGA GCT TCA AAC 
ACA TGC GCT T 
R:AAG CGC ATG TGT TTG AAG CTC 
ACC TCC ACC G 
Expression of the N-terminal 
EGFP tagged PRL-3-Y14F 




pEGFP-C1 human  
PRL-3 (Y40F) 
F: TCA TTG AGG ACC TGA AGA AGT 
TCG GGG CTA CCA 
R: TGG TAG CCC CGA ACT TCT TCA 
GGT CCT CAA TGA 
Expression of the N-terminal 
EGFP tagged PRL-3-Y40F 




pEGFP-C1 human  
PRL-3 (Y53F) 
F: GTG TGT GTG AAG TGA CCT TTG 
ACA AAA CGC CGC TG 
R: CAG CGG CGT TTT GTC AAA GGT 
CAC TTC ACA CAC AC 
Expression of the N-terminal 
EGFP tagged PRL-3-Y53F 




pEGFP-C1 human  
PRL-3 (Y126F) 
F: ATT GAG AGC GGG ATG AAG TTC 
GAG GAC GCC 
R: GGC GTC CTC GAA CTT CAT CCC 
GCT CTC AAT 
Expression of the N-terminal 
EGFP tagged PRL-3-Y126F 




pEGFP-C1 human  
PRL-3 (Y148F) 
F: CAG CAA GCA GCT CAC CTT CCT 
GGA GAA ATA CCG 
R: CGG TAT TTC TCC AGG AAG GTG 
AGC TGC TTG CTG 
Expression of the N-terminal 
EGFP tagged PRL-3-Y148F 




pEGFP-C1 human  
PRL-3 (Y152F) 
F: AGC TCA CCT ACC TGG AGA AAT 
TCC GGC CCA AAC 
R: GTT TGG GCC GGA ATT TCT CCA 
GGT AGG TGA GCT 
Expression of the N-terminal 
EGFP tagged PRL-3-Y152F 
fusion protein in mammalian 
cells. 
pGST-PRL-3 pGEX-KG human PRL-3 (wt) F: TAA GGATCC TATG GCT CGG ATG 
AAC CGC CCG G 
R: TAA GAATTC CTA CAT AAC GCA 
GCA CCG GGT CTT 
Expression of the N-terminal 
GST tagged PRL-3-wt fusion 








Acquired Expression of the N-terminal 
DsRed tagged β-catenin-S33Y 









F: AGC AAC AGT CTT ACC TGG ACT 
CTG GAA TCC ATT CTG 
R: CAG AAT GGA TTC CAG AGT CCA 
GGT AAG ACT GTT GCT 
Expression of the N-terminal 
DsRed tagged β-catenin-wt 









Acquired Expression of the C-terminal 
mCherry tagged Src-Y527F 











Acquired Expression of the C-terminal 
mCherry tagged Src-K295M 
fusion protein in mammalian 
cells. 
Enzyme restriction sites are underlined where applicable. Acquired plasmids previously generated by others are indicated so in the Primers 
used column. 
2.2.2. Other plasmids 
The plasmid for PRL-3 tagged with glutathione S-transferase (GST) at its amino-terminus 
(pGST-PRL-3) was generated by amplifying the PRL-3 coding sequence from pEGFP-PRL- 
using forward and reverse primers containing BamHI and EcoRI restriction sites, respectively 
(sequence details in Table 2). The gel-purified PCR amplicon and pGEX-KG vector were 
digested, ligated, transformed and sequenced as before to obtain pGST-PRL-3. The pDsRed-
β-catenin-S33Y plasmid was a gift from Professor Hong Wanjin, Institute of Molecular and 
Cell Biology, Singapore. Using the same mutagenesis approach described earlier, I used this 
plasmid as a template to restore wild-type β-catenin coding sequence by reverting Tyr33 to 
Ser using overlapping mutagenic primers (Table 2), thereby yielding pDs-Red-β-catenin-WT. 
Plasmids encoding constitutively active chicken Src (pSrcY527F-mCherry, containing Y527F 
mutation) or kinase dead chicken Src (pSrcK295M-mCherry, containing K295M mutation) 
carboxy-terminally tagged with mCherry were kind gifts from Dr. David Gill (Institute of 
Molecular and Cell Biology, Singapore) and detailed in a previous publication [131]. All 
plasmids were sequenced and verified before use. 
2.3. Cell lines and derivatives 
2.3.1. Cell culture 
A2780 ovarian carcinoma cells, SW480 colorectal carcinoma cells and HCT116 colorectal 
carcinoma cells (American Type Culture Collection, USA) were grown in Roswell Park 
Memorial Institute medium (RPMI-1640) medium supplemented with 10% FBS, 2 mM L-
glutamine and 1% antibiotic-antimycotic. MDA-MB-468 breast adenocarcinoma cells (a kind 
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gift from Dr. Cynthia Coffill, Institute of Molecular and Cell Biology, A*STAR, Singapore) 
were grown in Dulbecco’s modified Eagles medium 4500 mg/L high-glucose medium 
(DMEM-HG) supplemented with 10% FBS, 2 mM L-glutamine and 1% antibiotic-
antimycotic. Cells were cultured in sterilized tissue culture-treated vessels (Nunc, Denmark) 
at 37°C with 5% CO2 and 95% humidity. 
2.3.2. Generation of cancer cell lines stably expressing EGFP or EGFP-PRL-3 variants 
The day before transfection, A2780, A431, MDA-MB-468 or SW480 cells were seeded in 
their respective antibiotic-free media in a 12-well culture plate (1 x 105 cells/well). 
Transfection was achieved using Lipofectamine2000, a cationic lipid-based transfection 
reagent (Invitrogen, USA). 20 mins before transfecting cells, 0.8 µg of pEGFP-C1, pEGFP-
PRL-3-WT or engineered pEGFP-PRL-3 mutant plasmid DNA were mixed with 2 µL 
Lipofectamine2000 diluted in 200 µL OptiMEM medium to allow DNA-lipid complexes to 
form. After evenly adding the DNA-lipid mixture in a dropwise fashion over the cells, cells 
were left to incubate overnight. The next day, cells were trypsinized and transferred to a 150 
mm tissue culture dish in their respective growth media supplemented with 1 mg/mL 
neomycin, and selected for 2 weeks to obtain cell populations stably possessing at least 90% 
GFP positivity as verified using an Eclipse TE2000-U inverted fluorescence microscope 
(Nikon, Japan). There were no viable cells in mock-transfected cells after 2 weeks of 
neomycin selection. Stable cell pools were thereafter grown in complete media lacking 
neomycin. Early passage stocks were made in growth media supplemented with additional 




2.3.3. Generation of A2780 and HCT116 cancer cell lines with stable PRL-3 knockdown 
A2780 and HCT116 cells were transfected as described above using SureSilencing shRNA 
plasmids (Qiagen, USA) encoding either a non-targeting scrambled or human PRL-3-
targeting shRNA (5’-TTCTCGGCACCTTAAATTATT-3’). Cells were selected for 2 weeks 
in 1 μg/mL puromycin. Individual colonies were picked and expanded, and those showing 
≥75% knockdown of PRL-3 expression were pooled and used for subsequent analysis. There 
were no viable cells in mock-transfected cells after 2 weeks of puromycin selection. 
2.3.4. Small-interfering RNA (siRNA) knockdown 
The day before transfection, A431 cells were seeded into a 12-well culture plate (1 x 105 
cells/well) and allowed to attach overnight. 30 min prior to transfection, the culture medium 
was replaced with 500 μL antibiotic-free DMEM-HG. In a microtube, 2 μL of 
Lipofectamine2000 was added to 100 μL OptiMEM, mixed gently, and allowed to stand for 5 
min for equilibiration. 0.6 uL of either scrambled or PTP1B-directed siRNA (5’-CUU CCU 
AAG AAC AAA AAC C-3’; validated in [132]) stocks (10 μM each) was subsequently added 
to the tube, mixed, and left to stand for another 5 min to allow DNA-lipid complexes to form. 
100 μL of this mixture was added at-once to cells (final [siRNA] = 10 nM), agitated 
vigorously, and incubated overnight. The medium was replaced the next with complete media 
and harvested for lysis 48 h after transfection.  
2.3.5. Treatments 
Prior to any stimulation, cells were starved of growth factors first. To do this, exponentially 
growing cell monolayers (70-80% confluent) were rinsed in PBS once before incubating in 
serum-free media for 16 h. Cells were subsequently stimulated with FBS (25% final v/v), 
phorbol 12-myristate 13-acetate (PMA; 1 μM), recombinant human epidermal growth factor 
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(EGF; 100 ng/mL), recombinant human interferon-gamma (IFN-γ; 15 ng/mL), or 
recombinant human interleukin-6 (IL-6; 25 ng/mL) for various durations. For UV-C 
stimulation, culture media was aspirated before culture dishes were placed, lid removed, into 
a Model 2400 Stratalinker fitted with a UV-C bulb (Stratagene, USA) and subjected to a 40 
J/m2 irradiation dose using the ‘Energy’ mode for 2-3 seconds. Serum free media was 
immediately replaced and cells were returned to the incubator to recover for 1 h.  To induce 
osmotic stress, saline solution was added to cells (NaCl; 0.2 M final) for 30 min and 
subsequently allowed to recover for 30 min in serum-free medium. To induce oxidative stress, 
H202 was directly added to starved cells (1 mM final, 30 min). Finally, for PTP inhibition, 
H202 and sodium orthovanadate (1 mM, 30 min) were seperately to the culture media of 
starving cells to yield the potent PTP inhibitor, pervanadate (1 mM final, 30 min). In some 
experiments, cells were treated with DMSO (0.1%), Src-specific inhibitor PP2 (10 μM) or 
EGFR-specific inhibitor AG1478 (1 μM) 20 mins prior to EGF stimulation. For other 
inhibitor treatments, serum starved cells were treated with EGFR inhibitor tryphostin AG-
1478 (2 uM, 75 min), Src-family inhibitor PP2 (5 uM, 16 h), or the anti-EGFR antibody 
cetuximab (10 nM, 24 h) or the EGFR inhibitor erlotinib (2 µM, 3 h) prior to lysis. 
2.4. RNA isolation 
Cellular RNA was extracted using the RNeasy kit (Qiagen, USA). Briefly, sub-confluent cell 
monolayers (~80%; 1x106 cells) were harvested by trypsinization, washed, and lysed in 350 
µL of Buffer RLT containing 1% β-mercaptoethanol (v/v). For homogenization, lysates were 
passed through a QIAshredder spin column once (Qiagen, USA). 350 µL of 70% ethanol 
(v/v) was subsequently added to homogenates, mixed thoroughly, and the resultant mixture 
was transferred into an RNeasy spin column. After the initial spin, membrane-bound RNA 
was washed once with 700 µL Buffer RW1, twice with 500 µL Buffer RPE, and spun 
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completely dry before elution using 30 µL of RNase-free water. Purified RNA was 
quantitated using a Nanodrop spectrophotometer (Thermo Fisher Scientific, USA). 
2.5. Semi-quantitative (RT-PCR) and Quantitative Real Time-PCR (qRT-PCR) 
cDNA was first generated from cellular RNA using reagents provided in SuperScript III First 
Strand Synthesis System (Invitrogen, USA). Briefly, 2 µg of RNA sample were first mixed 
with 5 µM oligo(dT)20, 2 mM dNTP mix, and RNase-free water in a 10 uL volume and heated 
at 65°C for 5 min. After cooling on ice for 1 min, 10 µL of cDNA synthesis mix (2x RT 
buffer, 10 mM MgCl2, 20 mM DTT, 4 units RNase OUT, 20 units SuperScript III RT) was 
added to the tube, mixed gently, and heated at 50°C for 50 min to synthesize first-strand 
cDNA. The reaction was terminated by heating at 85°C for 5 min. cDNAs were used 
immediately for PCR or stored at -20°C until use. For RT-PCR, 2 µL cDNA was added to a 
reaction mix containing HotStarTaq Master Mix (1x) and 0.2 uM of gene-specific forward 
and reverse primer pair in a 50 uL reaction volume. The primer sequences used are as 
follows: human β-catenin forward (5’- CAC TTG CAA TAA TTA TAA GAA CCA G -3'), 
human β-catenin reverse (5’- GAT TTG CGG GAC AAA GGG CAA GAT -3'), human p53 
forward (5’- AGT CTA GAG CCA CCG TCC A -3'), human p53 reverse (5’- AGG TCT 
GAA AAT GTT TCC TGA CTC A -3'). RT-PCR cycling conditions were as follows:  initial 
denaturation – 95°C, 15 min; amplification – 30 cycles of 94°C, 30 sec, Tm, 30 sec, 72°C, 30 
sec; final extension – 72°C, 10 min. PCR products were resolved in TAE-agarose gels 
containing 1x GelRed and imaged in a UV trans-illumination chamber equipped with a CCD 
camera. For qRT-PCR, 100 ng cDNA was amplified using a commercially optimized 
TaqMan Gene Expression Assay Mix with primers specific for human PTP1B (PTPN1) or 
human GAPDH (Applied Biosystems, USA). As recommended by the manufacturer, the 
samples were analyzed using the pre-optimized Fast PCR program on a 7500 Fast Real-Time 
PCR system (Applied Biosystems, USA). To ensure reproducibility and robust statistical 
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significance, biological triplicates were used, with each gene-specific qRT-PCR reaction done 
in triplicate in an Optical 96-Well Fast Plate (Applied Biosystems, USA). 
2.6. Nucleo-Cytoplasmic Fractionation 
Nucleo-cytoplasmic fractionation of cells was done using the NE-PER kit (Thermo Scientific, 
USA). Briefly, sub-confluent monolayers of A2780 GFP or GFP-PRL-3 cells (2x106) were 
harvested by trypsinzation, washed in PBS, and resuspended in 200 µL ice-cold CER I 
reagent supplemented with protease and phosphatase inhibitor cocktails. The cell suspension 
was vortexed vigorously for 15 sec, incubated on ice for 10 min and 11 uL of CER II reagent 
was added. Following this, cells were vortexed vigorously several times before spinning 
down at 16,100 x g in a microcentrifuge (Eppendorf, Germany) for 10 min at 4°C. The 
supernatant at this stage was saved as the cytosolic extract. The pellet was resuspended in ice-
cold NER reagent supplemented with protease and phosphatase inhibitor cocktails, and 
vortexed vigorously for 15 sec every 10 min, over a total of 40 min. The resultant suspension 
was spun down at 16,100 x g in a microcentrifuge (Eppendorf, Germany) for 10 min at 4°C, 
and the supernatant at this stage was saved as the nuclear extract. All extracts were stored at -
80°C till use. 
2.7. Immunoprecipitation 
All immunoprecipitation (IP) reactions were done in spin columns (Thermo Scientific, USA) 
to facilitate washing and minimize loss of sample. Prior to IP, antibodies (4 uL each) were 
first bound to 20 uL equilibrated Protein-A/G beads by incubating them together in IP-Wash 
buffer (10 mM sodium phosphate, 150 mM NaCl; pH 7.2) for 1 h at room temperature (RT) 
on an end-over-end rotator. Unbound antibodies were washed away using three volumes of 
IP-Wash Buffer three times. In some cases, antibodies were subsequently crosslinked to 
Protein-A/G beads using 450 uM disuccinimidyl suberate (DSS) in IP-Wash buffer for 45 min 
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at RT. The crosslinking reaction was terminated by washing antibody-bead conjugates with 
two volumes of Elution buffer (0.1 M glycine; pH 2.8) twice, followed by four volumes of 
Lysis buffer (25 mM Tris, 150 mM NaCl, 1% NP-40, supplemented with a protease inhibitor 
cocktail and phosphatase inhibitor cocktail; pH 7.3) twice. Washed antibody-bead conjugates 
were immediately used for IP.  
For each IP reaction, cells grown in 60 mm culture dishes were harvested in 300 uL Lysis 
buffer. Lysates were incubated on ice for 10 min before being centrifuged for 10 min at 
16,000 x g at 4°C. Supernatants were collected, quantitated using the Bradford method, and 
normalized for similar protein amounts in an adjusted 350 uL volume before 30 uL aliquots 
were saved as an input control for each IP reaction. The remaining lysate was added to the 
antibody-bead conjugates described above and incubated 16 h at 4°C for IP. 
Immunoprecipitates were subsequently washed with one volume of Lysis buffer four times 
before elution twice with 40 uL Elution buffer each time. Lysates aliquots and eluted 
immunoprecipitates were stored at -80°C until use. 
2.8. Western Blotting 
2.8.1. Standard SDS-PAGE 
Cells were treated as indicated in the figures and harvested in Lysis buffer. Protein amounts in 
lysates were quantitated using the Bradford method. Home-made 10% acrylamide resolving 
gels were prepared as follows. For each resolving gel, 3.3 mL 30% bis-acrylamide, 2.5 mL 
1.5 M Tris-Cl pH 8.8, 4.1 mL H2O, and 100 uL 10% SDS (w/v) (sodium dodecyl sulphate) 
were gently mixed together in a 15 mL conical tube. Subsequently, 100 uL 10% APS (w/v) 
(ammonium persulfate) and 10 uL TEMED (tetramethylethylenediamine) were added, mixed 
gently by inverting, and immediately poured into glass plates with 1.5 mm spacers. After 
layering 70% ethanol (v/v) above the gel to remove all bubbles and establish a level surface, 
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resolving gels were left to polymerize for 30 min at RT. After polymerization, ethanol was 
removed using paper towels and deionized water was used to wash gel surfaces free of any 
residual ethanol. Staking gels were prepared as follows. For each gel, 0.3 mL 30% 
acrylamide, 0.5mL 0.5 M Tris-Cl pH 6.8, 1.2 mL H2O, and 20 uL 10% SDS (w/v) were 
gently mixed in a 2 mL eppendorf tube. Subsequently, 12 uL 10% APS (w/v) and 4 uL 
TEMED were added, mixed gently by inverting, and immediately poured above the resolving 
gels. Combs (10 well or 15 well) were immediately placed into the stacking buffer and left to 
polymerize for 30 min at RT before use. For all standard SDS-PAGE gels, gels were run in 
SDS-PAGE running buffer (250 mM Tris, 250 mM glycine, 0.1% SDS; pH not adjusted) at 
70 V for 15 min, followed by 120 V (constant) until the dye front reached the bottom of the 
gel. Protein markers (Bio-Rad, USA) were used to estimate protein sizes and facilitate sample 
orientation within the gel. 
2.8.2. PhosTag SDS-PAGE 
PhosTag SDS-PAGE is a modification of normal SDS-PAGE by the addition of PhosTag, 
an alkoxide-bridged dinuclear Mn2+ complex which specifically binds anionic substituents in 
proteins, especially phosphomonoester dianions. As a result, phosphorylated proteins migrate 
much more slowly in PhosTag-supplemented SDS-PAGE, making it easy to separate 
phosphorylated and non-phosphorylated isoforms of proteins. However, a limitation of 
PhosTag is its extreme sensitivity to salts, thus in this study it was only employed to analyze 
eluted IP products, which are essentially salt-free. Home-made 7.5% PhosTag acrylamide 
resolving gels were prepared as follows. For each resolving gel, 3.3 mL 30% bis-acrylamide, 
2.5 mL 1.5 M Tris-Cl pH 8.8, 4 mL H2O, 100 μL 10% SDS (w/v) (sodium dodecyl sulphate), 
50 μL 5 mM PhosTag AAL solution (10 mg PhosTag dissolved in 3% methanol), and 50 μL 
of 10 mM MnCl2 were gently mixed by inversion in a 15 mL conical tube for 5 mins. 
Subsequently, 100 μL 10% APS (w/v) (ammonium persulfate) and 15 μL TEMED 
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(tetramethylethylenediamine) were added, mixed gently by inverting, and immediately poured 
into glass plates with 1.5 mm spacers. After layering 70% ethanol (v/v) above the gel to 
remove all bubbles and establish a level surface, resolving gels were left to polymerize for 30 
min at RT. Stacking gels were prepared and layered as described earlier. For all PhosTag 
SDS-PAGE gels, gels were run in SDS-PAGE running buffer at 70 V for 15 min, followed by 
a constant current of 25 mA until the dye front reached the bottom of the gel. Protein markers 
were used to estimate protein sizes and facilitate sample orientation within the gel. 
2.8.3. Electroblotting 
SDS-PAGE gels were removed from glass plates and equilibrated in transfer buffer (25 mM 
Tris pH 7.3, 192 mM glycine, 20% methanol) 10 min prior to immunoblotting. Pre-cut fibre 
pads, filter papers and Hybond-C nitrocellulose membranes (GE Healthcare, USA) were 
similarly equilibrated in transfer buffer for 10 min. The transfer stack was subsequently 
assembled and electroblotting was achieved in ice-cold transfer buffer for 100 V, 1.5 h. 
Membranes were subsequently stained with 0.1% Ponceau S (w/v, in 5 % acetic acid) to 
visualize protein bands, allowing verification of the even transfer of proteins. The membrane 
was completely destained in TB-T buffer (50 mM Tris pH 7.4, 0.1 % Tween-20) for 5 mins at 
RT before proceeding to immunodetection. 
2.8.4. Immunodetection 
For phosphorylated antigens, 5% bovine serum albumin (BSA) in TB-T was used as a buffer 
and diluent in all blocking and antibody incubation steps, respectively. For non-
phosphorylated antigens, 5% skim milk in TB-T was used as a buffer and diluent in all 
blocking and antibody incubation steps, respectively. Electroblotted membranes were first 
blocked for 1.5 h at RT, followed by incubation with primary antibody overnight at 4°C. 
Membranes were subsequently washed four times in TB-T for 5 min each before incubating 
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with horse radish peroxidase (HRP)-conjugated secondary antibodies for 1.5 h at RT. 
Membranes were subsequently washed four times in TB-T for 5 min before incubation with a 
chemiluminescent substrate (Thermo Scientific, USA) for 2 min. X-ray films (Fujifilm, 
Japan) were exposed to the protein bands on membranes in a dark room for various durations 
before developing in an X-OMAT processor (Kodak, USA). Quantitiation of band densities 
was done using a GS-700 Imaging Densitometer (Bio-Rad, USA) using a fixed volume size 
for each band pair being compared. 
2.9. Production of GST fusion proteins for cytosolic pull-down assays 
Glycerol stocks of BL21 E.coli cells carrying either pGST-KG or pGST-PRL-3 plasmids 
were incubated overnight in 3 mL LB-ampicillin for expansion. The next day, all 3 mL of 
bacteria culture was added into 500 mL LB-ampicillin and grown till an OD600 of ~0.6 before 
induction with 0.25 mM IPTG for 3 h at 37°C. Bacteria cells were pelleted by centrifugation, 
resuspended in Bac-Lysis buffer [20 mM Tris pH 7.5, 500 mM NaCl, 1 mg/mL lysozyme, 2 
mM dithiothreitol (DTT), 2 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride 
(PMSF)], and homogenized on ice using a sonicator (large tip; 1 min, 3 times) with 1 min 
cooling between pulses. Resulting lysates were clarified by centrifugation. Glutathione 
sepharose beads (Amersham, USA) were washed with Bac-Lysis buffer twice, added to 
clarified lysates, and incubated for 3 h at 4°C on a rotator. Protein-bound beads were then 
washed thrice in Bac-Lysis buffer, twice in low-salt buffer (20 mM Tris pH 7.5, 200 mM 
NaCl, 2 mM DTT, 2 mM benzamidine, 0.1 mM PMSF), and immediately used for GST-
pulldown experiments. Before adding lysates to the beads, purified bead-bound GST fusion 
proteins were quantified by SDS-PAGE Coomassie blue staining using BSA as standard. 
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2.10. Antibody Arrays 
2.10.1. RayBio RTK Phosphorylation Antibody Array 
For the RTK activation study, antibody arrays against 71 unique RTKs (cat# AAH-PRTK-1-
2; RayBio, USA) were used according to the manufacturer’s protocol. Briefly, exponentially 
growing cells at 80% confluence in 10 cm culture dishes were harvested in ice-cold Lysis 
buffer, clarified by centrifugation, and quantitated using the Bradford method. Before adding 
lysates, membranes decorated with RTK-specific antibodies were first blocked with the kit-
supplied Blocking Buffer for 1 h at RT. 1.2 mg of cell lysates were subsequently added to 
each membrane and incubated overnight at 4°C. Membranes were washed four times for 5 
min each, and incubated with biotin-conjugated secondary antibody overnight at 4°C. 
Membranes were washed as before, incubated with streptavidin-HRP for 2 h at RT, and 
washed again before development. Quantitation of the dots was done using a densitometer as 
previously described, but using a fixed volume size for all spots. 
2.10.2. RayBio Human Growth Factor Antibody Array 
For secreted growth factor analysis, growth factor antibody arrays (cat# AAH-GF-1; RayBio, 
USA) were used in a similar manner as described for the RTK array, with the exception that 
instead of cell lysates, 1 ml conditioned media from 1 x107 A431 EGFP or EGFP-PRL-3 cells 
grown in serum free media (20 h incubation) were used as input analytes. 
2.11. Microscopy Analysis 
2.11.1. Hematoxylin-eosin Staining 
Exponentially growing cells grown on coverglasses No. 1 thickness (Marienfeld Superior, 
Germany) were fixed in 4% paraformaldehyde for 20 min, briefly rinsed in PBS several 
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times, followed by washing under running water for 5 min. The coverglasses were stained in 
Haematoxylin solution for 5 min and washed under running water until the excess stains were 
removed. The slides were dipped in acid-ethanol (1% concentrated hydrochloric acid (v/v), 
70% ethanol (v/v)) and washed again under running water for another 5 min. The slides were 
then stained in Eosin-ethanol (1% Eosin Y (w/v) in 80% ethanol (v/v)) for 3 min, subjected to 
sequential dehydration, and mounted for analysis. 
2.11.2. Immunohistochemistry 
Human ovarian cancer sections were purchased in a tissue microarray format from Cybrdi 
(Cat# CC11-11-005; USA). Alternatively, formalin-fixed and paraffin-embedded surgical 
specimens from human lung and colon cancer patients obtained from The First Affiliated 
Hospital of Zheng Zhou University (China) were prepared for immunohistochemistry (IHC) 
by sectioning into 5 μm-thick sections using a model 2050 microtome (Reichert-Jung, USA). 
Adjacent sections were subsequently mounted on polylysine coated slides (Polysciences Inc., 
USA) and dried on a Leica 1220 hot-plate (USA) set at 37°C overnight. For IHC, tissue 
sections were first depariffinized and rehydrated in the following sequence: xylene (2 x 3 
min), 100% ethanol (3 x 3 min), 90% ethanol (3 min), 70% ethanol (3 min), 50% ethanol (3 
min), water (2 x 3 min). Antigen retrieval was achieved by boiling sections in 0.1 M citrate 
buffer pH 6.0 for 14 min in a 2100 Retriever (PickCell Laboratories, USA) followed by 
cooling for 3 h at RT. Subsequently, sections were washed in PBS thrice, quenched with 1% 
H2O2 (v/v) for 5 min at RT, and washed with PBS-T (PBS with 0.2% Tween-20) another 3 
times. Sections were then blocked in FDB (PBS containing 5% goat serum and 2% BSA) for 
1 h at RT, and incubated overnight at 4°C with primary antibody diluted in FDB. Sections 
were washed 3 times with PBS-T and incubated with biotinylated secondary antibodies in 
PBS-T for 1 h at RT. After washing thrice in PBS-T, an avidin-biotin complex (Dako, 
Denmark) was incubated with the sections for 1 h at RT, washed 2 times with PBS and once 
39 
 
with TBS before finally incubating with 0.12% nickel-DAB solution (w/v) in TBS. Upon 
visible light brown staining of sections, development was stopped by washing slides in water 
twice for 5 min and finally mounted in aqueous mounting media for photomicrography using 
a Zeiss Axioplan upright microscope (Carl Zeiss AG, Germany) equipped with a SPOT 
Insight color camera (SPOT Imaging, USA). The intensity of PRL-3 immunoreactivity was 
assessed independently by 2 researchers and scored as 1 point for no staining, 2 points for 
weak staining, 3 points for moderate staining, and 4 points for strong staining. β-catenin was 
similarly analyzed but scored with an additional consideration of 5 points for the very strong 
staining seen in some samples. With regards to positive control, we used colon cancer 
sections previously known to overexpress PRL-3 or β-catenin. Negative controls had the 
primary antibody omitted.  
2.11.3. Immunofluorescence 
For immunoflourescence of tissue sections, a similar protocol to IHC was used, with the 
exclusion of the H2O2 quenching step and using fluorophore-conjugated secondary antibodies 
instead of biotinylated antibodies. For cultured cells on glass coverslips, cells were briefly 
rinsed in warm (37°C) PBSCM (PBS supplemented with 1 mM CaCl2 and 1 mM MgCl2), 
fixed in 4% methanol-free formaldehyde for 15 min at RT, and thoroughly washed in PBSCM 
3 times, 5 mins each. Cells were then permeabilized using 0.5% saponin (w/v) in PBSCM for 
10 min, washed 3 times in TBS-T, and incubated with primary antibodies diluted in FDB for 
1.5 h at RT. After washing 3 times with TBS-T, secondary antibodies diluted in FDB were 
added to cells for 1 h at RT. Following this, cells were washed for 5 mins each in the 
following sequence: once with TBS-T, once with TBS-T containing 0.5 ug/mL 
Hoescht33342, and once more in TBS-T. For F-actin staining, rhodamine-phalloidin diluted 
in PBS was added to permeabilized cells for 20 min, followed by washing as described above 
after secondary antibody. Coverslips were mounted with one drop of antifade reagent in PBS-
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glycerol (Biomedia Corp., USA) and immediately analyzed using an LSM700 confocal 
microscope equipped with its associated ZEN software (Carl Zeiss AG, Germany). 
2.12. Cell Proliferation Assays 
2.12.1. Trypan blue cell viability assay 
2 x 104 cells were seeded in 10% FBS media in quadruplate into a 6-well plate and allowed to 
attach overnight. The medium was then replaced with 0.5% FBS media with or without 10 
nM cetuximab, and left to incubate for 4 days. Subsequently, cells were harvested by 
trypsinization and were counted using a Vi-CELL XR cell viability analyzer (Beckman 
Coulter, USA), with viable cells identified by the absence of intracellular trypan blue staining 
[133]. 
2.12.2. MTS assay 
For MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assays, 2 x 103 cells were seeded in 10% FBS media into triplicate wells of a 96-
well plate and allowed to attach overnight. The medium was then replaced with 0.5% FBS 
media with or without 100 nM cetuximab, and left to incubate for 4 days. The media was 
subsequently aspirated, and replaced with 150 uL 0.5% FBS media containing MTS 
(Promega, USA) and formazan development was done for 2 h at 37° at 5% CO2 before 
measuring absorbance at 490 nm (formazan product) and 630 nm (reference wavelength) in a 
spectrophotometer. 
2.13. Monolayer Clonogenicity Assay 
300 cells were seeded in 10% FBS media into 10 cm dishes and allowed to attach overnight. 
The medium was then replaced with 10% FBS media with or without 20 nM cetuximab and 
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incubated for 10 days. To quantify colony formation, cells were washed twice with ice-cold 
PBS before fixing in ice-cold 20% methanol for 10 min. Subsequently, 0.5% crystal violet 
(w/v) in 25% methanol was used to stain colonies for 10 min, and thoroughly washed in 
deionized water before image acquisition. Colonies with diameters ≥ 2 mm were counted and 
used in statistical analysis. 
2.14. Cell-Cell Adhesion Assay 
This assay is a modification of a previously described method for quantitation of intercellular 
adhesion [134]. Briefly, ‘bait’ cells were seeded in triplicate in a 96-well plate (5 x 105 
cells/well) to obtain a confluent monolayer the next day. In a separate culture vessel, ‘prey’ 
cells were harvested by trypsinization, washed once with 10% FBS RPMI and twice with 
serum-free RPMI. Cells were suspended in serum-free RPMI containing 2 mg/mL HRP, and 
incubated for 15 min at 37°C to allow HRP internalization. After a further wash with serum-
free RPMI, 5 x 104 HRP-labelled ‘prey’ cells were added to ‘bait’ monolayers and incubated 
for 1 h at 37°C. Nonattached cells were removed by washing twice with warm (37°C) serum-
free RPMI. 200 μL HRP-substrate buffer (0.5 mg/mL OPD, 0.5% Triton X-100, 2.5 mM 
H2O2 in 0.1 M citrate buffer, pH 6.0) was added to each well and color development was 
stopped after 5 min by adding 50 uL 1.25 M H2SO4 per well. The OD of the colored product 
was measured at 492 nm, while the OD 670nm was used as a reference wavelength for 
background correction. 
2.15. Wound Healing Assay 
70 uL of trysinized cells in suspension (6 x 105 cells/mL) were seeded into each well of a cell 
Culture-Insert (ibidi GmbH, Germany) in 10% FBS media and allowed to attach overnight. 
The next day, the establishment of confluent monolayers was verified by phase-contrast 
microscopy prior to removal of the Culture-Inserts and formation of a 500 µm ± 50 µm gap 
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(or ‘wound’). Cells were then washed in serum free media before incubation with 0.5% FBS 
media containing PBS, cetuximab (30 nM), DMSO (0.1%) or erlotinib (2 μM). Cells were 
incubated for up to 96 h and photomicrographs were acquired at the specified intervals using 
an Eclipse TE2000-U inverted microscope (Nikon, Japan) coupled to a Camedia C-7070 
digital camera (Olympus, Japan). 
2.16. Bioinformatics Prediction of Phosphorylation Sites in PRL-3 
The coding sequence published for human PTP4A3 isoform 1 (PRL-3; CCDS ID 6382) in the 
Consensus Coding Sequence (CCDS) database was used as an input parameter for consensus 
phosphorylation site prediction using 2 unique, freely-available bioinformatic tools, GPS2.1 
and PhosphoMotif Finder. GPS2.1 uses a hierarchal prediction algorithm for discovering 
known and novel substrate motifs [135], whereas PhosphoMotif Finder limits prediction only 
to literature curated phosphorylation-based substrate motifs [136]. A low threshold was used 
in GPS2.1 to get maximum coverage of potential PRL-3 kinases. 
2.17. Human Breast Cancer Microarray Dataset Analysis 
A breast cancer dataset (GSE12276) comprising primary breast cancer specimens from 
patients with metastatic disease was used to investigate the association between mRNA 
expression levels of PRL-3 (PTP4A3) and PTP1B (PTPN1) as well as the correlation between 
mRNA expression of PRL-3 and patient survival. The dataset consisting of microarray and 
survival data from 204 breast cancer patients was available in Gene Expression Omnibus 
(GEO) database. The microarray data were pre-processed using RMA algorithm in 
Bioconductor for normalization. For survival analysis, patients were divided into 2 groups, 
high or low, based on the mRNA expression level of PRL-3 or PTP1B, using their median 
value as a cut-off point.  
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2.18. Statistical Analysis 
For the cell-cell adhesion assay and all proliferation assays, the Student’s t-test was used to 
test for significant differences. For qRT-PCR, the paired t-test was used to analyze biological 
triplicates for significance. For statistical correlation of PRL-3 and β-catenin expression levels 
in ovarian cancer IHC samples, Spearman’s rank test was used. Finally, in analyzing the 
human breast cancer sample microarray dataset, the association between mRNA expression of 
PRL-3 and PTPN1 was analyzed using Spearman’s rank test. Kaplan-Meier analysis, 
compared by log-rank test, was also used to test the correlation between PRL-3 expression 
and patient survival. Statistical analysis was done using the SPSS 15.0 software package 
(IBM, USA), and p values < 0.05 were considered statistically significant.  
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CHAPTER 3: THE ROLE OF PRL-3 IN EPIDERMAL GROWTH FACTOR 
RECEPTOR ACTIVATION IN HUMAN CANCER CELLS 
3.1. Background 
As normal cells evolve progressively towards a neoplastic state, they acquire several 
essential features of cancer including uncontrolled growth, the overcoming of growth 
suppressors, evasion of cell death, induction of vascularization, invasiveness and motility, and 
ultimately metastasis [137]. Each stage of neoplastic transformation requires the activation of 
oncogenic signaling pathways which culminate in phenotypical alterations of cancer cells 
and/or their microenvironment. These signaling pathways are often perturbed by 
overexpression or gain-of-function mutations in proto-oncogenes, which are often innately 
linked to receptors for growth factors and often result in the aberrant activation of all the 
processes described above. 
The growth factor receptor family is composed of receptor tyrosine kinases (RTKs), G-
protein coupled receptors, and nuclear steroid hormone receptors. By bringing about their 
hyperactivation, cancer cells exploit growth factor receptor signaling in several ways 
including 1) overproduction of autocrine mitogenic ligands, 2) stimulating cells in their 
micro-environment to produce such ligands, 3) overproduction of receptors thereby rendering 
cells hypersensitive to otherwise limiting amounts of ligand, or 4) constitutive activation of 
receptor or downstream pathways by gain-of-function mutations [138,139].  
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the 
ErbB family, which consists of four receptors: ErbB1 (EGFR or HER1), ErbB2 (HER2), 
ErbB3 (HER3) and ErbB4 (HER4). All family members have in common an extracellular 
ligand-binding domain, a single membrane-spanning region and a cytoplasmic protein 
tyrosine kinase domain. Binding of epidermal growth factor (EGF) and its related ligands to 
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the ErbB family of receptors leads to the formation of active homo- or hetero-dimers which 
auto-phosphorylate each other, thereby activating the receptor fully and creating binding sites 
for adaptor proteins triggering a plethora of downstream signaling pathways regulating cell 
growth, differentiation, apoptosis, adhesion and migration (reviewed in [138]). Cancerous 
cells recognize the value of this – both ErbB ligands and receptors, particularly EGFR and 
HER2, are frequently overexpressed in many solid tumors and correlate with an unfavorable 
prognosis, decreased survival and altered response to chemotherapy [140-144]. Notably, 
HER2 is a non-autonomous member of the ErbB family as it has no known ligand [138]. Yet, 
upon forming dimeric complexes with each other or other members of the ErbB family, 
HER2 generates prolonged, potent signaling driving cell proliferation, migration and evasion 
of apoptosis [145]. 
In view of their well-documented contribution to tumorigenesis, members of the ErbB family, 
particularly EGFR, have become a major focus of anticancer drug development. Today, four 
clinically available EGFR antagonists have been approved for use in metastatic non–small-
cell lung cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and 
pancreatic cancer [146-150]. These include two antibodies against the extracellular domain of 
the receptor (cetuximab, panitumumab) and two small-molecule inhibitors that selectively 
inhibit the kinase activity of the receptor (gefitinib, erlotinib). Although only about 10-20% of 
patients show a clinical response to these drugs, long-lasting therapeutic responses have been 
observed, with non-responders primarily suffering from activating mutations in downstream 
signaling pathways, or an interference with drug binding and thus acquiring resistance [151]. 
In response to this, 10 novel EGFR-targeting agents are now in advanced clinical 
development for the treatment of various human cancers [148,152]. Promising results have 
also recently been documented for the clinically available ErbB2 antagonists trastuzumab and 
lapatinib, a humanized anti-ErbB-2 monoclonal antibody and small-molecule tyrosine kinase 
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inhibitor, respectively, leading to increasing efforts in the development of new agents 
targeting this receptor [153]. 
A key signaling pathway activated by the ErbB family is the Ras- and Shc-activated mitogen-
activated protein kinase (MAPK) pathway. Indeed, this pathway is an invariable target of all 
ErbB receptors, regardless of ligand identity or trans-stimulation by other kinases [145,154]. 
Although EGFR signals principally through the classical MAPK pathway, which comprises 
the Ras-Raf-MEK-ERK cascade, alternative MAP kinases including c-Jun amino-terminal 
kinase (JNK) and p38 MAPK, have also been documented to be activated upon EGF 
stimulation in a Ras-dependent fashion (reviewed in [155]). Since classical MAPK signaling 
plays a critical role in proliferation, survival and motility, it represents the most commonly 
exploited signaling arm of MAPK signaling in malignant transformation and, consequently, 
therapeutic intervention [156].  
Another important signaling pathway downstream of ErbB is the PI3K-activated Akt 
pathway. PI3K is composed of a p85 regulatory subunit and a p110 catalytic subunit. In 
response to growth factors, activated receptors interact with p85 Src homology (SH2) 
domains of PI3K and localize it to the plasma membrane, where it phosphorylates PI(4,5)P2 
to produce PI(3,4,5)P3, a key activator of various signaling proteins including Akt (reviewed 
in [157]). Because PI3K couples directly with ErbB3 and ErbB4, but indirectly with ErbB1 
and ErbB2, the potency and kinetics of PI3K activation differ between ErbB members 
[158,159]. Phosphorylated and activated AKT subsequently disassociates from the plasma 
membrane and translocates to different subcellular compartments where it exerts its biological 
activities including promoting cell growth, survival, proliferation, and angiogenesis by 
phosphorylating a diverse array of substrates (reviewed in [160]). Alterations of PI3K 
pathway components such as the activation of oncogenes, gene amplification, and inactivation 
of tumor suppressors, commonly occur in many human cancers. Indeed, because of its well-
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established role in tumorigenesis, PI3K signaling has become the subject of intense 
pharmaceutical research, with several PI3K pathway-targeting drugs in clinical trials [160]. 
PRL-3 has previously been shown to promote the phosphorylation of Ser473 of AKT, a 
critical activating residue located in the hydrophobic region on this kinase [23,90,110]. In 
DLD-1 colorectal cancer cells, this phenomenon was concomitant with a downregulation in 
protein expression levels of PTEN [90], the main negative regulator of AKT activity by 
dephosphorylation of PI(3,4,5)P. However, recent evidence from our lab suggested that PRL-
3 could increase AKT phosphorylation independently of PTEN downregulation in HCT116 
and A2780 cells [112]. This led me to hypothesize that PRL-3 might also act upstream of 
PTEN by promoting PI3K activity. Amongst the best characterized activators of PI3K are the 
RTKs. Indeed, effective targeted therapies against EGFR, ALK, Her2, KIT and PDGFR  
RTKs all invariably result in the downregulation of PI3K/AKT signaling [161-164]. 
Furthermore, in KRAS mutant colorectal cancer cells such as DLD-1 and HCT116, RTKs 
have been demonstrated to exert dominant control over PI3K signaling [165]. In light of these 
observations, I proceeded to investigate: 
i) Whether PRL-3 could activate any RTK and its downstream signaling pathways;  
ii) The molecular mechanism behind PRL-3 driven RTK activation; and 
iii) The effect of RTK inhibition on PRL-3’s oncogenic signaling and pro-proliferative 
functions. 
3.2. Outline of Experiment 
1. For RTK activation, EGFR-overexpressing A431 epidermoid carcinoma cells 
engineered to express EGFP or EGFP-PRL-3 were established and analyzed using an 




2. Downstream signaling pathways from activated RTKs were analyzed for activity 
using phospho-specific antibodies and co-IP techniques. 
3. The mechanism of RTK activation was investigated using growth factor antibody 
arrays, kinase inhibitors and analysis of RTK phosphatase expression. 
4. The relationship between expression levels of PRL-3 and PTP1B, an RTK 
phosphatase, was analyzed in a microarray dataset from human cancer patient 
samples. 
5. Finally, the therapeutic significance of EGFR activity to PRL-3 driven oncogenic 
signaling and cellular proliferation was investigated using EGFR-specific inhibitors. 
3.3. Results 
3.3.1. PRL-3 overexpression results in altered RTK phosphorylation in A431 cells 
 To study if PRL-3 could activate any RTK(s), I first engineered A431 epidermoid 
carcinoma cells to stably express either EGFP or EGFP-tagged PRL-3 (EGFP-PRL-3). A431 
cells were initially chosen because they overexpress EGFR and constitute a well-established 
model system routinely used in RTK activation and network modeling studies [166-169]. For 
medium-throughput analysis of RTK activation, I used an immobilized antibody array to 71 
unique RTKs which, in combination with a secondary phospho-Tyr antibody, could be used 
to infer individual RTK activation status. Using tyrosine phosphorylation as an indicator of 
activity, I observed several differences in RTK activation status between A431 cells stably 
expressing either EGFP or EGFP-PRL-3 (Fig.3A, B). Using a densitometer, I quantified the 
blot density for each RTK pair (spotted on the array in duplicate) and compared the fold 
changes between A431 EGFP and EGFP-PRL-3 cells. Densitometry analysis revealed that in 
A431 EGFP-PRL-3 cells, ErbB2, Axl and EGFR had the highest upregulated tyrosyl 
phosphorylation, whereas Lyn, Tie-2 and ZAP70 had the greatest decrease in tyrosl 
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phosphorylation (Fig. 3C). The complete list of densitometry results is provided in Appendix 
III. To validate the results from the antibody array, I used phospho-specific antibodies against 
EGFR (Tyr1068) and ErbB2 (Tyr887) to monitor their phosphorylation status. Axl, due to a 
lack of phospho-specific antibody, was instead analyzed by immunoprecipitation and general 
phospho-Tyr immunoblotting. In each case, I managed to recapitulate the increased 
phosphorylation of all three RTKs in A431 EGFP-PRL-3 cells directly by Western blotting 
(Fig. 3D). Notably, although ErbB2, Axl and EGFR all showed increased phosphorylation in 
A431 EGFP-PRL-3 cells, for ErbB2, this was related to an increase in total ErbB2 expression 
level (Fig. 3D). In conclusion, PRL-3 overexpression results in changes in the tyrosine 




Figure 3: PRL-3 overexpression results in changes in RTK phosphorylation in A431 
cells. A, exponentially growing A431 EGFP or EGFP-PRL-3 cells were lysed and analyzed 
using an antibody array to 71 unique RTKs. A phospho-Tyr secondary antibody was used to 
visualize ‘activated’ RTKs. Top three ‘activated’ RTKs are boxed in blue, whereas top three 
‘inactivated’ RTKs are boxed in red. The rightmost panel shows the stable expression levels 
of EGFP and EGFP-PRL-3 in the cells used for the analysis. B, antibody map of the RTK 
array used. C, arrays from A were analyzed using densitometry and fold changes in individual 
spots were quantitated after normalizing to the positive controls on each membrane. The top 
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three ‘PRL-3-activated’ or ‘PRL-3-inactivated’ RTKs are indicated. The dashed line indicates 
the lowest limit of densitometry detection. D, validation of the antibody array results from A. 
A431 EGFP or EGFP-PRL-3 immunoprecipitates (IP: Axl) or total cell lysates (TCL) were 
immunoblotted with antibodies against phospho-tyrosine (Axl), activated phospho-EGFR 
(Y1068) or activated phospho-ErbB2 (Y887). Blots for phosphorylated EGFR and ErbB2 
were subsequently stripped and reprobed for their total protein counterparts. GAPDH served 
as a loading control. 
 
3.3.2. PRL-3 constitutively activates EGFR and its downstream signaling pathways 
 Since PRL-3 is a dual-specificity PTP, the finding that PRL-3 overexpression could 
result in increased RTK phosphorylation was intriguing and prompted me to analyze the net 
effect of the observed RTK activity changes. When comparing the tyrosine phosphorylation 
levels of total cell lysates from A431 EGFP and EGFP-PRL-3 cells, in the latter, I noted a 
pronounced increase in tyrosine phosphorylation of an approximately 160kDa protein under 
unstimulated, serum-starved conditions (Fig. 4A). In addition, the phosphorylation of this 
160kDa protein could be massively upregulated upon EGF stimulation (Fig. 4A). Since A431 
cells overexpress EGFR, these results collectively suggested the 160kDa protein to be either 
EGFR or an EGFR downstream substrate such as ErbB2, which was also earlier identified as 
an activated RTK in A431 EGFP-PRL-3 cells. To validate this possibility, I analyzed the 
phosphorylation of EGFR under both serum starved (0% serum) and normal culture 
conditions (10% serum). Intriguingly, activation-associated phosphorylation of EGFR at 
Tyr1045 was consistently higher in A431 EGFP-PRL-3 compared to A431 EGFP cells, 
regardless of serum supplementation (Fig. 4B). To investigate if the increased EGFR Tyr1045 
phosphorylation correlated with downstream signaling in EGFP-PRL3 cells, I  
immunoprecipitated EGFR from A431 EGFP and EGFP-PRL-3 cells to check for binding of 
Grb2, an adaptor protein which couples EGFR activation to Ras signaling by binding directly 
at Tyr1068 of the activated receptor [170,171]. In unstimulated conditions, more Grb2 was 
found bound to EGFR in A431 EGFP-PRL-3 compared to A431 EGFP cells (Fig. 4C). This 
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result hinted that PRL-3 might increase the basal activity of EGFR, an intriguing possibility 
which I went on to test further. Using phospho-specific antibodies against different activated 
EGFR downstream targets, I found increased phosphorylation of Src homology 2 domain 
containing transforming protein 1 (Shc), signal transducer and activator of transcription 1 
(STAT1), E twenty-six ETS-like transcription factor 1 (ELK1), and the MAP kinases 
ERK1/2, JNK and p38 MAPK in A431 EGFP-PRL-3 cells compared to A431 EGFP cells 
(Fig. 4D). ErbB2, a well-characterized heterodimeric binding partner and substrate of EGFR, 
was also more highly phosphorylated in A431 EGFP-PRL-3 cells (Fig. 4D), in agreement 
with my previous result. GRB2-associated-binding protein 1 (Gab1) is a docking protein 
which, upon RTK-induced tyrosyl-phosphorylation, recruits PI3K to RTKs and results in 
activation of PI3K/AKT signaling [172]. In A431 EGFP-PRL-3 cells, Gab1 was found to be 
more highly phosphorylated, with a corresponding increase in AKT phosphorylation (Fig. 
4D). Significantly, this phenomenon was uncoupled to downregulation of PTEN (Fig. 4D). In 
light of these results, I concluded that PRL-3 increases EGFR phosphorylation and its 
corresponding signaling along several signaling pathways including the Ras/MAPK, 




Figure 4: PRL-3 overexpression induces constitutive EGFR signaling in A431 cells. A, 
A431 EGFP and EGFP-PRL-3 cells were serum starved for 16 h and stimulated with 100 
ng/mL EGF (20 min) where indicated. Lysates were collected and used for immunoblotting 
with anti-phospho-Tyr and anti-EGFP antibodies. Arrow, a PRL-3-induced, EGF-responsive 
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tyrosine-phosphorylated 160kDa protein, detected under starved conditions. Molecular 
weights in kilodaltons (kDa) are indicated on the left of the blot. B, lysates from A431 cells 
grown overnight in culture media with 10% FBS or 0% FBS were analyzed by 
immunoblotting with anti-phospho-EGFR (Y1045) and total EGFR antibodies. GAPDH 
served as a loading control. C, after treatment as in A, lysates from A431 EGFP and EGFP-
PRL-3 cells was used for immunoprecipitation with an anti-EGFR antibody and 
immunoblotted with anti-EGFR and anti-Grb2 antibodies. TCL, total cell lysate. D, the 
activation status of various signaling components downstream of EGFR was analyzed in 
A431 EGFP and EGFP-RL-3 cells directly using phospho-specific antibodies, or by 
immunoprecipitation and phospho-tyrosine immunoblotting (Gab1). Also included were 
antibodies against total EGFR, ERK1/2 and PTEN. GAPDH served as a loading control. 
 
3.3.3. PRL-3 activation of EGFR is independent of ligand stimulation and partially 
dependent on Src activity 
  Upon validation of the PRL-3 induced activation of EGFR and its downstream 
signaling pathways, I next sought out the molecular mechanism responsible for this 
phenomenon. RTK phosphorylation is regulated by (1) ligand binding and subsequent auto-
activation, (2) trans-activation by other kinases, and (3) inactivation of intracellular 
phosphatases. Obviously, PRL-3 could not be the direct EGFR phosphatase, as its increased 
expression corresponded to increased EGFR phosphorylation. To investigate the involvement 
of any secreted ligands for the RTK activation observed, I used an antibody array against 41 
different growth factors to analyze the conditioned medium from A431 EGFP or EGFP-PRL-
3 cells. No difference in secreted growth factor levels were observed between A431 EGFP 
and A431 EGFP-PRL3 cells, including known EGFR ligands such as EGF, transforming 
growth factor-α (TGF-α), heparin-binding EGF-like growth factor (HB-EGF) and 
amphiregulin (AR) (Fig. 5A, B). This result made it unlikely that the changes in RTK 
activation were due to increased autocrine stimulation. Src is a pleiotropic kinase which is 
known to modulate the activity and signaling of multiple RTKs, particularly EGFR and 
platelet-derived growth factor receptor (PDGFR), by direct phosphorylation [173,174]. Since 
PRL-3 was previously reported to activate Src in transformed human embryonic kidney cells 
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[18], I investigated the involvement of Src in PRL-3-induced EGFR phosphorylation in A431 
cells. In agreement with previous reports [18], overexpression of PRL-3 led to the 
downregulation of inhibitory Tyr530 phosphorylation on Src (Fig. 5C).  Alluding to a role for 
Src in EGFR activation, treatment of A431 cells with PP2, a potent Src family kinase 
inhibitor, slightly reduced EGFR Tyr1068 phosphorylation in A431 EGFP-PRL-3 cells but 
not A431 EGFP cells (Fig. 5C). In contrast, treatment with tryphostin AG-1478, a highly 
selective and potent EGFR inhibitor, abolished EGFR Tyr1068 phosphorylation in both cell 
lines (Fig. 5C). This suggested that intrinsic EGFR activity was predominantly responsible 
for auto-phosphorylation on Tyr1068 of the receptor. As mentioned previously, activation of 
EGFR in A431 EGFP-PRL-3 cells results in elevated activity of multiple signaling pathways, 
including STATs. As a positive control for Src inhibition, I analyzed the phosphorylation of 
STAT5, a Src substrate [175,176]. Unlike EGFR phosphorylation, STAT5 phosphorylation in 
A431 EGFP-PRL-3 cells was abolished upon PP2 treatment (Fig. 5C), indicating that the Src 
was only partially involved in PRL-3-induced EGFR hyperphosphorylation. Supporting a 
dominant role for Csk in the regulation of Src Y530 phosphorylation, EGFR inhibition did not 
abolish the PRL-3 mediated downregulation of Src Y530 phosphorylation (Fig. 5C). 
Collectively, these results implied that PRL-3-induced RTK phosphorylation, at least for 
EGFR, was independent of autocrine growth ligand stimulation and unlikely attributed to Src 




Figure 5: EGFR activation by PRL-3 is independent of autocrine ligand stimulation and 
Src activity. A, A431 EGFP and EGFP-PRL-3 cells were grown for 20 h in serum-free 
medium before the conditioned medium was collected and used on an antibody array for 41 
different growth factors. EGFR ligands are boxed in blue.  B, antibody map of the array used 
in A. C, exponentially growing A431 EGFP and EGFP-PRL-3 cells were treated with DMSO 
(0.1%, 16 h), PP2 (5μM, 16 h) or AG-1478 (2μM, 75 min) before lysates were collected and 
analyzed by immunoblotting with antibodies against phospho-EGFR (Y1068), phospho-
STAT5 (Y694), phospho-Src (Y527/Y530) and GFP. Blots for phosphorylated proteins were 
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subsequently stripped and reprobed for their total protein counterparts. GAPDH served as a 
loading control. 
 
3.3.4. PRL-3 transcriptionally downregulates PTP1B, an EGFR phosphatase 
 Besides ligand binding and Src activity, the third mechanism regulating EGFR 
phosphorylation is the activity of EGFR-directed phosphatases. EGFR dephosphorylation is a 
physiologically important means of terminating receptor signaling [177]. Since PRL-3 itself 
could not be the direct EGFR phosphatase, we investigated changes in PTP1B, a well-
characterized EGFR tyrosyl-directed phosphatase [178-180]. Interestingly, immunoblot 
analysis of A431 EGFP and EGFP-PRL-3 cells revealed a 1.6-fold decrease in PTP1B protein 
expression, concomitant with a 2-fold increase in the ratio of phosphorylated EGFR to total 
EGFR (pEGFR:EGFR) (Fig. 6A). To validate this finding in other cell types, I generated 
separate pools of MDA-MB-468 breast cancer cells overexpressing EGFP or EGFP-tagged 
PRL-3 and HCT116 colon cancer cells stably expressing either a scrambled or PRL-3-specific 
RNAi construct. Unexpectedly, unlike A431 cells, PRL-3 expression in both MDA-MB-468 
and HCT116 cell types affected total EGFR levels. Whereas PRL-3 induced EGFR activation 
in MDA-MB-468 cells was accompanied by a decrease in total EGFR levels, in HCT116 cells 
depleted of PRL-3, EGFR accumulation was evident (Fig. 6A). Nonetheless, when comparing 
the ratio of active EGFR to total EGFR (pEGFR:EGFR), a clear positive correlation was 
evident between PRL-3 expression and the proportion of activated EGFR in both these cell 
types (Fig. 6A), similar to that previously observed in A431 cells. Strikingly, the increase in 
ratio of phosphorylated EGFR in both these cell types were, similar to A431 cells, inversely 
related to PTP1B expression levels (Fig. 6A). To investigate if PRL-3 was downregulating 
PTP1B at protein or transcript level, I did quantitative real-time PCR (qRT-PCR) for PTP1B 
in A431 EGFP and EGFP-PRL-3 cells. A431 EGFP-PRL-3 cells had a 30% decrease in 
PTP1B mRNA levels, compared to A431 EGFP cells (Fig. 6B). This decrease mirrored a 
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similar reduction in PTP1B protein expression (37.5%; Fig. 6A), suggesting that PRL-3 was 
regulating PTP1B primarily at transcript level.  To validate if reduction in PTP1B mRNA 
expression could indeed regulate EGFR phosphorylation, I depleted A431 cells of PTP1B 
using a previously validated siRNA sequence [132]. In agreement with previous observations 
[178-180], PTP1B depletion resulted in an increase in EGFR phosphorylation (Fig. 6C). 




Figure 6: EGFR activation correlates with PRL-3 driven transcriptional downregulation 
of PTP1B. A, lysates from A431 EGFP, A431 EGFP-PRL-3, MDA-MB-468 EGFP, MDA-
MB-468 EGFP-PRL-3, and HCT116 cells stably expressing a scrambled (sh-scr) or PRL-3 
specific shRNA (sh-PRL-3) were analyzed by immunoblotting with antibodies against 
phospho-EGFR (Y1068), total EGFR, PTP1B, GFP and PRL-3. GAPDH served as a loading 
control. The top row of numerical values reflects the fold change in p-EGFR/EGFR blot 
densities between cell pairs, whereas the second row of numerical values reflects the fold 
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change in PTP1B/GAPDH blot densities between cell pairs. B, quantitative-PCR was used to 
analyze RNA extracted from A431 EGFP and EGFP-PRL-3 cells using primers specific to 
PRL-3, normalized to GAPDH (biological triplicate; mean ± SD, paired t-test, *p = 0.012). C, 
A431 cells were transiently transfected with non-specific siRNA (si-scr) or PTP1B-targeting 
siRNA (si-PTP1B), lysed, and analyzed with antibodies against phospho-EGFR and PTP1B. 
GAPDH served as a loading control. 
3.3.5. PRL-3 and PTP1B mRNA expression is inversely correlated in a cohort of metastatic 
breast cancer patients 
 The novel finding of an antagonistic relationship between two previously unrelated 
phosphatases, PRL-3 and PTP1B, was particularly intriguing as this relationship existed on 
the expression level of both phosphatases. To investigate the clinical relevance of this 
observation, I chose to analyze primary tumors in a publically available microarray dataset 
generated from a cohort of 204 metastatic breast cancer patients [181]. In a previous study 
using this dataset, the EGFR ligand HB-EGF was identified as a key mediator of breast 
cancer metastasis to the brain, suggesting that EGFR signaling played an important role in the 
metastatic dissemination of primary tumors in these patients [181]. When analyzing the raw 
data, tumors were first stratified into two groups according to PRL-3 expression level, with 
the higher quartile of PRL-3 expression used as a cut-off point (n = 51, high PRL-3; n = 152, 
low PRL-3). Using Kaplan-Meier analysis, I found that patients with high PRL-3 mRNA 
expression were found to have significantly shorter disease-free survival time (median 
survival = 20.5 months, 95% CI = 16.0 – 25.0) compared to those with low PRL-3 mRNA 
expression in their primary tumors (median survival = 28.1 months, 95% CI = 24.4 – 31.8, p 
= 0.021) (Fig. 7A). Adopting a similar approach for PTP1B revealed that although patients 
with low PTP1B had a shorter disease-free survival time compared to patients with high 
PTP1B expression, the observation was not significant (p = 0.113; data not shown). This 
result suggested that PRL-3 likely regulates molecular pathways other than those regulated by 
PTP1B alone in bringing about more aggressive disease. Nonetheless, when analyzing the 
raw data, I found that the levels of PRL-3 and PTP1B were significantly negatively correlated 
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(Spearman’s rank test, r = -0.168, p = 0.016; Fig. 7B). Indeed, patients expressing high levels 
of PRL-3 had a significantly lower PTP1B expression (mean ± S.E.M = 212.1 ± 10.3) 
compared to those expressing low levels of PRL-3 (mean ± S.E.M = 298.0 ± 18.4; Mann-
Whitney U test, p = 0.001; Fig. 7C), reinforcing the earlier correlation analysis using the raw 
microarray data. Thus, PRL-3 and PTP1B expression are antagonistically related in human 






Figure 7: PRL-3 expression is inversely correlated to disease-free survival and PTP1B 
expression in metastatic breast cancer patients. A, PRL-3 mRNA expression was 
negatively correlated with disease-free survival in metastatic breast cancer patients (n = 204; 
log rank test, p = 0.021). B, the absolute mRNA levels of PRL-3 and PTP1B were 
significantly negatively correlated in the raw dataset (n = 204; Spearman’s rank test, r = -
0.168, p = 0.016). C, stratified PRL-3 mRNA expression levels were significantly negatively 
correlated to raw PTP1B mRNA expression levels in metastatic breast cancer patient samples 
(n = 204; Mann-Whitney U test, p = 0.001).  
 
3.3.6. PRL-3 induces the dissolution of stress fibers and enriches F-actin filaments at sites 
of membrane protrusions in an EGFR-dependent manner 
 Because the patient dataset encompassed samples from metastatic breast cancer patients, 
I investigated if EGFR activation by PRL-3 could play a role in breast cancer cell migration.  
Cell migration involves the orchestrated assembly and disassembly of actin filaments. Using 
immunoflourescence analysis, I found a marked decrease in cytoskeletal F-actin stress fibers 
in MDA-MB-468 EGFP-PRL-3 cells compared to MDA-MB-468 WT or EGFP cells (Fig. 
8A). This observation is in agreement with previously published results [90], and is consistent 
with increased cell migration [182]. To validate if EGFR activation by PRL-3 could be 
involved in the decrease of stress fibers, I treated MDA-MB-468 EGFP-PRL-3 cells with 
erlotinib, a clinically-approved EGFR inhibitor [147]. Erlotinib treatment completely 
abolished PRL-3-induced stress fiber dissolution and returned the cells back to a similar state 
as seen in control cells (Fig. 8A). Besides modulation of stress fiber assembly, EGF 
stimulation has been previously shown to stimulate cell migration by formation of actin-rich 
membrane protrusions (lamellipodia) at the leading edge of migratory cells in a PI3K-
dependent manner [183]. In MDA-MB-468 EGFP-PRL-3 cells, I noted such an increase in F-
actin rich membrane protrusions at their leading edge (Fig. 8B). Similar to stress fiber 
disassembly, PRL-3-induced F-actin membrane projections could be completely blocked by 
EGFR inhibition using cetuximab (Fig. 8B), another clinically-approved EGFR inhibitor 
[149]. Interestingly, I observed that PRL-3 was polarized to the sites of membrane protrusions 
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(Fig. 8B, C), similar to previous observations [90]. PRL-3 has been reported to promote 
migration of cells in an ERK1/2-dependent manner [18,95]. Since 1) ERK1/2 lies 
downstream of EGFR and 2) EGFR inhibition could abolish the motile phenotype of MDA-
MB-468 EGFP-PRL-3 cells, I did a wound healing assay to analyze the effect of EGFR 
inhibition on the migration of these cells. Remarkably, erlotinib treatment dramatically 
retarded MDA-MB-468 EGFP-PRL-3 cell migration (Fig. 8D), suggesting that EGFR was a 
key intermediary between PRL-3 and cell motility. Collectively, these results suggest that 




Figure 8: PRL-3 promotes dissolution of stress fibers and increases F-actin rich 
membrane protrusions in an EGFR-dependent manner. A, MDA-MB-468 WT, EGFP or 
EGFP-PRL-3 cells were seeded on glass coverslips and fixed 48 h later. For erlotinib 
treatment, cells were incubated with 2 μM erlotinib 16 h prior to fixing. Cells were stained 
with AlexaFluor568-phalloidin to visualize F-actin. Bar, 20 µm. B, MDA-MB-468 EGFP or 
EGFP-PRL-3 cells were seeded and treated as in A but analyzed by dual immunoflourescence 
instead. For cetuximab treatment, cells were incubated with 100 nM cetuximab 16 h prior to 
fixing. Green, EGFP signal; red, F-actin. Bar, 10 µm. C, enlarged image of MDA-MB-468 
EGFP-PRL-3 cells showing co-localization of EGFP-PRL-3 and F-actin at membrane 
protrusions. Bar, 10 µm. D, monolayers of MDA-MB-468 EGFP-PRL-3 cells seperated by a 
0.5 mm gap were incubated in 0.5% FBS medium supplemented with DMSO or 2 uM 
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erlotinib and left to incubate for up to 96 h at 37°C. Phase-contrast images were captured at 
the indicated intervals. 
 
3.3.7. PRL-3 overexpressing cells are hypersensitive to EGFR inhibition in vitro 
 Because PRL-3 overexpressing cells constitutively displayed enhanced activation of 
signaling components involved in pro-survival and proliferative pathways including 
PI3K/AKT and MAPK, I investigated if inhibition of EGFR could potentially abrogate these 
tumorigenic signaling events. Treatment of both A431 EGFP and EGFP-PRL-3 cells with 
AG-1478 reduced both AKT and ERK1/2 phosphorylation levels. Unexpectedly, the 
reduction in phosphorylated AKT and ERK1/2 upon EGFR inhibition by AG-1478 was 
overtly greater in A431 EGFP-PRL-3 cells than in A431 EGFP cells (Fig. 9A). To confirm 
this phenomenon, I treated A431 EGFP and EGFP-PRL-3 cells with cetuximab, an FDA-
approved chimeric antibody which targets the extracellular domain of EGFR and leads to 
downstream signaling inhibition [184]. Treatment of these cells with a physiologically 
relevant cetuximab dose resulted in potent downregulation of phosphorylated EGFR in both 
cell lines (Fig. 9B). Significantly, phosphorylated AKT and ERK1/2 were reduced by a 
greater extent in A431 EGFP-PRL-3 cells compared to A431 EGFP cells (Fig. 9B), in 
agreement with the AG-1478 treatment results. Similar results were obtained upon treatment 
of MDA-MB-468 EGFP and EGFP-PRL-3 cells with erlotinib and cetuximab (Fig. 9C, D), 
thereby making the hypersensitive response to EGFR inhibition observed in PRL-3 
overexpressing cells unlikely to be cell type-specific. 
Since both AKT and ERK1/2 signaling play critical roles in growth and survival, I 
hypothesized that the inhibition of the hyperactivated EGFR signaling pathway in PRL-3 
overexpressing cells might have pronounced consequences on their growth and survival. To 
test this, I analyzed cell viability with or without cetuximab treatment using a trypan blue dye 
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exclusion assay. This assay is based on the principle that live cells possess intact cell 
membranes that exclude trypan blue [133]. Using this method, I found that exposure to 10 nM 
cetuximab for 4 days led to a significant decrease in A431 EGFP-PRL3 cell proliferation 
compared to A431 EGFP cells (72% versus 36% respectively, compared to the respective 
untreated cells; p < 0.001) (Fig. 9E). I repeated my study in the moderately cetuximab-
sensitive MDA-MB-468 cell line [185] to validate my observations. In line with previous 
reports on the sensitivity MDA-MB-468 to cetuximab [185], I found that lower 
concentrations of cetuximab (10 nM) did not elicit any significant difference between 
untreated and treated groups of MDA-MB-468 EGFP and EGFP-PRL3 cell proliferation (data 
not shown). However, when I increased the cetuximab concentration to 100 nM, I found a 
significant decrease in MDA-MB-468 EGFP-PRL3 cell proliferation compared to MDA-MB-
468 EGFP cells (31% versus 18% respectively, compared to untreated cells; p < 0.05) (Fig. 
9F). In a parallel approach, I investigated the ability of cetuximab to inhibit colony formation 
of A431 EGFP and EGFP-PRL3 cells using a monolayer clonogenicity assay. Although A431 
EGFP-PRL-3 cells formed significantly more colonies than A431 EGFP cells in control 
treated conditions, cetuximab treatment reduced A431 EGFP-PRL3 colony formation by a 
significantly greater extent than that of A431 EGFP (84% versus 66% respectively, compared 
to untreated cells; p < 0.05) (Fig. 9G).  ERK1/2 is an important mediator of PRL-3 mediated 
cell motility [18,61,95]. Since EGFR inhibition resulted in the enhanced reduction of ERK1/2 
phosphorylation in PRL-3 overexpressing cells (Fig. 9A-C), I did a wound healing assay on 
A431 EGFP and EGFP-PRL-3 cells in the presence of cetuximab.  Although both untreated 
cell types completed wound closure within 24 h, A431 EGFP-PRL-3 cells were slower than 
A431 EGFP cells in wound closure in the presence of cetuximab (Fig. 9H). This result was in 
agreement with my earlier results showing the ability of cetuximab and erlotinib to inhibit 
MDA-MB-468 EGFP-PRL-3 lamellopodia formation and cell motility, repectively (Fig. 8B, 
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D). Thus, hyperactivation of EGFR acts as the driver of PRL-3 induced AKT and ERK1/2 
activation in cancer cells and increases the susceptibility of these cells to EGFR inhibition. 
 
Figure 9: PRL-3 overexpressing cells are hypersensitive to EGFR inhibition. A, A431 
EGFP and EGFP-PRL3 cells were starved overnight and treated with DMSO (0.1%) or AG-
1478 (2 µM, 75 min) prior to lysis and immublotting with antibodies against phospho-EGFR 
(Y1068), phospho-AKT (S473), phospho-ERK1/2 (T202/Y204) and GFP. Two different 
exposures of phospho-AKT (S473) are shown for clarity. Blots for phosphorylated proteins 
were subsequently stripped and reprobed for their total protein counterparts. GAPDH served 
as a loading control. B, A431 EGFP and EGFP-PRL3 cells were starved in 0.5% FBS 
medium for 24 h in the presence of PBS or 10 nM cetuximab before lysis and analyzed as in 
A. Total ERK1/2 served as a loading control. C, MDA-MB-468 EGFP and EGFP-PRL3 cells 
were starved in 0.5% FBS medium for 3 h in the presence of DMSO (0.1%) or 2 μM erlotinib 
before lysis and analyzed as in A. D, MDA-MB-468 EGFP and EGFP-PRL3 cells were 
starved in 0.5% FBS medium for 24 h in the presence of PBS or 100 nM cetuximab before 
lysis and analyzed as in A. E, the inhibition of A431 EGFP or EGFP-PRL3 cell proliferation 
after 4 days treatment with PBS or 10 nM cetuximab in 0.5% FBS medium was measured by 
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counting viable cells using the trypan blue dye exclusion method (mean ± SD, n = 4, unpaired 
t–test, *p < 0.001). F, the inhibition of MDA-MB-468 EGFP or EGFP-PRL3 cell 
proliferation after 4 days treatment with PBS or 100 nM cetuximab in 0.5% FBS medium was 
measured by counting viable cells using MTS assay (mean ± SD, n = 3, unpaired t–test, *p < 
0.05). G, the inhibition of A431 EGFP or EGFP-PRL3 colony formation after 11 days 
treatment with PBS or 20 nM cetuximab in 10% FBS medium was visualized using crystal 
violet staining. Colonies with diameters larger than or equal to 2mm were counted and tested 
for significance (mean ± SD, n = 2, unpaired t–test, *p < 0.05, **p < 0.001). H, monolayers 
of A431 EGFP and EGFP-PRL-3 cells separated by a 0.5 mm gap were incubated in 0.5% 
FBS medium supplemented with PBS or 30 nM cetuximab and left to incubate for up to 48 h 
at 37°C. Phase-contrast images were captured at the indicated intervals. Dotted lines indicate 
cell monolayer borders on either side of the wound. 
 
3.4. Discussion 
 Despite previous observations on the activation of Src and AKT by PRL-3 in different 
cancer cell lines, no unifying mechanism has been proposed to explain the diverse signaling 
pathways regulated by PRL-3. Here, I present evidence for the activation of multiple RTKs, 
particularly EGFR, by PRL-3. PRL-3-induced EGFR hyperphosphorylation was linked to 
activation of MAPK, STAT and PI3K/AKT signaling pathways, and pharmacological 
inhibition of EGFR potently inhibited PRL-3-driven cell proliferation and migration. 
Untangling the mechanism of PRL-3 induced EGFR activation revealed a role for Src kinase 
and PTP1B, a well-characterized EGFR phosphatase, in trans-activation of the receptor. 
Significantly, an inverse relationship was found between PRL-3 and PTP1B expression in 
various cell lines as well as human breast cancer samples. Most importantly, I identified the 
heightened sensitivity of PRL-3 overexpressing cells to EGFR inhibition, thereby establishing 
a translational relevance of these findings. A proposed model for PRL-3 in regulation of 




Figure 10: Proposed model of PRL-3’s role in EGFR signaling. Dotted lines indicate 
indirect relationships, whereas solid lines indicate direct interaction. Although PRL-3 
localizes to both plasma and endosomal membranes, it is not reflected here for visual clarity 
of pathway interactions. See text for details. 
 
The aberrant activation of RTKs has been linked to malignant progression of many diseases, 
including cancer [186]. RTK co-activation imposes daunting challenges against effective 
molecular-targeted therapy of cancer due to signaling redundancies and receptor crosstalk 
[187,188]. In A431 cells, PRL-3 was found to modulate the activation of multiple RTKs, 
leading to activation of some (EGFR, ErbB2, Axl) and inhibition of others (Lyn, Tie-2, 
ZAP70) (Fig. 3). Although PRL-3 induced EGFR hyper-activation was consistently observed 
in MDA-MB-468 breast carcinoma cells and HCT116 colon carcinoma cells, it should be 
highlighted that the global changes in RTK activation pattern was not studied in these cell 
lines. To better understand the existence of conserved pathways and involvement of RTK co-
activation in PRL-3-induced oncogenesis, further experiments must be done using RTK 
activation arrays across these different cell types. Notably, I found PRL-3 overexpression to 
specifically increase the phosphorylation of the EGFR substrate ErbB2, but not ErbB3, in 
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A431 cells, implying that there exist additional levels of PRL-3 regulation beyond EGFR 
activation alone, such as selective receptor hetero-dimerization [145]. Another key finding 
from the activation array used in this study was the identification of Axl as a PRL-3 activated 
RTK (Fig. 3). Gas6 is a ligand for the TAM receptor family, which includes Tyro-3, Axl and 
Mer. Upon Gas6 binding, Gas6/Axl transduces intracellular signals via MAPK and 
PI3K/AKT pathways in a highly analogous manner to EGFR (reviewed in [189]). Like 
EGFR, Axl too is frequently overexpressed in many cancers, and its expression constitutes a 
poor prognostic factor in multiple cancer types [189]. Interestingly, although the trans-
activation of Axl by EGFR has not been described, Axl has been shown to be activated by 
heterodimerization with interleukin-15 receptor alpha [190]. Since activated EGFR has been 
reported to co-activate up to 10 other RTKs [167], it is plausible that EGFR could behave as 
the kingpin in activating the multiple RTKs observed in this study. This complex level of 
interaction needs to be further dissected using RTK-specific inhibitors or RNA interference to 
validate such a role for EGFR and identify other key RTK(s) regulated by PRL-3.  
Besides RTK activation, I also observed significant decrease in tyrosyl phosphorylation of 
several RTKs including ZAP-70, Tie-2 and Lyn (Fig. 3). Interestingly, none of these RTKs 
have documented roles in the progression of solid tumors. Whereas ZAP70 and Lyn have 
known functions in hematopoietic cells, Tie-2 is expressed almost exclusively on endothelial 
cells and plays important roles in vascularization [191-193]. Although the RTK array results 
were not validated for these receptors, it is plausible to hypothesize that PRL-3 might play a 
role in dephosphorylating these RTKs, revealing potentially novel roles for these receptors in 
solid tumor malignancies. Interestingly, phospho-activation of ZAP-70 has been shown to 
promote apoptosis during T-cell activation [191]. Nonetheless, amongst the RTKs identified 
in the initial screen, EGFR activation by PRL-3 appears important, at least in promoting PRL-
3 induced cell proliferation. 
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PRL-3 has previously been reported to indirectly activate c-Src via translational 
downregulation of c-Src kinase (Csk) in transformed human embryonic kidney cells [18,96]. 
Csk suppresses c-Src activation by phosphorylating Tyr530 (Tyr527 in chicken) in the 
carboxy-terminus of Src, leading to the formation of an inhibitory intramolecular interaction 
with the SH2 domain of Src itself [194]. Interestingly, c-Src trafficks with and transactivates 
EGFR by direct phosphorylation of Tyr845 in the cytoplasmic side of the receptor leading to 
further phosphorylation of the receptor at Tyr1068 and Tyr1173 in a manner comparable to 
that observed upon EGF stimulation [195,196]. In A431 EGFP-PRL-3 cells, I noted a 
reduction in Src phosphorylation at Tyr530, the major negative regulator of Src activity [194], 
in agreement with previous observations [18,96]. However, only a slight reduction in EGFR 
phosphorylation was observed in these cells upon treatment with Src inhibitor PP2, whereas 
STAT5 phosphorylation was completely abolished (Fig. 5C). These results argued in favor of 
alternative, non-Src-dependent pathways regulating EGFR phosphorylation.  
Several phosphatases have been reported to catalyze EGFR dephosphorylation, including 
protein tyrosine phosphatase 1B (PTP1B), T-cell protein tyrosine phosphatase (TC-PTP), 
receptor-type protein-tyrosine phosphatase κ (RPTPκ), and the non-receptor SH2-domain 
containing PTPs (SHP1/2) (reviewed in [177]). In this study, although the involvement of the 
other phosphatases described cannot be ruled out, I found PTP1B to be a predominant EGFR 
phosphatase associated with PRL-3 driven EGFR hyper-phosphorylation. The loss of PTP1B 
in A431 and MDA-MB-468 cell overexpressing PRL-3, and the accumulation of PTP1B in 
HCT116 cells depleted of PRL-3 were, in each case, concomitant with an increase or decrease 
in EGFR phosphorylation, respectively (Fig. 6A). These results give weight to the existence 
of a PRL-3-PTP1B-EGFR regulatory axis. The tumor-specific role of PTP1B is still poorly 
understood. PTP1B has been shown to suppress transformation of rat fibroblasts and retard 
lymphomagenesis in p53-null mice [197,198]. Recently, an analysis of system-wide PTP1B 
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candidate substrates revealed the tyrosyl phosphorylation levels of PLC-γ1, Gab1, SHP2, 
EGFR and SHP1 to be reduced by PTP1B [199]. Remarkably, all of these proteins are 
substrates and/or regulators of EGFR signaling [200]. The authors further showed that in 
transformed embryonic kidney cells, PTP1B’s primary output was to negatively regulate ERK 
phosphorylation and activation [199]. However, in stark contrast to these reports and my 
results here suggesting a tumor suppressive role for PTP1B, PTP1B has also been described 
as an activator of c-Src in cancer cells [180,201,202] and been shown to be required for 
ErbB2 transformation of breast cancer cells and play important roles in ErbB2-induced 
mammary tumorigenesis and lung metastasis [132,203,204]. Here, it should be noted that 
most reports of the oncogenic function of PTP1B have been related to cellular transformation 
mediated primarily by ErbB2 (or Her2/Neu), suggesting that such oncogenic functions of 
PTP1B may be specifically selected during cancer progression in tumors sharing this 
background. Collectively, these data suggest that the subtle control mechanisms of PTP1B 
action are heavily dependent on the cellular and genetic context, and that EGFR signaling is 
negatively regulated by PTP1B. Interestingly, in this study, I found a significant negative 
correlation between PRL-3 and PTP1B expression in human breast cancer patients where 
EGFR signaling was found to play a key role in metastatic dissemination of primary tumors 
[181]. In view of the fact that this dataset catalogued relatively aggressive primary tumors of 
metastatic breast cancers in which multiple pathways are undoubtedly working in concert to 
drive tumorigenesis, the ability to identify PRL-3, but not PTP1B, as a significant prognostic 
factor above this background reflects the importance of PRL-3, but not PTP1B, in the general 
etiology of metastasis. 
During the course of this study, two recently published reports hinted at the involvement of 
PRL-3 in RTK signaling. In the first study, a cell-based RNAi screen in two stable 
Drosophila cell lines implicated a role for PRL in insulin receptor signaling along the classic 
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RTK-Ras-ERK cascade [205]. Interestingly, Drosophila melanogaster only has a single PRL 
ortholog, sharing 53% identity with human PRL-3 [206]. In a second, more relevant study 
investigating candidate gene expression signatures related to cetuximab therapy response in 
CRC patients, PRL-3 (PTP4A3) was identified from a panel of 110 CRC-associated genes to 
strongly associate with therapy benefit across all three endpoints used – progression-free 
survival, objective response and disease control (p <0.0001) [207]. Remarkably, this latter 
result exactly mirrored my independent findings in vitro using A431 epidermoid cancer cells 
and MDA-MB-468 breast cancer cells wherein PRL-3 overexpression promoted 
hypersensitivity to cetuximab treatment in vitro (Fig. 9). This phenomenon is reminiscent of 
the concept of “oncogene addiction”, in which growth and survival of cancer cells may be 
overly dependent on a single dominant oncogene [208]. A profound implication of this 
concept is that terminating the signaling of a critical pathway on which cancer cells have 
become dependent should have detrimental effects on cell growth and survival whilst sparing 
normal cells less reliant on these pathways. Many dominant oncogenes have been described 
to confer such addiction (reviewed in [209]). For instance, in non-small cell lung cancer 
(NSCLC), activating mutations in EGFR and increased copy numbers have been found to 
both predict and underlie better response to gefitinib therapy [210,211]. In sharp contrast, 
activating PIK3CA and KRAS mutations abrogate any beneficial effect of cetuximab therapy 
as they activate signaling downstream and independently of EGFR [212,213]. In this study, I 
found that inhibition of EGFR signaling crippled MAPK and AKT signaling in PRL-3 
overexpressing cells, whereas control cells were significantly less affected (Fig. 9A-D).  
My results here, taken together with the identification of PRL-3 as a predictor of favorable 
patient response to cetuximab therapy, strongly suggests that PRL-3 hyper-activation of 
EGFR stems an “addiction” to pro-proliferative signaling from the receptor. Although further 
experimentation will be required to validate such dependence in different cancer cell types, it 
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remains an exciting and, in view of the availability of FDA-approved anti-EGFR drugs [214], 
a readily translatable therapeutic option against tumors overexpressing this phosphatase. 
Since phosphorylated EGFR positively correlates to AKT activation, invasiveness, and 
metastasis of invasive breast carcinomas and unfavourable overall survival [215], the 
activation of EGFR by PRL-3 could be an important keystone in EGFR-driven cancer 
progression. In this regard, prospective validation of PRL-3 overexpression as a predictor of 
the response to anti-EGFR therapy might be warranted, particularly in patients without 
activating mutations in PIK3CA or KRAS. 
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CHAPTER 4: THE ROLE OF PRL-3 IN CELL-CELL ATTACHMENT AND 
REGULATION OF ΒETA-CATENIN, AN ADHERENS JUNCTION COMPONENT, 
IN HUMAN OVARIAN CARCINOMA CELLS 
4.1. Background 
 The metastatic spread of tumor cells to distant sites represents the major cause of cancer-
related deaths. An early, pivotal event during the progressive evolution of solid cancers 
towards metastasis is the acquisition of cellular characteristics promoting invasiveness and 
motility. Adhesion molecules play important roles in the development of invasive, distant and 
recurrent metastasis by endowing tumor cells with the capacity to gain or lose interactions 
with their microenvironment and/or each other, permitting them to “move” or “stay” within 
local and distant microenvironments, respectively. Cell adhesion generally comprises two 
components: cell-matrix adhesion, and cell-cell adhesion. These comprise, and are regulated 
by, distinct subsets of more than 50 different cell adhesion molecules, many of which are 
differentially exploited by cancer cells to achieve metastasis (reviewed in [216]).  
Intercellular adhesion constitutes a significant physiological barrier to tumor cell 
dissemination during metastatic progression. The first key indicator of this was the classic 
observation that squamous cell carcinoma cells bound to each other with lower avidity than 
non-tumor cells [217]. Cell-cell adhesion is regulated by several protein families including 
cadherins, selectins, and the Ig superfamily [218]. Of these, cadherins are the best 
characterized for their involvement in cancer. Cadherin genes are often considered tumor 
suppressors because a reduction or loss of their expression has been consistently correlated 
with tumor progression [219,220]. The cadherin family consists of transmembrane Ca2+-
dependent adhesion receptors whose extracellular domains interact primarily in a homophilic 
fashion between neighboring cells, playing essential roles in tissue morphogenesis, cell 
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recognition, and cell segregation during development [221]. Classical cadherins include E-
cadherin, N-cadherin and P-cadherin. On the plasma membrane, these cadherins cluster in 
specialized cell-cell adhesion sites called adherens junctions. Within such adherens junctions, 
cadherin cytoplasmic tails interact with several key adaptor proteins responsible for 
connecting the cadherin macromolecule to the actin cytoskeleton, triggering activation of 
signal transduction cascades, and regulation of cadherin intracellular trafficking [222-224]. Of 
these, the best characterized adaptors are members of the armadillo/catenin family comprising 
α-catenin, β-catenin, γ-catenin/plakoglobin and p120-catenin. Because cadherin/catenin 
complexes synergistically regulate the function of adhesion complexes, the dysregulated 
expression or function of many of these adherens junctions components have been linked to 
malignancy [216]. Amongst the cadherins, E-cadherin represents the most dysregulated 
member – indeed, the loss of E-cadherin is central to the acquisition of invasive potential of 
tumor cells during EMT [219,225]. Likewise, since the loss of catenins generally reduces 
intracellular adhesion and promote motility, catenins too are subject to dysregulation in 
human cancers [218,226]. However, non-adhesion roles have also been well described for 
catenins, particularly p120 catenin and β-catenin [226]. Importantly, in contrast to negatively 
regulating tumor-suppressive adhesion, many of these non-adhesion roles contribute 
positively to the progression of multiple tumor types [227,228], demonstrating that the 
involvement of such catenins in malignancy is highly complex and tightly regulated. 
β-catenin is a prime example of such a tightly regulated multi-functional adhesion protein. 
Although initially discovered as a cadherin-binding protein [229], β-catenin was subsequently 
demonstrated to function as a transcriptional activator in the nucleus in complex with 
members of the TCF/LEF family of transcription factors [230]. β-catenin is the mammalian 
orthologue of armadillo, a segment polarity gene involved in the highly conserved 
wingless/Wnt signaling pathway first described in Drosophila [231]. A schematic of the 
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canonical Wnt signaling pathway involved in β-catenin regulation is shown in Fig. 11. 
Activation of the Wnt signaling pathway begins with binding of secreted Wnt glycoproteins 
to a family of seven-pass transmembrane receptors encoded by the frizzled gene and possibly 
with the single-pass transmembrane protein LDL-receptor-related proteins 5 and 6 (LRP5 and 
LRP6) [232-234]. Receptor activation leads to the phosphorylation of dishevelled (Dvl) 
which, through Frat-1/GBP, results in its association with glycogen synthase kinase 3β 
(GSK3β) and inhibition of the latter [235-238]. Key GSK3β substrates include β-catenin, as 
well as the negative regulators adenomatous polyposis coli (APC) and axin. Incidentally, in 
unstimulated conditions, these proteins, together with casein kinase I (CKI), co-exist in a 
large, multi-protein complex (Axin/APC degradation complex) which serves to constitutively 
bind and phosphorylate free cytosolic β-catenin on its four key amino-terminus residues 
Ser33, Ser37, Thr41 and Ser45 [239-243]. Amino-terminally phosphorylated β-catenin is 
subsequently recruited by β-TrCP into a distinct SCFβ-TrCP ubiquitin ligase complex, 
ubiquitinated and subject to proteasome-mediated degradation [240,244]. Upon GSK3β 
inhibition by activated Dvl, unphosphorylated β-catenin escapes B-TrCP-mediated 
ubiquitination, accumulates in the cytoplasm and translocates into the nucleus where it 
engages transcription factors TCF and LEF and exerts its role as a transcriptional activator 
[230,245]. An additional component of this pathway includes the protein Naked cuticle 
(Nkd). Nkd has been proposed to inhibit Dvl (Dsh in zebrafish) by directly binding and 
promoting its subsequent degradation [246-248]. Interestingly, Nkd1 was recently also shown 
to directly bind β-catenin and prevent its nuclear accumulation [249]. In agreement with a role 
in  β-catenin signaling, Nkd proteins have been shown to antagonize both canonical and non-
canonical Wnt signaling [246,248-250]. The degradation of Nkd proteins, in turn, is 
negatively regulated by direct interaction with the cytoplasmic tails of TGF-α in an EGFR-





Figure 11: The canonical Wnt signaling pathway regulating β-catenin stability. The blue 
shaded oval encompasses the core Axin/APC degradation complex responsible for N-
terminus phosphorylation of β-catenin. See text for details. 
 
Cytosolic β-catenin can also be targeted for proteosomal degradation independently of β-
TrCP recognition and phosphorylation via an alternative E3 complex comprising F-box 
protein Ebi and RING finger protein Siah [252]. Interestingly, p53 regulates the degradation 
of β-catenin via this latter pathway by controlling the expression of Siah [243]. Whereas the 
degradation machinery of free cytosolic β-catenin is relatively well studied, the regulation of 
cadherin-associated β-catenin degradation is poorly understood. Interestingly, the 
phosphorylation of both cadherins and β-catenin has been implicated in regulating the 
association of β-catenin with adherens junctions (reviewed in [253]). Significantly, β-catenin 
released from such cadherin/catenin complexes can enter the cytosolic pool and be subjected 
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to the abovementioned degradation mechanisms. Recently, Ozz, a member of the suppressors 
of cytokine signaling (SOCS) family, was reported to specifically target membrane-bound β-
catenin for degradation via a RING-type E3 ligase complex [254]. However, Ozz-E3 
expression is muscle-specific, and no reports to date have shown its involvement in β-catenin 
degradation in other cell types. 
Today, it is well recognized that aberrations in Wnt signaling contribute to cancer progression 
in human patients. This can occur via a number of genetic defects including the 
overexpression of Dvl, stabilizing mutations in β-catenin, downregulation of axin, and the 
inactivation of APC function via loss of heterozygosity, truncations, or mutations disrupting 
its ability to bind axin and β-catenin (reviewed in [255]). Indeed, dysregulation of Wnt 
signaling components has been reported in a plethora of malignancies including colorectal 
cancer, hepatocellular carcinoma, medulloblastomas, melanoma, endometrial cancer, 
hepatoblastoma, pancreatic cancer and prostate cancer [256-258]. Although many of these 
genetic insults result in β-catenin stabilization and inappropriate target gene activation, it is 
becoming increasingly apparent that the involvement of Wnt signaling in malignancy is not 
restricted to canonical β-catenin activation alone. In one such study, melanoma cells 
constitutively expressing Wnt5a were found to possess increased invasiveness independent of 
changes in β-catenin expression or nuclear translocation, but instead linked to an activation of 
protein kinase C (PKC) via a non-canonical pathway [259]. Similarly, Wnt11 stimulation of 
intestinal epithelial cells promoted its proliferation, migration and transformation in a manner 
independent of changes in β-catenin nuclear translocation, but again linked to an activation of 
PKC [260]. Collectively, the large body of evidence presented to date points to an important 
role for the activation of Wnt signaling, and consequently β-catenin, in cancer progression. 
Ovarian cancer causes more deaths of women in the United States than any other 
gynecological malignancy [261]. Relatively little is known about the molecular events that 
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lead to the development of ovarian cancer. Although most malignant ovarian tumors are 
epithelial and are thought to arise from the ovarian surface epithelium, different pathways and 
genetic alterations have been implicated in the development of cystadenomas, borderline 
tumors, and carcinomas of different histological subtypes and stages of progression [262-
264]. Prior to my joining Dr. Zeng Qi’s lab, a cursory low-throughput search using 
immunoblotting against a candidate list of potential PRL-3 regulated oncogenes in A2780 
ovarian carcinoma cells unexpectedly identified β-catenin as a downregulated protein (Wang 
HH, unpublished results). From the standpoint of its role as an oncogenic transcription factor 
in canonical Wnt signaling, this seemed contradictory to PRL-3’s described role as an 
oncogene. However, several accounts of a ‘tumor-suppressive’ role of β-catenin have been 
reported [265,266]. Particularly, correlations between reduced β-catenin expression and 
favorable patient prognosis have been reported in ovarian cancers [126,127,267]. It thus 
seemed plausible that this Jekyll and Hyde behavior might depend on which cellular pool of 
β-catenin is affected – that is, whether nuclear or membranous β-catenin is activated or 
downregulated [268]. To address the involvement of β-catenin in PRL-3 driven ovarian 
cancer progression, I set out to: 
i) Establish a relationship between differences in cell-cell adhesion and β-catenin 
expression; and, 
ii) Investigate the mechanism of PRL-3 downregulation of β-catenin expression; 
iii) Investigate the clinical relevance of the observed inverse relationship in human cancer 
samples. 
4.2. Outline of Experiment 
1. A2780 ovarian cancer cells either overexpressing either EGFP or EGFP-PRL-3, or 
stably expressing PRL-3-targeting shRNA constructs, were established and analyzed 
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for cellular morphology, cell-cell adhesion (using a modified cell adhesion assay) and 
β-catenin expression under normal growing conditions. 
2. The downregulation of β-catenin was investigated at transcript (RNA) and protein 
levels using semi-quantitative RT-PCR and immunoblotting, respectively, in the 
presence or absence of proteasome inhibition.  
3. Exogenous wild-type or a degradation-resistant mutant of β-catenin (β-catenin S33Y) 
was used to validate proteasomal regulation of β-catenin in A2780 cells (functional β-
catenin degradation complex) and SW480 cells (non-functional β-catenin degradation 
complex).  
4. Commercial antibodies against Wnt signaling pathway components were employed to 
detect the expression levels of various proteins involved in regulating β-catenin 
stability. 
5. Finally, the clinical relevance of the PRL-3-β-catenin relationship was analyzed in 
cancer patients’ tissue sections using immunohistochemistry (IHC) and 
immunofluorescence-IHC (IF-IHC) techniques. 
4.3. Results 
4.3.1. PRL-3 overexpression in A2780 cells results in altered cell morphology 
 The first clue of PRL-3’s possible involvement in cell adhesion came from general 
morphological observations of stable A2780 cell variants using phase-contrast microscopy. 
Whereas A2780 EGFP cells possessed an epithelial-like morphology, A2780 EGFP-PRL-3 
cells appeared smaller and highly rounded, with indistinct cell boundaries (Fig. 12A). This 
morphology of EGFP-PRL-3-transfected cells was not found to be changed because of the 
increase in cell density under the cell culture condition (data not shown). To confirm this 
overt phenotype, I generated A2870 cells stably depleted of PRL-3 and analyzed their 
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morphology. In stark contrast to A2780 EGFP and EGFP-PRL-3 cells, PRL-3 depletion in 
A2780 cells caused cells to appear somewhat “fused” – cell clusters seemingly shared 
continuous outer membranes encompassing enlarged, diffused cytoplasmic compartments 
(Fig. 12B). In fact, only upon trypsin treatment could individual cells be visibly distinguished 
in the latter (data not shown). These results strongly suggested that PRL-3 had an effect on 
cell adhesion and boundary formation in A2780 cells. 
 
Figure 12: A2780 cells display altered morphologies directly related to PRL-3 expression 
levels. A, phase-contrast photomicrograph of A2780 EGFP and EGFP-PRL-3 cells growing in 
culture dishes. B, H&E-stained photomicrograph of A2780 cells stably depleted with a PRL-




4.3.2. PRL-3 negatively regulates the intercellular adhesiveness of A2780 cells 
 As mentioned earlier, cell adhesion comprises both intercellular and cell-matrix 
interactions. To test the hypothesis that PRL-3 is affecting cell-cell adhesion, I used a 
modified cell-matrix adhesion assay [134]. A schematic of the assay is shown in Fig. 13A. In 
this assay, cell monolayers were first established in 96-well culture plates, carefully ensuring 
that no culture vessel surface was exposed. HRP-loaded cells were then added to the 
monolayer, incubated for 1 h at 37°C, and unbound cells were gently washed away. 
Subsequently, quantification of cell adhesion was done via a simple HRP-catalyzed reaction 
producing a colored dye measurable with a spectrophotometer. Important features of this 
assay are that the use of HRP label is nontoxic, does not affect the adhesion properties of 
cells, and the quantity of dye formed is proportional to the number of adherent cells [134]. 
Using this assay, A2780 EGFP-PRL-3 cells were measured to have a 37% reduction in cell-
cell adhesion compared to control A2780 EGFP cells (p < 0.001; Fig. 13B, C). In contrast, 
A2780 cells depleted of PRL-3 displayed a 107% increase in cell-cell adhesion compared to 
control A2780 EGFP cells (p < 0.05; Fig. 13B, D). These results mirrored that of the previous 





Figure 13: PRL-3 inhibits cell-cell adhesion of A2780 cells. A, schematic of the cell-cell 
adhesion assay employed. B, A2780 cells overexpressing EGFP, EGFP-PRL-3 or depleted of 
PRL-3 (shRNA PRL-3) were grown to confluent monolayers in separate wells of a 96-well 
plate. HRP-loaded cells of the same cell type were added to each well, and bound cells were 
quantified by a HRP-catalyzed colorimetric reaction (mean ± SD, n = 3, unpaired t–test, two-
tailed *p<0.01, **p < 0.001). C, relative stable expression levels of EGFP and EGFP-PRL-3 
in A2780. D, efficiency of PRL-3 knockdown in A2780 cells relative to A2780 EGFP cells. 
 
4.3.3. PRL-3 downregulates global β-catenin levels in A2780 cells 
 As mentioned earlier, β-catenin was identified in a screen as a PRL-3-downregulated 
protein in A2780 cells prior to my joining the lab. I verified this result and, importantly, 
showed that depletion of PRL-3 could also trigger pronounced accumulation of β-catenin in 
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A2780 cells (Fig. 14A), thus reaffirming a relationship between PRL-3 and β-catenin. There 
are two pools of β-catenin in mammalian cells: a cadherin-interacting, membrane-bound pool 
involved in adhesion, and a nucleo-cytoplasmic pool involved in transcription [269]. In light 
of this, it was of interest to investigate if PRL-3 might be regulating β-catenin in one or more 
of these subcellular compartments. To understand whether the nuclear and cytoplasmic levels 
of β-catenin were affected, I proceeded to sub-fractionate cells into these two compartments 
and analyze β-catenin expression. Remarkably, regardless of subcellular compartment, β-
catenin was potently downregulated in the presence of PRL-3 overexpression (Fig. 14B). An 
interesting observation to highlight here was the detection of EGFP-PRL-3 in the nucleus, but 
not free EGFP nor the cytosolic marker GAPDH (Fig. 14C). This observation is in line with 
previous reports suggesting a nuclear role for PRL-3 [26,79]. Nuclear β-catenin plays a role in 
the transcriptional activation of pro-proliferative genes including cyclin D1 and c-myc [227]. 
Surprisingly, the loss of β-catenin in A2780 EGFP-PRL-3 cells was correlated with an 
increase in cell proliferation (Fig. 14C), suggesting that PRL-3 promoted the proliferation of 
these cells in a β-catenin-independent manner. To address if the membranous pool of β-
catenin was downregulated by PRL-3, I did immunofluorescence analysis of the A2780 cell 
variants using an antibody against β-catenin. This antibody recognizes the amino-terminus of 
β-catenin, and detected predominantly membrane-bound, rather than cytoplasmic or nuclear, 
β-catenin (A2780 EGFP; Fig. 14D). Nonetheless, it was immediately apparent that an inverse 
correlation existed between PRL-3 expression and membranous β-catenin: in cells expressing 
PRL-3, membranous β-catenin was almost undetectable (A2780 EGFP-PRL-3; Fig. 14D). In 





Figure 14: PRL-3 is a potent negative regulator of global β-catenin protein expression in 
A2780 cells. A, exponentially growing A2780 EGFP, EGFP-PRL-3 or shRNA PRL-3 cells 
were lysed and analyzed for β-catenin expression levels. GAPDH was used as a loading 
control. B, A2780 EGFP and EGFP-PRL-3 cells were fractionated into nuclear and 
cytoplasmic fractions, and analyzed for β-catenin and EGFP. GAPDH served both as a 
loading control and cytosolic marker. Histone H3 was used as a nuclear marker. C, the 
proliferation of exponentially growing A2780 EGFP or EGFP-PRL3 cells as measured by 
using the MTS assay. D, A2780 EGFP and EGFP-PRL-3 cells were grown on glass 
coverslips for 24 h, fixed, and analyzed by immunofluorescence using an anti-β-catenin 
antibody. Merged images are shown in the bottom panel. Green, GFP signal; red, β-catenin.  




4.3.4. PRL-3 enhances the proteasomal degradation of β-catenin in APC-wild type A2780 
cells but not in APC-mutant SW480 cells 
 My earlier results clearly pointed to a global downregulation of β-catenin expression by 
PRL-3. Next, I investigated whether PRL-3 was regulating β-catenin at the protein level or 
transcript level. Since β-catenin is a proteasomally-degraded protein, inhibition of the 
proteasome results in accumulation of β-catenin in cells [270]. In agreement with this, 
treatment of A2780 EGFP and EGFP-PRL-3 cells for 6 h with MG132, a potent proteasome 
inhibitor, resulted in the accumulation of β-catenin (Fig. 15A). Significantly, β-catenin levels 
were rescued to similar levels as in control A2780 EGFP cells, implying that proteasome 
inhibition alone was sufficient to overcome the PRL-3-induced downregulation of β-catenin. 
To validate the regulation of β-catenin protein stability by PRL-3, I checked the mRNA level 
of β-catenin and found no difference between A2780 EGFP and EGFP-PRL-3 cells with or 
without MG132 treatment (Fig. 15B), supporting a role for PRL-3 in destabilizing β-catenin 
at the protein level. Phosphorylation of β-catenin on Ser33 has previously been shown to be 
critical for its degradation [270]. To confirm the PRL-3-mediated destabilization of β-catenin, 
I transfected cells with β-catenin constructs encoding the wild-type protein or β-catenin-
S33Y, which harbors a Ser33 to Tyr mutation that effectively renders it resistant to 
degradation [271]. As expected, transfection of wild-type β-catenin into A2780 EGFP and 
EGFP-PRL-3 cells revealed accumulation of the exogenous β-catenin only in A2780 EGFP 
cells (Fig. 15C), in line with the regulation of endogenous β-catenin. In contrast, β-catenin-
S33Y accumulated in both cell lines (Fig. 15C), confirming that the PRL-3-mediated 
regulation of β-catenin was, at least in part, via its phospho-regulated degradation. Finally, I 
analyzed the ability of PRL-3 to downregulate β-catenin in SW480 cells. SW480 cells were 
chosen because they harbor a truncated APC protein that is unable to bind and promote β-
catenin phosphorylation for subsequent ubiquitination and proteasomal degradation [272]. 
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Thus, if downregulation of β-catenin by PRL-3 was indeed regulated by phosphorylation of β-
catenin via the Axin/APC degradation complex, PRL-3 would be expected to have no effect 
on β-catenin stability in these cells. Indeed, both endogenous and exogenous wild-type β-
catenin protein expression levels were unaffected by PRL-3 in SW480 cells (Fig. 15D), 
reflecting a requirement for an intact β-catenin-degradation system for PRL-3 to 
downregulate this protein. Collectively, the data clearly prove that PRL-3 destabilizes β-
catenin by promoting its proteosome-mediated degradation. 
 
Figure 15: PRL-3 enhances the proteasome-mediated degradation of β-catenin. A, 
A2780 EGFP and EGFP-PRL-3 cells were treated with DMSO (-) or 10uM DMSO (+) for 6 
h. Lysates were checked for changes in expression levels of β-catenin and EGFP-PRL-3. p53 
was used as a positive control for proteasome inhibition. GAPDH served as a loading control.  
B, total RNA was isolated from cells treated as in A and used in semi-quantitative PCR to 
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detect β-catenin and p53 mRNA expression levels. C, A2780 EGFP and EGFP-PRL-3 cells 
were transiently transfected (24 h) with either DsRed-tagged β-catenin-WT or β-catenin-
S33Y. Lysates were analyzed for β-catenin and EGFP-PRL-3 expression. GAPDH served as a 
loading control. D, SW480 EGFP and EGFP-PRL-3 cells were transiently transfected (24 h) 
with DsRed-tagged β-catenin-WT or mock transfected. Lysates were analyzed for β-catenin 
and EGFP-PRL-3 expression. GAPDH served as a loading control. 
 
4.3.5. PRL-3 alters the expression of Naked (Nkd) and Dishevelled (Dvl) proteins involved 
in regulation of the axin/APC degradation complex 
 β-catenin degradation is mediated by the Wnt-regulated axin/APC degradation complex, 
a large, multi-component protein assembly containing a variety of proteins involved in 
binding β-catenin and regulating its phosphorylation ([243]; reviewed in [253]). To 
investigate if PRL-3 might regulate the function of this complex, I screened lysates from 
A2780 and SW480 cells overexpressing EGFP or EGFP-PRL-3 with an antibody sampler kit 
detecting a panel of integral proteins within the Wnt signaling pathway including Wnt3a, 
Wnt5a/b, LRP6, phospho-LRP6, Dvl2, Dvl3, Naked1 (Nkd1), Naked2 (Nkd2) and Axin1 
[273]. Although no changes were noted in most of the components listed, there was a 
surprisingly conserved regulation of Dvl2, Dvl3, Nkd1 and Nkd2 by PRL-3 in both cell line 
pairs tested. Significantly, PRL-3 promoted the upregulation of β-catenin negative regulators 
Nkd1 and Nkd2, whilst downregulating β-catenin positive regulators Dvl2 and Dvl3 (Fig. 
16A). Nkd1 and Nkd2 have previously been reported to promote Dvl degradation, thereby 
antagonizing canonical and non-canonical β-catenin signaling [246,247,250]. These changes 
were significant because they supported a requirement of an intact Axin/APC degradation 
complex for PRL-3 downregulation of β-catenin, and explained why no downregulation of β-
catenin was observed in SW480 cells despite similar alterations in these β-catenin regulatory 
proteins as in A2780 cells. Because Nkd2 levels were the most dramatically changed, and in 
view of its upstream role of regulating Dvl stability, I investigated if PRL-3 might upregulate 
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gene expression of Nkd2 by RT-PCR. No difference in Nkd2 levels were detected between 
A2780 EGFP and EGFP-PRL-3 cells (Fig. 16B). Interestingly, EGFP-PRL-3 overexpression 
promoted the accumulation of the fastest migrating bands of both Nkd1 and Nkd2 (Fig. 16A), 
suggesting that PRL-3 might regulate the post-translational modification of these proteins and 
their subsequent stability. In conclusion, PRL-3 increases the activity of the Axin/APC 
destruction complex by upregulating the negative regulators of β-catenin stability, Nkd1 and 
Nkd2, while downregulating the positive regulators of β-catenin stability, Dvl2 and Dvl3.  
 
 
Figure 16: PRL-3 overexpression leads to downregulation of β-catenin positive 
regulators, Dvl2 and Dvl3, and upregulation of β-catenin negative regulators, Nkd1 and 
Nkd2, in both A2780 and SW480 cells. A, lysates from exponentially growing A2780 
EGFP, EGFP-PRL-3 and SW480 EGFP, EGFP-PRL-3 cells were analyzed for expression 
levels of Dvl2/3 and Nkd1/2. GAPDH served as a loading control.  B, cDNA isolated from 
A2780 EGFP and EGFP-PRL-3 cells were analyzed by semi-quantitative PCR to detect 




4.3.6. PRL-3 and β-catenin are inversely correlated in human cancer patient specimens 
 Although the upregulation of Wnt/β-catenin signaling has previously been implicated in 
the progression of multiple cancer types [227,274], my results presented thus far suggested a 
tumor-inhibitory role for β-catenin in PRL-3 driven metastasis. To investigate the possible 
clinical relevance of PRL-3-mediated downregulation of β-catenin, I analyzed tissue samples 
from different human cancers using immunohistochemistry and immunofluorescence 
techniques. Since A2780 cells were derived from an ovarian carcinoma tumor, I first analyzed 
a commercially-prepared ovarian cancer tissue microarray for PRL-3 and β-catenin 
expression by immunohistochemistry. Fig. 17A shows representative staining results from 
PRL-3+/β-catenin- and PRL-3-/β-catenin+ cancer samples. As described in the Materials and 
Methods section, patient samples were independently scored for PRL-3 or β-catenin 
expression levels; the results of this analysis are given in Appendix IV. When I tested the 
correlation between PRL-3 and β-catenin in tumors staining positive for at least one of the 
two proteins in adjacent sections of the tumor tissue samples on the microarray, I found a 
statistically significant inverse relationship between the expression levels of these two 
proteins (n = 42, Spearman’s rank test, p < 0.05). These results indicated that overexpression 
of both PRL-3 and β-catenin was rarely observed in the same ovarian cancer tissues. To 
analyze if this negative correlation existed in other cancer tissues, I analyzed individual 
adjacent tissue samples from colon and lung cancer patients. Interestingly, in both cancer 
samples tested, I found occurrences of a profound negative relationship between PRL-3 and 
β-catenin expression. Representative results from this individual patient-specific analysis are 
presented in Fig. 17B, C. PRL-3 overexpression in both cancer types correlated with a 
reduction in membrane-bound β-catenin staining, supporting the PRL-3 driven 
downregulation of this protein at adherens junctions (Fig. 17B, C). Interestingly, I noted an 
upregulation of PRL-3 in migratory cells, apparently dissociated from the surrounding tumor 
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epithelium, which completely lacked membrane-bound β-catenin staining (Fig. 17C, centre of 
viewing field). In conclusion, my results here suggested that a negative relationship existed 
between PRL-3 and β-catenin in different human cancer samples, supporting the in vitro data 
obtained previously. 
 
Figure 17: PRL-3 and B-catenin expression is inversely correlated in human cancer 
samples. A, the expression of PRL-3 and β-catenin in adjacent sections of a human ovarian 
cancer tissue array was analyzed using the immunohistochemistry technique. Upper panel, a 
representative PRL-3-positive, β-catenin-negative tissue sample; lower panel, a representative 
β-catenin-positive, PRL-3 negative tissue sample. Magnification, 400X. B, PRL-3 and β-
catenin expression in a representative human colon cancer sample analyzed using 
fluorescence-immunohistochemistry. Blue, DAPI-labeled cell nuclei; green, PRL-3; red, β-
catenin. C, PRL-3 and β-catenin expression in a representative human lung cancer sample 





 In this chapter, I sought to investigate the relationship of β-catenin to PRL-3-driven 
oncogenesis. Overexpression or ablation of PRL-3 in A2780 ovarian cancer cells resulted in a 
decrease and increase of β-catenin expression, respectively. The PRL-3-induced changes in β-
catenin expression correlated with the levels of intracellular adhesion in these cells. PRL-3 
achieved the downregulation of β-catenin by promoting its proteasomal-mediated degradation 
via upregulation of the negative inhibitors of the Wnt pathway, Nkd1 and Nkd2, and 
downregulating the positive regulators, Dvl2 and Dvl3. This upregulation was at the post-
transcriptional level of Nkd, which in turn promotes the degradation of Dvl proteins. 
Significantly, I provided evidence of a negative relationship between PRL-3 and β-catenin in 
different human cancer samples, thereby establishing a clinical relevance of these findings.  
Wnt signaling is commonly dysregulated in a variety of human cancers [258], a disease in 
which PRL- 3 has been both associated with and implicated to play key roles in metastatic 
progression [8,39]. The clinical data presented here, in the form of immunohistological 
analysis of human cancer samples, suggest a profound relationship between PRL-3 and β-
catenin expression. In line with a role for PRL-3 in invasiveness and motility, in a subset of 
patient samples, I noted the upregulation of PRL-3 in motile cancer cells detached from the 
epithelial layer (Fig. 17C). These same cells lacked membrane-bound β-catenin expression, 
supporting my in vitro results from A2780 cells suggesting a negative relationship between β-
catenin expression and intracellular adhesion. The loss of intracellular adhesion and rounding 
up of A2780 cells upon PRL-3 overexpression was reminiscent of the phenotype induced in 
embryonic epithelial cells upon expression of a cadherin binding-deficient form of the 
Drosophila β-catenin orthologue, armadillo [275]. In a separate study using skin epidermal 
cells genetically ablated of α-catenin, besides a loss of cell adhesion, an increase in cell 
proliferation and the appearance of disorganized, neoplastic tissue was observed in mice 
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[276]. More recently, JNK-mediated phosphorylation of adherens junctions-associated β-
catenin was shown to promote β-catenin dissociation from adherens junctions and negatively 
regulate cell adhesion, suggesting a mechanism for JNK in promoting invasion and motility 
[265]. In light of these observations, it is tempting to hypothesize that oncogenic PRL-3 
likewise downregulates the expression of β-catenin in such cancerous epithelial cells in a bid 
to dissolve cell-cell contacts and promote tumor cell dissemination and epithelial-
mesenchymal transition [277]. It is worth highlighting that E-cadherin, a key interacting 
cadherin with β-catenin, is expressed at low levels in the A2780 cell line used in this study 
[278]. Since E-cadherin has been shown to stabilize β-catenin, presumably by sequestering it 
away from the axin/APC degradation complex [279-281], the low E-cadherin content in such 
cells may increase the free pool of β-catenin susceptible to PRL-3-mediated degradation via 
the axin/APC complex. This hypothesis will be tested in future work. 
Several studies have associated PRL-3 with the regulation of cadherin/catenin complexes. In 
one such study, the authors reported the discovery of cadherin-22 as a PRL-3 interacting 
protein via the yeast-2-hybrid system and validated this using co-immunoprecipitaiton in 
SW480 and SW620 colorectal cancer cells [73]. In their study, they showed that PRL-3 
overexpression resulted in the ablation of cadherin-22 expression in SW480 cells, although no 
opposite effect upon PRL-3 knockdown was observed. Most notably, in sharp contrast to my 
results here, the authors reported that PRL-3 overexpression in SW480 colorectal cancer cells 
actually upregulated β-catenin expression, without changes in α-catenin or γ-catenin 
expression. Yet, the authors presented data showing that PRL-3 knockdown also promoted β-
catenin accumulation, accompanied by pronounced changes in α-catenin and γ-catenin 
expression [73]. The upregulation of β-catenin was proposed to be due to the inactivation of 
GSK3β in PRL-3 overexpressing cells, yet no discussion was offered to explain this 
observation in light of the absence of a functional GSK3β-regulated axin/APC degradation 
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complex in the SW480 cells used [272]. Nonetheless, a similar role for PRL-3 in GSK3β 
inactivation has been reported elsewhere [90]. In that study, the inactivation of GSK3B in 
DLD-1 colorectal cancer cells was convincingly attributed to the activation of the PI3K/Akt 
pathway, which correlated with a decrease in E-cadherin and γ-catenin expression. However, 
like SW480 cells, DLD-1 cells also harbor an impaired axin/APC degradation complex, 
making the GSK3β-mediated regulation of β-catenin in these cells unlikely [272].  
Interestingly, reduced membranous β-catenin expression has been observed in up to 78% of 
ovarian carcinomas [126], and serves as a predictor of poor prognosis in ovarian endometrioid 
carcinoma [127]. Reduced staining for α- and β-catenin has also been reported to correlate 
with a more spindly, less adhesive morphology and increased invasive potential in matrigel 
[282]. Beyond intracellular adhesion, the downregulation of β-catenin expression by PRL-3 
might have other biological ramifications. Recently, several novel ‘tumor-suppressive’ 
functions of β-catenin have been described, including a pro-apoptotic role [283,284] and the 
maintenance of genetic stability by ensuring proper bipolar spindle formation and centrosome 
separation during mitosis [285,286]. Interestingly, in 32% (6 out of 19) ovarian cancer cell 
lines tested, Furlong et al. reported a twofold repression of TCF/β-catenin transcriptional 
activity [287], suggesting that constitutive transcriptional repression from TCF sites is more 
common in this tumor type. This observation echoes patient data associating increased 
nuclear β-catenin to a favorable prognosis in ovarian cancers [126,288]. Reduced expression 
of β-catenin has also been correlated with poorly differentiated tumors, advanced stage, and 
poor survival in gastric and oesophageal carcinomas [289-291]. Such a double-edged role for 
a cell junction protein has been reported for the cell polarity-cell plasticity module, Scrib. 
Under normal circumstances, Scrib functions to maintain basal-apical polarity, thereby 
opposing tumorigenicity during early phases of cell transformation [292,293]. However, in 
more advanced stages of tumorigenesis, abberantly overexpressed Scrib contributes to 
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metastatic progression by enhancing random cell migration, invasion and preventing anoikis 
[294,295]. Interestingly, the disassociation between the expression of β-catenin and 
proliferation observed in the A2780 cells in this study suggests that in the backdrop of 
alternative pathways driving proliferation, β-catenin loss might indeed be favored to facilitate 
invasion and motility early in tumorigenesis.  
Recent studies in mouse models of hepatocarcinogenesis support such a tumor inhibitory role 
of β-catenin. Firstly, in a comparison of the susceptibility of mice to N-nitrosodiethylamine 
(DEN)-induced tumorigenesis, β-catenin conditional knockout mice displayed accelerated 
hepatic tumor formation related to an increase in inflammation, oxidative stress and 
hepatocyte proliferation [266]. Secondly, in a c-myc/TGF-β1 double transgenic mouse model 
of spontaneous hepatocarcinogenesis, downregulation of β-catenin was observed in up to 80% 
of the basophilic-clear cell foci, hepatocellular adenomas and hepatocellular carcinomas 
(HCC) that developed [296]. Thirdly, in a c-myc/TGF-α double transgenic mouse model of 
spontaneous hepatocarcinogenesis, a remarkable 57% of the HCCs that develop undergo loss 
of heterozygosity at the β-catenin locus in the absence of any β-catenin stabilizing mutation 
[297]. Collectively, these reports suggest a tumor suppressive role for β-catenin in the absence 
of oncogenic mutations that promote its stability and/or nuclear functions. Interestingly, PRL-
3 is upregulated in HCC [63]. Given the profound inhibitory role of β-catenin in the 
progression of this cancer type (like in ovarian cancer), it is of significant interest to analyze 
whether a similar inverse relationship between PRL-3 and β-catenin plays a role in the 
development of the different subsets of neoplastic cell types during hepatocarcinogenesis.  
In this study, I found that PRL-3 regulates several components upstream of the axin/APC 
complex, in particular the Naked and Dvl family of proteins. Nkd1 and Nkd2 have been 
shown to antagonize both canonical and non-canonical Wnt signaling [250], either by 
promoting the ubiquitination and degradation of Dvl [246,248], or by directly binding to β-
97 
 
catenin and preventing its nuclear accumulation and transcriptional activities [249]. Based on 
this relationship, it is likely that PRL-3 regulates the upstream Nkd proteins, which in turn 
regulate expression of Dvl. The observation that PRL-3 regulation of Nkd occurs at post-
transcriptional level, coupled with the PRL-3 mediated accumulation of a faster migrating 
isoform of Nkd1 and Nkd2 proteins, suggests that PRL-3 could regulate the 
dephosphorylation and subsequent stabilization of these proteins, although no such 
modification has been reported in the literature. Interestingly, the stability of Nkd2 was 
recently shown to be regulated via a direct interaction with the cytoplasmic tail of TGF-α, 
which protects Nkd2 from AO7-mediated recruitment into the AO7/RNF25 E3-ligase 
complex [251]. Significantly, this regulation of Nkd2 happens only at the protein and not the 
mRNA level. This attractive possibility is being explored as a possible mechanistic 
explanation for Nkd accumulation prompted by PRL-3 overexpression. Besides a role in the 
canonical Wnt pathway, it should be highlighted that Dvl is also involved in non-canonical 
Wnt pathways including the Wnt-PCP (planar cell polarity), Wnt-GSK3β-microtubule, Wnt-
calcium, Wnt-aPKC and Wnt-mTor signaling pathways [298]. Although not examined here, it 
is plausible that PRL-3 regulates the signaling output of these alternative pathways. In view of 
recent reports describing pro-apoptotic roles of Wnt signaling via the non-canonical pathway 




CHAPTER 5: THE POST-TRANSLATIONAL MODIFICATION OF PRL-3 BY 
PHOSPHORYLATION 
5.1. Background 
 Besides RNA processing, post-translational modifications (PTMs) account for a large 
extent of the tremendous diversity of the proteome, permutations of which far exceed the 
30,000 genes within human DNA. Indeed, about 5% of the genome encodes PTM enzymes 
dedicated to maintaining this diversity, including some 500 protein kinases, 150 protein 
phosphatases, and 500 proteases [29]. Common PTMs include phosphorylation, 
ubiquitination, acetylation, glycosylation, methylation and oxidation. Such covalent 
modifications impart changes unto the chemical and molecular characteristics of the residues 
they are attached to, thereby eliciting local and/or global conformation changes which play 
fundamental regulatory roles in the biological activity, molecular interactions, and dynamics 
of these proteins. Thus, PTMs often constitute the key regulatory checkpoint controlling the 
biological output of proteins, regardless of their expression level. 
Strikingly, phosphorylation alone accounts for more than 50% of all PTMs known. 
Phosphorylation-dephosphorylation cycles on Ser, Thr, and Tyr residues are the best 
characterized modifications in the mammalian regulation of molecular interactions in 
signaling pathways, as well as the reversible activation and inactivation of enzymes [301]. A 
significant challenge in the study of protein phosphorylation stems from the rapid dynamics 
of the phosphorylation-dephosphorylation cycle and the (generally) small fraction of proteins 
that undergo this dynamic process (<0.1%) in vivo. Since phosphorylation can modulate a 
protein’s intrinsic biological activity, subcellular location, half-life and molecular interactions 
[1], the identification of protein phosphorylation sites (and their cognate kinases) is regarded 
as a key step to delineate molecular dynamics and plasticity underlying various cellular 
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processes. With continual advancements in proteomic methodology, researchers are now able 
to identify unique phosphorylation sites of proteins within whole proteomes in a high-
throughput manner with increasingly better coverage, using tools ranging from high-
resolution mass spectrometry to protein microarray chips to flow cytometry-based 
phosphoproteomics [302-304]. However, these methods are both costly and technically 
challenging, making it advantageous to cut down on the number of experimental steps by 
integrating computational approaches into the validation procedures. To this end, much effort 
has been put into developing predictive software for identifying potential phosphorylation 
sites in known and novel proteins, as well as performing large scale predictions and 
constructing reliable phosphorylation networks. To date, nearly 10 kinase-specific prediction 
programs have been developed, including PhosphoMotif Finder [136], ScanSite [305], 
KinasePhos [306], NetPhosK [307], and GPS2.0 [135]. These differ principally in the 
conservativeness of prediction – whereas some strictly use substrate motifs curated from the 
literature (e.g. PhosphoMotif Finder), others use complex algorithms to predict novel 
substrate motifs, thereby expanding the repertoire of predicted phosphorylated proteins (e.g. 
ScanSite, KinasePhos, NetPhosK). GPS2.1, the latest iteration of GPS2.0, goes one step 
further and predicts kinase-specific phosphorylation sites in hierarchy, considering not only 
single positions but also relatedness in three-dimensional structures and biological functions 
of each phosphorylation site peptide (PSP) in their prediction analysis. This results in a much 
lower false positive rate and, compared with the other existing tools, greater computational 
power with superior performance. 
A recurring challenge encountered in experimental validation of protein phosphorylation is 
the requirement for the highly sensitive, non-biased enrichment of Ser, Thr and Tyr 
phosphorylated proteins, particularly those in low abundance or with low stoichiometry of 
phosphorylation, prior to analysis. Various methods have been described to address this 
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problem, such as using immunopurification with anti-phospho-Tyr antibodies, or using 
immobilized metal affinity chromatography for global phosphoprotein enrichment [308]. A 
recent advancement in immobilized metal affinity chromatography (IMAC) technology was 
the development of the phosphate-binding tag, PhosTag. By preferentially capturing 
phosphomonoester dianions bound to Ser, Thr, and Tyr residues, PhosTag allows for the 
specific analysis of phosphorylated proteins or peptides, and can be adapted for use in their 
affinity purification or by causing motility shifts in SDS-PAGE gels, wherein phosphorylated 
proteins migrate slower compared with corresponding dephosphorylated proteins [309]. Since 
pSer, pThr and pTyr are estimated to be present in cells in an approximately 1800:200:1 ratio 
[310], PhosTag is superior to traditional methods of affinity purification, such as using anti-
phospho-Tyr specific antibodies, as global phosphorylation events are better represented in a 
non-biased fashion. Although many cellular proteins that are known to be phosphorylated do 
not shift reliably in standard SDS-PAGE, PhosTag SDS-PAGE allows for dramatic gel shifts 
to be readily observed for various phosphoprotein isotypes, thereby enabling hypothesis-free 
investigation of their phosphorylation state(s) [311]. Thus, the ability to visualize 
phosphorylation events by simple immunoblotting without phospho-specific antibodies makes 
analysis using PhosTag SDS-PAGE gels a straightforward and highly reproducible affair. 
Despite considerable headway in understanding the effects of prenylation, oligomerization 
and reversible oxidation on PRL function [8], no report has described the in vivo regulation of 
this phosphatase family by phosphorylation. This is particularly queer, considering that 
almost a decade ago, PRL-1 was already reported to have consensus sequences for Src and 
could be directly phosphorylated by pp60Src in vitro [5]. Thus, in light of my previous results 
on EGFR activation by PRL-3, the high homology between PRL-1 and PRL-3, and the 
described importance of phosphorylation in regulating the biological function or proteins, I 
proceeded to investigate:  
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i) If PRL-3 harbored any kinase consensus sequences;  
ii) Whether PRL-3 could be a kinase substrate in vitro and in vivo; and  
iii) What effect phosphorylation would have on PRL-3’s protein-protein interactions. 
 
 
5.2. Outline of Experiment 
1. GPS2.1 and PhosphoMotif Finder were used to analyze the human PRL-3 (PTP4A3 
isoform 1) protein sequence for putative phosphorylation sites. Candidate kinases 
(based on predicted consensus scoring/cutoff) were identified for experimental 
validation in vivo. 
2. A431 cells overexpressing PRL-3 were subjected to treatment with a variety of 
known activators of these candidate kinases, or left untreated as a control. PRL-3 was 
then immunopurified and analyzed for phosphorylation using the PhosTag system 
and anti-phospho-Tyr antibodies (clone 4G10). 
3. Stimuli resulting in PRL-3 phosphorylation were used in further experiments and 
validated in conjunction with kinase-specific inhibitors to delineate the responsible 
kinase(s) involved.  
4. Direct phosphorylation was attempted using recombinant purified kinase and PRL-3 
in vitro. 
5. After validation of PRL-3 phosphorylation, the biological consequence of PRL-3 





5.3.1. PRL-3 harbors consensus phosphorylation sequences for multiple tyrosine and 
serine/threonine kinases 
 To investigate if PRL-3 could be a kinase substrate, I first chose to use two distinct, 
freely available bioinformatics tool for prediction of protein phosphorylation sites. GPS2.1 
uses a hierarchal prediction algorithm for discovering known and novel substrate motifs 
[135], whereas PhosphoMotif Finder limits prediction only to literature curated 
phosphorylation-based substrate motifs [136]. Using both of these prediction software (with 
low threshold chosen for GSP2.1), I found consensus sites for multiple tyrosine and 
serine/threonine kinases within the human PRL-3 protein sequence. Amongst the extensive 
list, I noticed that a plethora of the kinases identified belonged to members of the Src family, 
sharing complete coverage of all 6 Tyr sites within PRL-3 between them (Table 3; complete 
list in Appendix V).  
TABLE 3. Consensus sites for EGFR and Src family tyrosine kinases in PTP4A3. 































Consensus sites were identified using GPS2.1 and PhosphoMotif Finder (PMF) for all 6 tyrosine residues 
within PRL-3 (PTP4A3). The complete list of predicted consensus sites within PRL-3 and their cognate 
kinases are provided in Appendix V. 
 
The most common predicted kinases for the remaining 6 Ser and 12 Thr sites within the PRL-
3 sequence belonged to the STE and CMGC kinase families, as well as casein kinase I and II 
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(CK1/2) (Table 4; complete list in Appendix VI). Interestingly, the STE and CMGC kinase 
families include the MAPK growth and stress-response kinases, the cell cycle cyclin-
dependent kinases (CDKs), as well as other kinases involved in metabolic control and 
splicing [312]. It is worth noting that T168 came up as the highest scoring site as predicted by 
GPS2.1, with the predicted kinases targeting this site including CK1, PDK1, ROCK, DAPK 
and MAP3K11 (Table 4). From the prediction results of both bioinformatics software used, I 
concluded that that PRL-3 might be a phosphoprotein under conditions when its cognate 
kinase is activated. 
TABLE 4. Consensus sites for Ser/Thr kinases in PTP4A3. 
































































































Consensus sites were identified using GPS2.1 and PhosphoMotif Finder (PMF) for all serine and threonine 
residues within PRL-3 (PTP4A3). The complete list of predicted consensus sites within PRL-3 and their 





5.3.2. PRL-3 is phosphorylated upon EGFR phospho-activation 
 To identify the conditions under which PRL-3 might get phosphorylated, I stimulated 
A431 EGFP-PRL-3 cells with various stimuli known to activate multiple kinases across 
diverse signaling cascades. These included serum starvation [313,314], stimulation with the 
cytokines interferon-gamma (IFN-γ), interleukin-6 (IL-6) and EGF [315-317], stimulation 
with the phorbol ester phorbol 12-myristate 13-acetate (PMA) [318,319], UV-C irradiation 
[320], hyperosmotic stress [321], as well as oxidative stress induced by H2O2 [322]. PRL-3 
immunoprecipitates from control or such treated cells were resolved on a PhosTag SDS-
PAGE gel, which selectively retards any protein phosphorylated on Tyr, Ser and/or Thr [309]. 
Using this unbiased approach, I found shifted bands of EGFP-PRL-3 specifically in cells 
treated with EGF and H202, but not with any other physiological stimuli tested (Fig. 18A). 
Besides the predominantly shifted band, faster migrating bands, presumably accounted for by 
differentially phosphorylated PRL-3, was also observed (Fig. 18A). Since protein 
phosphorylation-dephosphorylation cycles occur rapidly under basal conditions, I treated 
A431 EGFP-PRL-3 cells with pervanadate, which potently blocks PTP activity and thus 
permits accumulation of basally tyrosine phosphorylated proteins and activation of kinases 
that are normally retained in inactive forms by dephosphorylation [323]. Pervanadate 
treatment potently promoted the accumulation of the same phospho-isoforms of EGFP-PRL-3 
induced upon EGF and H2O2 treatment, as well as an additional, more extensively 
phosphorylated isoform which migrated at an even slower rate (Fig. 18A). Interestingly, 
EGFP-PRL-3 phosphorylation correlated with EGFR Y1068 phosphorylation, a marker of 
EGFR activation [324], but not with p38 or ERK1/2 activation (Fig. 18A). Since the 
phosphorylation of EGFP-PRL-3 could be strongly induced by EGF treatment, this became 
the stimulus of choice for further study. 
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To validate if the shifts observed were due to EGFP-PRL-3, and not from EGFP tagging, 
lysates from serum starved A431 EGFP and EGFP-PRL-3 cells treated with EGF were used 
in immunoprecipitation using an anti-GFP antibody. I found a sole tyrosine phosphorylated 
band (above a constant background) correlating to the molecular weight of EGFP-PRL-3 in 
EGF-treated samples from A431 EGFP-PRL-3 cells but not in A431 EGFP cells (Fig. 18B). 
Resolution of these immunoprecipitates on a PhosTag SDS-PAGE gel revealed a visibly 
shifted band for EGFP-PRL-3 but not EGFP (Fig. 18C). To ensure the results seen in Fig. 
18A were not artifacts from using PRL-3 antibody for immunopurification, I used it for 
immunoprecipitating PRL-3 from both A431 EGFP and EGFP-PRL-3 cells. Whereas a 
tyrosine phosphorylated band corresponding to the molecular weight of EGFP-PRL-3 was 
enriched from EGF-treated A431 EGFP-PRL-3 cells, no band was observed in similarly 
treated A431 EGFP cell immunoprecipitates (Fig. 18D). Collectively, these results indicated 
that PRL-3 is indeed a phosphoprotein, with tyrosine phosphorylation inducible upon EGF 




Figure 18: EGFP-PRL-3 is phosphorylated upon the phospho-activation of EGFR in 
A431 cells. A, immunopurified EGFP-PRL-3 from A431 EGFP-PRL-3 cells growing in 
complete 10% FBS medium (growing), serum starved overnight (-), or serum starved 
overnight followed by stimulation with 25% FBS (15 min), PMA (1 μM, 15 min), IFN-γ (15 
ng/mL, 15 min), IL-6 (25 ng/mL, 15 min), UV-C (40 J/m2, followed by 20 min recovery), 
EGF (100 ng/mL, 20 min), NaCl (0.2M, 30min followed by recovery in serum free medium 
for 30 min), H202 (1 mM, 30 min) or pervanadate (1 mM, 30 min) were resolved on a 
PhosTag SDS-PAGE gel and immunoblotted with an anti-GFP antibody. Corresponding total 
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cell lysates were resolved on standard SDS-PAGE gels and probed for phospho-EGFR 
(Y1068), phospho-p38 and phospho-ERK1/2 levels. GADPH was used as a loading control. 
B, A431 EGFP and A431 EGFP-PRL-3 cells were serum starved for 16 h and stimulated with 
100 ng/mL EGF (20 min) where indicated. Anti-GFP (clone B-2) immunoprecipitates from 
these cells were resolved on a standard SDS-PAGE gel and immunoblotted with antibodies 
against phospho-Tyr. The blot was stripped and subsequently reprobed with an anti-GFP 
antibody. Note that a 45kDa non-specific cross-reacting band to anti-GFP antibody is visible 
in A431 EGFP-derived samples. Molecular weights in kDa are indicated on the left of each 
blot.  C, anti-GFP immunoprecipitates from B were resolved on a PhosTag SDS-PAGE gel 
and immunoblotted with an anti-GFP antibody. D, A431 EGFP and A431 EGFP-PRL-3 were 
treated as in B, and anti-PRL-3 (clone 318) immunoprecipitates were resolved on a standard 
SDS-PAGE gel and immunoblotted with anti-phospho-Tyr and subsequently reprobed with 
anti-GFP antibodies. Arrows, predominantly phosphorylated isotype of EGFP-PRL-3. 
Molecular weights in kDa are indicated on the left of each normal SDS-PAGE immunoblot.   
 
5.3.3. EGF-induced PRL-3 phosphorylation is rapid and abolished upon treatment with 
EGFR or Src inhibitors 
 To investigate the kinetics of PRL-3 phosphorylation upon EGF stimulation, I treated 
A431 EGFP-PRL-3 cells with EGF for various durations and analyzed PRL-3 
phosphorylation using both PhosTag SDS-PAGE and a phospho-tyrosine antibody in parallel. 
I found that PRL-3 was phosphorylated within 5 min of EGF induction, and this 
phosphorylation level remained unchanged until 60 min, when it just began to peak (Fig. 
19A). Interestingly, besides an increase in the predominant PRL-3 phospho-isoform, an 
increase in abundance of the fastest migrating phospho-isoform of PRL-3 was also evident in 
the PhosTag gel at 60 min post-stimulation (Fig. 19A). The kinetics of PRL-3 
phosphorylation mimicked that of Her2 and Src, two well-characterized direct EGFR 
substrates, but not that of ERK1/2, an indirect EGFR downstream target. Whereas Her2 and 
Src phosphorylation remained high between 5 min to 60 min, ERK1/2 phosphorylation was 
high up until 10 min, after which it visibly decreased (Fig. 19A).  
Src has been described as both a downstream substrate as well as activator of EGFR. EGF-
induced activation of EGFR results in phosphorylation and activation of Src [325-328], which 
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then potentiates EGFR signaling by further phosphorylation of the activated receptor at Y845 
located in the activation segment of its catalytic domain [329,330]. Recently, acute ligand-
independent Src activation was even shown to mimic EGFR surface signaling [331]. To 
delineate these two related events, I stimulated A431 EGFP-PRL-3 cells with EGF after 
pretreatment with either PP2, a Src-family kinase selective inhibitor [332], or AG1478, an 
EGFR specific inhibitor [325]. Pretreatment with either PP2 or AG1478 abolished EGF-
induced PRL-3 phosphorylation (Fig. 19A). Strikingly, the loss of PRL-3 global 
phosphorylation, as inferred from PhosTag SDS-PAGE, appeared directly related to its 
tyrosine phosphorylation (Fig. 19A). Similar results for PP2 and AG1478 were observed in 
PRL-3 immunoprecipitates from identically treated MDA-MB-468 EGFP-PRL-3 cells (Fig. 
19B). Notably, the reduction in EGFP-PRL-3 phosphorylation here was less obvious upon 
PP2 treatment compared to that observed in A431 EGFP-PRL-3 cells, suggesting that non-Src 
kinases downstream of EGFR could also phosphorylate PRL-3. Since PP2 could partially 
inhibit EGFR at the concentration used in this study [332], I analyzed the phosphoactivation 
of both Src and ERK1/2 as an indicator of inhibitor specificity. Whereas AG1478 abolished 
both Src and ERK1/2 phosphorylation, PP2 treatment only abolished EGF-induced Src 
phosphorylation but not ERK1/2 phosphorylation, indicating that the inhibitors were working 
specifically on either EGFR or Src, respectively (Fig. 19A). These results collectively 





Figure 19: EGF-induced PRL-3 tyrosine phosphorylation occurs within 5 min of EGF 
stimulation and depends on both EGFR and Src activity. A, A431 EGFP-PRL-3 cells 
were serum starved for 16 h and stimulated with 100 ng/mL EGF for various durations just 
before lysis. Where indicated, cells were pretreated with DMSO (0.1%), Src-specific inhibitor 
PP2 (10 μM in 0.1% DMSO) or EGFR-specific inhibitor AG1478 (1 μM in 0.1% DMSO) for 
20 min prior to EGF stimulation just before lysis. Anti-PRL-3 (clone 318) 
immunoprecipitates were probed with antibodies against phospho-Tyr and GFP and where 
indicated. Total lysates were probed with antibodies against phospho-Her2 (Y887), phospho-
Src (Y416), phospho-ERK1/2 (T202/Y204), total Src or total ERK1, which also serves as a 
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loading control. Except for the anti-GFP immunoblot (third row from top) which was run on a 
PhosTag SDS-PAGE gel, all other samples were run on standard SDS-PAGE gels. B, MDA-
MB-468 EGFP-PRL-3 cells were starved, treated (20 min) and processed as in A. Resultant 
PRL-3 immunoprecipitates was resolved on PhosTag SDS-PAGE and immunoblotted with an 
anti-GFP antibody. Arrow, phosphorylated EGFP-PRL-3. 
 
5.3.4. PRL-3 is phosphorylated by Src in vivo and in vitro 
 Because my data suggested that Src might be the downstream kinase of EGFR 
responsible for PRL-3 phosphorylation, I investigated if overexpression of Src alone could 
recapitulate the phosphorylation of PRL-3 induced by EGF stimulation. Src is kept inactive in 
cells by c-Src kinase (Csk) phosphorylation of Tyr530 (Tyr527 in chicken), which creates a 
binding site for the SH2 domain of Src itself, thereby prompting a ‘closed’ configuration and 
reduced activity [333]. Overexpression of a tagged version of the constitutively active form of 
chicken Src (SrcY527F, in which the critical negative regulatory phosphosite is removed) in 
A431 EGFP-PRL-3 cells resulted in the phosphorylation of PRL-3 (Fig. 20A). Notably, 
phospho-isoforms of PRL-3 were observed in Src-Y527F overexpressing cells that were 
similar to those observed with EGF stimulation (Fig. 20A; i, ii). However, Src seemed to 
promote the accumulation of a faster migrating phospho-isoform of PRL-3 (Fig. 20A; ii). To 
verify the specificity of Src activity, I overexpressed a dominant negative, tagged version of 
kinase dead chicken Src (Src-K295M; ref. [334]) in these cells. In agreement with a 
requirement for Src kinase activity, SrcK295M failed to induce PRL-3 phosphorylation (Fig. 
20A). Since Src was involved in PRL-3 phosphorylation and had consensus phosphorylation 
sites within PRL-3 (Table 3), I investigated if Src could act directly as a PRL-3 kinase. 
Bacterially-expressed GST and GST-PRL-3 proteins were affinity purified for an in vitro 
kinase reaction with human Src (Fig. 20B). Unlike the GST control reaction where Src failed 
to induce tyrosine phosphorylation of any band corresponding to the size of free GST, a 
prominent tyrosine-phosphorylated band correlating to the size of GST-PRL-3 was observed 
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in the GST-PRL-3 kinase reaction (Fig. 20C). Collectively, the results from my in vitro and 
in vivo experiments suggested that Src could indeed be a potential PRL-3 kinase. 
 
Figure 20: PRL-3 is phosphorylated by Src in vivo and in vitro. A, A431 EGFP-PRL-3 
cells growing in a 12-well plate were transiently transfected for 48 h with 1 μg of plasmids 
encoding either constitutively active chicken Src (SrcY527F-mCherry) or kinase dead 
chicken Src (SrcK295M-mCherry). For EGF stimulation, cells were serum starved for 16 h 
and stimulated with EGF (100 ng/mL, 20 min) just before lysis. PRL-3 immunoprecipitates 
were resolved on a PhosTag SDS-PAGE gel and immunoblotted with an anti-GFP antibody. 
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Two unique isoforms of phosphorylated EGFP-PRL-3 are labeled as i and ii. Total cell lysates 
from these cells, after resolution on standard SDS-PAGE gels, were probed for phospho-Her2 
(Y887), phospho-Src (Y416), phospho-ERK1/2 (T202/Y204), total Src or total ERK1, which 
also served as a loading control. B, purified recombinant GST (2 μg), GST-PRL-3 (2 μg) and 
His-GST-Src (1 μg) were resolved on a standard SDS-PAGE gel and stained with Coomassie 
blue to demonstrate protein purity. Molecular weights in kDa are indicated on the left of the 
gel image.  C, in vitro kinase reactions containing 50 ng of recombinant His-GST-Src and 400 
ng of GST or GST-PRL-3 proteins were activated by adding 0.1 mM ATP and incubated for 
30 min at 30°C. Kinase reactions were terminated by adding 2 x loading buffer and boiling 
for 5 min before resolving on standard SDS-PAGE gels and immunoblotting using anti-
phospho-Tyr and anti-Src antibodies. The anti-phospho-Tyr blot was stripped and reprobed 
with an anti-GST antibody. Arrow, position of Src-phosphorylated GST-PRL-3. Molecular 
weights in kDa are indicated on the left of each blot.   
 
5.3.5. EGF induced PRL-3 phosphorylation is dependent on PRL-3’s proper membrane 
localization and is affected by its intrinsic catalytic activity 
 ERK has previously been reported to modulate neurite growth via a spatially 
compartmentalized switch operating downstream of integrin activation [335]. To investigate 
if PRL-3 activation might be spatially regulated by its localization in cells, I used a 
prenylation-deficient mutant which lacks Cys170, the critical Cys residue within the C-
terminus prenylation motif (CAAX) of PRL-3. EGFP-PRL-3 C170S, unlike membrane-
associated EGFP-PRL-3 WT, localized predominantly in the nucleus accompanied by a lower 
level cytoplasmic distribution (Fig. 21A). EGF-stimulation of A431 cells overexpressing 
EGFP-PRL-3-WT, phosphatase-dead mutant EGFP-PRL-3-R110S [12], or EGFP-PRL-3-
C170S resulted in robust tyrosine phosphorylation of both membrane-localized EGFP-PRL-3-
WT and EGFP-PRL-3-R110S but this was greatly reduced in EGFP-PRL-3-C170S (Fig. 
21B). Densitometric quantitation of the differences in phosphorylation of the three variants 
tested revealed an interesting trend: whereas mislocalized, prenylation-deficient EGPF-PRL-
3-C170S showed approximately 90% less phosphorylation, phosphatase-dead EGFP-PRL-3-
R110S displayed an approximately 40% increase in phosphorylation level, both relative to 
EGFP-PRL-3-WT (Fig. 21B). These results suggested that PRL-3 tyrosine phosphorylation 
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required proper membrane localization and might be inhibited by its intrinsic catalytic 
activity. 
 
Figure 21: PRL-3 tyrosyl phosphorylation requires proper membrane localization and is 
affected by its intrinsic catalytic activity. A, A431 EGFP-PRL-3-WT and A431 EGFP-
PRL-3-C170S cells were seeded onto glass slides 24 h before fixing and fluorescence 
imaging.  B, A431 EGFP-PRL-3-WT, A431 EGFP-PRL-3-R110S and A431 EGFP-PRL-3-
C170S cells were serum starved for 16 h and stimulated with 100 ng/mL EGF (20 min) prior 
to lysis. Anti-PRL-3 (clone 318) immunoprecipitates from these cells were resolved on a 
standard SDS-PAGE gel and immunoblotted with antibodies against phospho-Tyr and GFP 
and where indicated. The desitometric quantitation of the phospho-PRL-3:total PRL-3 ratio of 
the blots is shown on the right, normalized to EGFP-PRL-3-WT. 
 
5.3.6. PRL-3 interacts and co-localizes with EGFR 
 Since PRL-3 is a cell surface- and endosomally-targeted membrane-associated protein, 
and in light of my results showing that phosphorylation was dependent on its proper 
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membrane association, I investigated if PRL-3 might physically interact with EGFR, which is 
known to be localized and regulated by association within similar membranous compartments 
[336]. Indeed, immunoflourescence analysis of A431 and MDA-MB-468 cells showed 
significant co-localization of EGFR and EGFP-PRL-3 at both cell surface and intracellular, 
endosomal membranes (Fig. 22A, B). Interestingly, EGFR immunoprecipitates from 
unstimulated, exponentially growing A431, SW480 and MDA-MB-468 cells overexpressing 
EGFP or EGFP-PRL-3 revealed a specific interaction between EGFP-PRL-3, but not free 
EGFP, with the EGFR complex in all cell lines tested (Fig. 22C). The PRL-3-EGFR 
interaction was confirmed by reverse co-immunoprecipitation of PRL-3 from unstimulated 
A431 EGFP and EGFP-PRL-3 cells. In this case, only EGFP-PRL-3 specifically co-
immunoprecipitated EGFR, discounting any possible cross-reactivity of the antibody to either 
EGFR or the EGFP tag (Fig. 22D). Previously, I showed that prenylation-deficient PRL-3 
was poorly phosphorylated upon EGF stimulation. In light of my results here, I hypothesized 
that this could be due to a loss of interaction between PRL-3 and the EGFR complex. 
Supporting this idea, I found that EGFP-PRL-3 C170S interacted poorly with EGFR 
compared to wild-type EGFR-PRL-3 (Fig. 22E). Interestingly, a Cys-to-Ser catalytic dead 
mutant of PRL-3 (EGFP-PRL-3 C104S) bound to EGFR more avidly than EGFP-PRL-3 WT 
(Fig. 22E). Finally, using recombinant GST or GST-PRL-3 protein in a pull-down experiment 
with unstimulated A431 cell lysate as input, I found that only GST-PRL-3, but not GST, 
interacted specifically with EGFR (Fig. 22F). These results conclusively proved that PRL-3 




Figure 22: PRL-3 binds to the EGFR complex and co-localizes with it. A, A431 EGFP-
PRL-3 cells were seeded onto glass slides 24 h before fixing and processing for 
immunofluorescence using an anti-EGFR antibody. Green, EGFP-PRL-3; red, EGFR. Bar, 20 
μm. B, MDA-MB-468 EGFP-PRL-3 cells were prepared and analyzed as in A. Green, EGFP-
PRL-3; red, EGFR. Bar, 20 μm. .C, lysates from exponentially growing A431, SW480 and 
MDA-MB-468 cells stably expressing EGFP or EGFP-PRL-3 were immunoprecipitated with 
an anti-EGFR antibody and resolved on standard SDS-PAGE gels before immunoblotting 
with anti-GFP or anti-EGFR antibodies. Asterisks, non-specific bands. D, A431 EGFP and 
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EGFP-PRL-3 lysates from C were immunoprecipitated with an anti-PRL-3 antibody and 
immunoblotted with anti-EGFR and anti-GFP antibodies. E, MDA-MB-468 stably expressing 
EGFP, wild-type EGFP-PRL-3 or mutant PRL-3 were processed as in C with the exception 
that the anti-EGFR antibody used for IP was not cross-linked and thus co-elutes with EGFR 
interacting proteins (IgG heavy chain).  F, purified recombinant GST and GST-PRL-3 were 
used in a pull-down experiment using A431 cell lysate as input. Proteins bound to GST or 
GST-PRL-3 were eluted and resolved on standard SDS-PAGE and immunoblotted with anti-
EGFR. A Coomassie stained gel image is included to reflect recombinant protein loading 
amounts used for pull down.  
 
5.3.7. PRL-3 phosphorylation disrupts its interaction with the EGFR complex  
 Amongst the main roles of protein phosphorylation as a critical post-translational 
modification is the regulation of protein-protein interactions. To investigate if 
phosphorylation of PRL-3 might modulate its protein-protein interactions, I used silver 
staining to analyze immunoprecipitated PRL-3 from EGF-simulated cells as well as cells 
pretreated with Src-family inhibitor PP2 and EGFR inhibitor AG-1478, both of which were 
earlier shown to abolish EGF-induced PRL-3 phosphorylation. Remarkably, a prominent 
band of molecular weight around 170,000 Daltons (hereinafter referred to as p170) was 
observed to visibly change in its association with PRL-3 under stimulated and inhibited 
conditions (Fig. 23A). Intriguingly, p170 ran as a faster migrating band under AG1478 
inhibition of EGF-stimulation, compared to control and PP2 treated cells (Fig. 23A). Since 1) 
shifts in protein migration in SDS-PAGE are related to phosphorylation, 2) AG1478 is an 
EGFR-specific inhibitor abolishing EGF-induced EGFR autophophorylation, and 3) EGFR is 
naturally overexpressed in A431 cells [166], I tested the possibility of p170 being EGFR 
itself. Indeed, EGF-stimulation of A431 EGFP-PRL-3 cells resulted in a significant decrease 
in the PRL-3-EGFR interaction (Fig. 23B). This result was validated by immunoblotting for 
EGFR in the samples from EGF-stimulated control, PP2 and AG1478 pretreated cells, where 
the antagonistic relationship between PRL-3 phosphorylation and PRL-3-EGFR interaction 
was most evident (Fig. 23C). In conclusion, my data suggest that EGF-induced 
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phosphorylation of PRL-3 negatively regulates its interaction with the activated EGFR 
complex in A431 cells. 
 
Figure 23: EGF-induced PRL-3 phosphorylation negatively regulates the PRL-3-EGFR 
interaction. A, A431 EGFP-PRL-3 cells were serum starved for 16 h and pretreated with 
DMSO (0.1%), Src-specific inhibitor PP2 (10 μM in 0.1% DMSO) or EGFR-specific 
inhibitor AG1478 (1 μM in 0.1% DMSO) 20 min prior to 100 ng/mL EGF stimulation (20 
min). Lysates were prepared and cross-linked anti-PRL-3 (clone 318) immunoprecipitates 
were resolved on a standard SDS-PAGE gel and silver stained to visualize differential binding 
partners. Arrow, p170, a prominent PRL-3 binding partner. Molecular weights in kDa are 
indicated on the left of the gel image.  B, PRL-3 immunoprecipitates and total cell lysates 
from control or EGF-stimulated A431 EGFP-PRL-3 cells were resolved on a standard SDS-
PAGE gel. Immunoprecipitates were immunoblotted with anti-phospho-tyrosine and anti-
EGFR antibodies. The phospho-tyrosine blot was subsequently stripped and reprobed for 
GFP. Total cell lysates were immunoblotted with anti-EGFR, anti-phospho-ERK1/2 and 
GAPDH antibodies. Molecular weights in kDa are indicated on the left of each immunoblot. 
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C, immunoprecipitates from A were run on a standard SDS-PAGE gel and immunoblotted 
with anti-phospho-tyrosine and anti-EGFR antibodes. The phospho-tyrosine blot was 
subsequently stripped and reprobed for GFP. Molecular weights in kDa are indicated on the 
left of each immunoblot. 
5.3.8. EGF induces PRL-3 phosphorylation on multiple sites 
 To identify the phosphorylated site(s) within PRL-3, I generated EGFP-tagged constructs 
harboring individual site-directed Tyr to Ala mutations at all six tyrosines of PRL-3, namely 
Tyr14, Tyr40, Tyr53, Tyr126, Tyr148 and Tyr152. These sites were previously predicted to 
harbor Src family kinase consensus sequences (Table 3). Next, A431 cells stably expressing 
these constructs were generated. Since prenylation and membrane localization was earlier 
shown to be an important determinant of PRL-3 phosphorylation, I analyzed the intracellular 
localization of each PRL-3 mutant. All mutant PRL-3 versions displayed normal PRL-3 
localization (data not shown), making the possibility of mislocalization affecting PRL-3 
phosphorylation unlikely. These cells were subsequently stimulated with EGF to analyze 
PRL-3 phosphorylation. Surprisingly, no single Tyr site mutant could abolish the prominent 
EGF-induced PRL-3 shifts as analyzed using the PhosTag system (Fig. 24A, B). In 





Figure 24: The predominant EGF-induced PRL-3 phospho-isoform is not determined by 
phosphorylation on a single Tyr residue. A, A431 cells stably expressing EGFP or the 
various EGFP-PRL-3 variants listed were serum starved for 16 h and stimulated with 100 
ng/mL EGF (20 min). PRL-3 immunoprecitates were resolved on PhosTag gels and probed 
with an anti-GFP antibody. Two different exposures of the same blot are shown for gel 
loading reference. Total cell lysates (TCL) were probed with antibodies against GFP and 
GAPDH. B, A431 EGFP-PRL-3-WT, EGFP-PRL-3-Y40F and EGFP-PRL-3Y152F were 
starved overnight, stimulated with EGF (100 ng/mL; 20 min) where indicated, and 
subsequently processed as in A. The slightly higher position of unstimulated EGFP-PRL-3-
WT (leftmost lane) is due to gel running conditions and not phosphorylation status. Arrow, 
predominant phospho-isoform induced upon EGF stimulation. 
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 5.4. Discussion 
 The experiments described in this chapter attempted to address three important 
biochemical questions. The first and second relate to the phosphorylatabililty of PRL-3, and 
the molecular mechanisms underlying PRL-3 phosphorylation. Finally, the consequence of 
PRL-3 phosphorylation was investigated in relation to its protein-protein interactions. My 
results here suggested that PRL-3 is indeed a phosphorylatable protein specifically induced 
upon EGFR and downstream Src activation. I went on to show that PRL-3 was a direct Src 
substrate in vitro. Interestingly, PRL-3 interacts with EGFR in vivo, an event which is 
dependent on proper membrane localization of PRL-3 and might be required for EGF-induced 
phosphorylation. Finally, I demonstrated that EGF-induced PRL-3 phosphorylation could 
promote dissociation of the EGFR-PRL-3 complex in vivo. 
The phosphorylation of proteins plays important roles in their intrinsic biological activity, 
subcellular location, half-life and molecular interactions. For instance, phosphorylation of the 
carboxyl-terminus of PTEN keeps it in an inactive state, and contributes to the stabilization 
the protein [337]. Even single site- or mono-phosphorylation can have important biological 
effects. A classic example is phosphorylation of human c-Src at Tyr530, which plays a 
pronounced role in inactivating this kinase by promoting the formation of an intramolecular 
interaction with the amino-terminus SH2 domain [194]. Unfortunately, in this study, I could 
not identify the specific phosphorylation site in PRL-3.  This was primarily due to an inability 
to design a mutant version of PRL-3 that would not get phosphorylated, despite site-directed 
Tyr to Ala mutagenesis of individual Tyr residues within PRL-3 (Fig. 24). A likely 
explanation for this problem is that PRL-3 undergoes multisite phosphorylation upon EGF 
stimulation. In this case, individual site-mutants would fail to abrogate PRL-3 
phosphorylation completely, as compensatory phosphorylation on alternative sites would 
mask any loss. Such a phenomenon has been described for Mrc1, for which Rad3-dependent 
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phosphorylation has been described to occur redundantly on both Thr645 and Thr653. 
Importantly, mutagenesis of both these sites were required to abolish Mrc1 checkpoint 
signaling function [338]. Similarly, mutagenesis of all four phosphorylated carboxyl-terminus 
residues, Ser380, Thr382, Thr383 and Ser385, was reported to be necessary to elicit a 
significant reduction in PTEN phosphorylation and phosphatase activity [337]. Alternatively, 
the major shifted band in PhosTag analysis of PRL-3 phosphorylation might be attributed to 
an overrepresentation of Ser/Thr phosphorylation. Indeed, if this alternative is true, it would 
explain the failure to abolish the major PhosTag shift upon individual Tyr site-directed 
mutations (Fig. 24). Taken collectively, multiple point mutations in varying combinations 
would be necessary to reveal the critical residue(s) involved in phosphorylation of PRL-3. 
Undoubtedly, such a phospho-deficient mutant would allow for the analysis of the effects of 
phosphorylation on PRL-3 catalytic activity, stability, and localization.  
In this study, the identification of EGFR as a phospho-regulated binding partner for PRL-3 
should be interpreted with some caution. Because EGF stimulation was used to effect PRL-3 
phosphorylation and subsequent analysis of binding proteins, it must be kept in mind that 
broadly-acting stimuli such as EGF stimulation or pervanadate treatment undoubtedly affect 
phosphorylation of many other proteins. This makes analysis of protein-protein interactions 
less straightforward as one cannot delineate between 1) non-phosphorylated PRL-3 
interacting with a phosphorylated protein; 2) phosphorylated PRL-3 interacting with a non-
phosphorylated protein; or 3) phosphorylated PRL-3 interacting with a phosphorylated 
protein. In the case of EGFR, either scenario 1 or 3 above might apply, as EGFR is definitely 
phosphorylated upon EGF stimulation. To this end, a phosphorylation-deficient mutant of 




To date, all studies supposedly implicating a catalytic function of PRL-3 use the Cys104 to 
Ser (C104S) mutant as a catalytically-dead negative control for PRL-3 phosphatase activity. 
In this study, I found that the PRL-3 C104S mutant bound to the EGFR complex more avidly 
than its wild-type counterpart (Fig. 22E).  The likely reason for this is that although the 
C104S mutation invariably results in a phosphatase-dead PRL-3, it also makes this mutant 
PRL-3 function as a “substrate-trap”. In C104S mutants, the phosphate group of incoming 
substrates are targeted for nucleophilic attack by the substituted serine but, unlike cysteine, 
results in the formation of an extremely stable phosphothioester intermediate which has low 
dissociation constant and thus remains “trapped” in the enzyme active site [339]. Indeed, 
many phosphatase substrates have been discovered using similar catalytic mutants [339]. 
Unfortunately, while being a useful tool for identifying substrates, this feature also poses 
problems during the interpretation of involvement of phosphatase catalytic activity when 
using such mutants, including 1) trapping of phosphatases at the site of substrate localization, 
2) phosphatase sequestration of substrates away from their sites of action, 3) altering 
degradation patterns of the phosphatase and/or its substrate, 4) masking of important binding 
domains in phosphatases and/or its substrate, and 5) the aggregation of phosphatase-substrate 
complexes in cases of multi-site phosphorylated substrates. In agreement with these 
possibilities, ‘unusual’ results using such substrate trapping mutants of PRLs have been 
reported, including unexpected gain-of-function, dominant negative, or residual ‘phosphatase-
like’ biological activities of catalytic mutants [78,79,105,340]. An intriguing possible 
explanation for these observations is that in addition to its role as a phosphatase, PRL-3 could 
possess other phosphatase-independent functions.  In view of this, there is an urgent need to 
define an alternative, non-substrate trapping mutant of PRLs. Interestingly, a recent paper 
describes how the mutation of the conserved Arg of the C(X)5R motif in PRL-1, R110S, 
results in a catalytically dead mutant which does not bind covalently to substrates [12]. Future 
work in the PRL field should employ such non-trapping catalytic mutants and keep in 
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consideration the possibility of phosphatase-independent functions for this elusive family. In 
this study, I found that the PRL-3 R110S mutant has elevated Tyr phosphorylation in 
response to EGF stimulation (Fig. 21B), suggesting that PRL-3 might auto-dephosphorylate 
itself. Interestingly, several phosphatases closely related to PRL-3 have been reported to auto-
dephosphorylate, including PTEN, VHR, and Cdc14 [341-343]. This could serve as a 
feedback mechanism regulating PRL-3 function and will be addressed in future work. 
Recent estimates describe the global distribution of pTyr, pThr and pSer sites to be 
approximately 1.8%, 11.8% and 86.4% in human cells [310]. This suggests that Tyr residues 
are over-represented in PRL-3, where Tyr, Ser and Thr residues are distributed in a 1:1:2 ratio 
(6 Tyr, 6 Ser, 12 Thr). Furthermore, endogenous PRL-3 is expressed at low abundance in 
cells – a feature of proteins suggested to be predominantly regulated by Tyr phosphorylation 
[310]. Although PRL-3 phosphorylation was indeed verified to occur on tyrosine residues in 
this study, I did not investigate the phosphorylation of Ser and Thr residues. Although all 6 
Tyr residues are perfectly conserved amongst human PRL family members, marked 
differences exist between PRL members with respect to Ser and Thr residues (Appendix VII). 
For example, all three CK2 consensus sites in PRL-3 (T32, T64, T147) are completely absent 
in both PRL-1 and PRL-2 (Table 4; Figure 1). This observation is interesting because 
overexpression of protein kinase CK2 has been described as an unfavorable prognostic 
marker in several cancers, and inhibition of CK2 activity has emerged as a relevant anticancer 
therapeutic approach [344]. Could such isoform-specific phosphorylation sites contribute to 
the specific regulation of PRL family members? Indeed, the possibility of generic regulation 
of PRL family members on Tyr residues versus individual PRL-specific regulation on Ser/Thr 
residues in regulating PRL activity is a subject of significant interest in my future studies. 
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CHAPTER 6: CONCLUSIONS 
 In a recent review, I proposed that PRL-3 is a key metastasis-initiating gene deregulated 
early in the metastatic process, driving metastatic progression from primary to distant sites 
[8]. The results presented here support two important roles for PRL-3 in the early stages of 
metastasis. Firstly, by activating EGFR, and possibly other RTKs, PRL-3 promotes cell 
proliferation and motility. Secondly, PRL-3 promotes the loss of intercellular adhesion to 
promote motility and invasiveness of cancer cells, a process likely mediated via dissolution of 
adherens junctions due to β-catenin downregulation. To my knowledge, this is the first study 
documenting a role for any human PRL member in RTK activation or β-catenin 
downregulation in human cancers, and contributes significantly to the understanding of how 
this elusive phosphatase exercises its oncogenic prowess. 
PRL-3 exhibits pleiotropic signaling by activating multiple RTKs, the most upstream factor in 
multiple signaling cascades. I propose that PRL-3 hyper-activation of EGFR via PTP1B 
downregulation might reflect an “umbrella effect” wherein a key upstream signaling node is 
targeted in preference to activation of pathway-restricted kinases, such as Src, in promoting 
tumorigenesis. Indeed, EGFR activation alone could potentially explain the activation of 
PI3K/AKT, Src/STAT, and Ras/MAPK signaling by PRL-3 in many previous studies. This 
“umbrella effect” of EGFR activation by PRL-3 could unify these disparate results and indeed 
constitute a key node of PRL-3 signaling in oncogenesis (Fig. 25). More work on the nodal 
role of EGFR in PRL-3 signaling will shed light on the validity of this hypothesis, and 




Figure 25: Proposed model of convergence between PRL-3 regulated EGFR and Wnt 
signaling pathways. PRL-3 upregulates Naked while downregulating Dvl expression to 
enhance Axin/APC degradation complex activity to downregulate β-catenin. In another 
signaling arm, PRL-3 activates EGFR by downregulation of PTP1B expression. EGFR in turn 
transactivates Src, MAPK and AKT pathways to drive proliferation and motility. EGFR may 
also phosphorylate β-catenin on its C-terminus to promote dissociation from cadherin 
complexes and increase the cytosolic pool of B-catenin subject to Axin/APC mediated 
degradation. Dotted lines indicate indirect relationships, whereas solid lines indicate direct 
interaction. Although PRL-3 localizes to both the plasma and endosomal membranes, this is 
not reflected here for visual clarity of pathway interactions.  
 
With pronounced overexpression in multiple metastatic tumor types and direct implications in 
cellular transformation and key metastatic events, PRL-3 represents an ideal candidate for 
personalized cancer therapy. The discovery of PRL-3’s activation of EGFR, and the 
corresponding dependency of cancer cells on pro-proliferative signals downstream of the 
EGFR, suggests an unorthodox way of treating dual PRL-3- and EGFR-positive cancers. The 
in vitro inhibition of PRL-3-driven cellular proliferation upon treatment with anti-EGFR 
agents is suggestive of a possible role for such agents in anti-PRL-3 therapy. My future work 
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encompasses validating the translational relevance of this finding in mice xenograft models of 
EGFR-overexpressing human cancers using anti-PRL-3, anti-EGFR, and combinatorial anti-
EGFR and anti-PRL-3 immunotherapy. In addition, the screening of human cancers for a 
correlation between PRL-3 and phosphorylated EGFR are also underway, which should shed 
light on the feasibility of such a therapeutic approach. Indeed, this could accelerate tailored 
therapeutic regimes against human cancers overexpressing PRL-3, particularly since no PRL-
3-targeting agent has even reached clinical trials to date.  
Interestingly, in A2780 cells, PRL-3 overexpression promoted proliferation, despite a loss of 
β-catenin and, presumably, the pro-proliferative signals associated with it. This suggests that 
alternative pro-proliferative signaling pathways, such as the PI3K/AKT and Ras/MAPK 
pathways previously linked to PRL-3-induced RTK activation, might be involved (Fig. 25). 
Interestingly, EGFR activity has been shown to promote cadherin-catenin dissociation by C-
terminus phosphorylation of β-catenin [345], which in turn could increase the cytosolic pool 
of β-catenin subject to Axin/APC-mediated degradation. However, in the A2780 cells used in 
this study, I failed to detect basal EGFR phosphorylation, likely due to low EGFR expression 
(data not shown; [346]). This makes it unlikely that PRL-3 signals via EGFR to regulate the 
malignant properties of these cells.  It should be noted that the expression level of β-catenin 
was not found to change in any of the cell types used in Chapter 3 where hyperactivation of 
EGFR was observed (data not shown).  As discussed earlier, since ovarian cancers are unique 
in their etiology, perhaps PRL-3 is uniquely tuned (regulated) to downregulate β-catenin in 
these cells to alleviate its associated tumor suppressive effects. However, since PRL-3 has 
also been shown to activate multiple other RTKs, further work would address a role for RTK 
signaling in PRL-3-driven proliferation of A2780 cells.  
In yet another paradigm of PRL-3 signaling, I demonstrated a novel role for PRL-3 
downstream of EGFR. Could a feedback loop exist between EGFR and PRL-3? If so, would it 
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be a negative or positive feedback loop? The failure to detect phosphorylated PRL-3 in 
unstimulated A431 cells suggests that PRL-3 phosphorylation might serve as a negative 
feedback mechanism for receptor activation. Notably, although PRL-3 overexpression results 
in hyper-phosphorylation of EGFR, EGF stimulation results in a much more intense 
phosphorylation and activation of the receptor. In this case, phosphorylation of PRL-3 and its 
subsequent dissociation from EGFR might result in a reduction of Src trans-activation of the 
receptor and/or initiate downstream signals to relieve the transcriptional regulation of PTP1B 
and promote EGFR dephosphorylation. This would be imperative to the survival of these 
cancer cells, as prolonged, intense EGFR activity has previously been shown to induce cell 
cycle arrest and trigger apoptosis [347,348]. However, it should be kept in mind that the pool 
of PRL-3 regulating EGFR hyperphosphorylation (by PTP1B downregulation) might be 
different from that bound to the receptor. This latter possibility would implicate distinct roles 
for PRL-3 upstream and downstream of EGFR signaling.  To definitively answer these 
questions, future work will focus on the identification and characterization of prenylated 
EGFR-binding mutants and phospho-deficient mutants of PRL-3, and their relationship to 
EGFR activation. 
Interestingly, a comparison of human PRL-1, PRL-2 and PRL-3 amino acid sequences 
revealed perfect conservation of all six tyrosine residues within the family (Fig. 1). 
Significantly, all these tyrosine residues were identified to exist in Src-directed consensus 
sequences, which were also conserved. In view of my identification of PRL-3 as a Src 
substrate in vitro, recapitulating a previous finding with PRL-1 [5], it is tempting to 
hypothesize that PRL-1 and PRL-3, and possibly PRL-2, might share common substrates and 
regulatory features to compensate for each other in developmental processes as well as 
oncogenic signaling. Several lines of evidence support this notion. Firstly, all three PRLs 
possess structurally identical catalytic pockets and are localized to similar intracellular 
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membranes. Secondly, overexpression of either PRL-1 or PRL-3 could promote the 
migration, invasion and metastasis of otherwise non-metastatic Chinese Hamster Ovary cells 
to similar extent [17]. Thirdly, all PRL members have been implicated in cancer progression 
[8]. Fourthly, analysis of PRL-1 and PRL-3 expression in multiple human cancer samples 
revealed an upregulation of either PRL, but rarely both, in neoplastic tissues [46]. Finally, 
both PRL-1 and PRL-3 are under similar transcriptional regulation mechanisms, and both 
result in the downregulation of p53 tumor-suppressor [23,89,349]. These reports collectively 
suggest that PRL family members, particularly PRL-1 and PRL-3, might be functionally 
redundant. Unfortunately, there is a dearth of reports analyzing the biological effects of all 
three PRLs in parallel using identical cellular systems. Although several groups have 
attempted parallel comparisons between two PRL members, including PRL-1 and PRL-2 
[350] and PRL-1 and PRL-3 [17,97], only one group has simultaneously compared all three 
PRLs in parallel [87]. The lack of comprehensive three-way studies makes distinguishing 
differences in PRL function difficult, as different reports use different biological systems to 
assess the function of individual PRLs in isolation. Ultimately, the acid test of redundancy 
would be the generation of conditional knockout mice for each PRL; to this end, one group 
has recently reported creating a conditional PRL-3 knockout mouse model [351]. Results 
from such initiatives would shed insight into the functions of the different PRLs, allowing 
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List of reagents used in this study (excluding antibodies). 
Purpose Item name Source# Methods section* 





Cloning Agarose, ultra-pure 
BamHI-HF restriction enzyme 
Big Dye 
EcoRI-HF restriction enzyme 
EDTA 
GelRed, 10 000X 
Gel Purification Kit 
HotStarTaq Master Mix, 2X 
pEGFP-C1 vector 
Quikchange Mutagenesis Kit 

























DMSO, cell culture grade 
Erlotinib 
FBS 
Human EGF, recombinant 
Human IFN-γ, recombinant 
Human IL-6, recombinant 




Non-essential amino acids, 100X 
OptiMEM 
PBS 










































RT-PCR, qRT-PCR Agarose, ultra-pure 
HotStarTaq Master Mix, 2x 







TaqMan Gene Expression Assay Mix ABI 
Subcellular  
fractionation 
Complete Protease Inhibitor cocktail, 
EDTA-free 
Halt Phosphatase Inhibitor cocktail  






IP Crosslink IP kit TS-Pierce 2.7 
Western blotting 10% NP-40 (v/v) 





Manganese (II) chloride (MnCl2) 
Methanol, 100%  
PhosTag AAL 
Ponceau S solution 



















































Proliferation assays CellTiter96 Aqueous One Solution (MTS) Promega 2.12 
Cell-cell adhesion  
assay 
Horse radish peroxidise 
OPD 







*Values here refer to the subheading number, as listed in the Methods section, where the reagent was first 
mentioned.  
#1st Base (Singapore); ABI, Applied Biosystems International (USA); Bio-Rad (USA); Biotium (USA); BSF, 
Biopolis Shared Facility (Singapore); Calbiochem (USA); Clontech (USA); Invitrogen (USA); LC Labs (USA); 
Merck (USA); NEB, New England Biolabs (USA); PAA, PAA Laboratories (Austria); Peprotech (USA); 
Polysciences, Polysciences Inc (USA); Promega (USA); Roche (USA); Sigma-Aldrich (USA); Stratagene 




List of antibodies used in this study. 
Target (human) Species MW (kDa) Source
ζ Cat. no. Application# 
β-catenin Rabbit 92 Cell Signaling 9587 WB, IF-ICC, IF-IHC 
AKT Rabbit 60 Cell Signaling 9272 WB 
p-AKT (Ser473) Rabbit 60 Cell Signaling 9271 WB 
Axl Rabbit 138 Cell Signaling 4566 WB, IP 
Dvl2 Rabbit 90-95 Cell Signaling 3224 WB 
Dvl3 Rabbit 88-93 Cell Signaling 3218 WB 
EGFR Rabbit 175 Cell Signaling 2232 WB, IF-ICC, IP 
EGFR Rabbit 175 Cell Signaling 4267 WB 
EGFR Mouse 175 Cell Signaling 2256 IP 
p-EGFR (Tyr1045) Rabbit 175 Cell Signaling 2237 WB 
p-EGFR (Tyr1068) Rabbit 175 Cell Signaling 2236 WB 
p-ELK1 (Ser383) Rabbit 62 Cell Signaling 9181 WB 
ErbB2/Her2 Rabbit 185 Milipore 06-562 WB 
p-ErbB2/Her2 (Tyr887) Rabbit 185 Cell Signaling 2241 WB 
ERK1 Mouse 44/42 BD 610030 WB 
ERK1/2 Rabbit 44/42 Cell Signaling 4695 WB 
p-ERK1/2 Mouse 44/42 BD 612358 WB 
Gab1 Rabbit 110 Cell Signaling 3232 WB, IP 
GAPDH Mouse 37 Milipore MAB374 WB 
GFP Rabbit - Cell Signaling 2956 WB 
GFP Mouse - SCBT sc-9996 WB, IP 
Grb2 Mouse 24 Cell Signaling 3972 WB 
Histone H3 Rabbit 17 Cell Signaling 9715 WB 
Naked1 Rabbit 59-61 Cell Signaling 2201 WB 
Naked2 Rabbit 59-62 Cell Signaling 2073 WB 
p-JNK Mouse 56/43 BD 612540 WB 
p-p38 Mouse 42 BD 612280 WB 
p-Shc Rabbit 66/52/46 SCBT sc-18074-R WB 
p-STAT1 Mouse 91/84 BD 612232 WB 
p-Tyr, clone 4G10 Mouse - Milipore 05-321 WB 
PRL-3, clone 318 Mouse 20 In-houseδ - WB, IP, IF-IHC, IHC 
PTEN Rabbit 54 Cell Signaling 9552 WB 
PTP1B Rabbit 50 Cell Signaling 5311 WB 
Src Rabbit 60 Cell Signaling 2109 WB 
p-Src (Tyr527) Rabbit 60 Cell Signaling 2105 WB 
STAT5 Rabbit 90 Cell Signaling 9363 WB 
p-STAT5 (Tyr694) Rabbit 90 Cell Signaling 9351 WB 
Anti-mouse IgG, HRP-conjugated - GE NA9310 WB 
Anti-rabbit IgG, HRP-conjugated - Cell Signaling 7074 WB 
Anti-mouse IgG, AF568-conjugated - Invitrogen A11004 IF-ICC, IF-IHC 
Anti-rabbit IgG, AF633-conjugated - Invitrogen A21071 IF-ICC, IF-IHC 
#The Application column lists how the antibody was used in this study. WB, western blotting; IF-ICC; 
immunofluorescence (cultured cells); IF-IHC, immunofluorescence (tissue sections); IHC, immunohistochemistry 
(tissue sections); IP; immunoprecipitation. 
δThis monoclonal antibody against PRL-3 was generated in our lab and has been characterized elsewhere [46]. 







  A431 EGFP   A431 EGFP-PRL-3   
RTK Average Denstity (OD/mm2)  Std Deviation Average Denstity (OD/mm2) Std Deviation 
ABL1 0.064 0.018 0.116 0.018 
ACK1 0.217 0.006 0.346 0.027 
ALK 0.040 0.000 0.095 0.017 
Axl 0.169 0.000 0.617 0.045 
Blk 0.012 0.001 0.025 0.001 
BMX 0.521 0.010 0.696 0.016 
Btk 0.033 0.003 0.062 0.011 
Csk 0.011 0.018 0.022 0.002 
Dtk 0.031 0.009 0.069 0.010 
EGFR 1.414 0.001 3.346 0.060 
EphA1 0.045 0.002 0.081 0.023 
EphA2 0.010 0.018 0.027 0.000 
EphA3 0.081 0.019 0.134 0.008 
EphA4 0.007 0.002 0.006 0.004 
EphA5 0.012 0.013 0.033 0.010 
EphA6 0.005 0.003 0.027 0.004 
EphA7 0.002 0.003 0.012 0.003 
EphA8 0.039 0.000 0.063 0.000 
EphB1 0.042 0.001 0.058 0.003 
EphB2 0.067 0.001 0.056 0.004 
EphB3 0.043 0.011 0.061 0.007 
EphB4 0.006 0.012 0.021 0.001 
EphB6 0.003 0.000 0.011 0.000 
ErbB2 0.053 0.001 0.196 0.007 
ErbB3 0.175 0.001 0.199 0.014 
ErbB4 0.024 0.001 0.017 0.000 
FAK 0.033 0.003 0.044 0.002 
FER 0.060 0.002 0.073 0.004 
FGFR1 0.022 0.004 0.024 0.010 
FGFR2 0.328 0.012 0.403 0.002 
FGFR2α 0.065 0.003 0.082 0.016 
Fgr 0.219 0.004 0.193 0.005 
FRK 0.041 0.002 0.049 0.001 
Fyn 0.027 0.011 0.033 0.001 
Hck 0.598 0.002 0.775 0.059 
HGFR 0.851 0.014 1.043 0.021 
IGF-I R 0.192 0.118 0.227 0.018 
Insulin R 0.018 0.002 0.013 0.011 
Itk 0.090 0.002 0.098 0.001 
JAK1 0.047 0.007 0.060 0.010 
JAK2 0.808 0.003 0.850 0.052 
JAK3 0.078 0.002 0.097 0.001 
LCK 0.013 0.094 0.025 0.001 
LTK 0.049 0.006 0.048 0.003 
Lyn 0.327 0.003 0.257 0.003 
MATK 0.118 0.007 0.126 0.016 
M-CSFR 0.017 0.038 0.020 0.003 
MUSK 0.037 0.007 0.047 0.000 
NGFR 0.025 0.001 0.035 0.003 
PDGFR-α 0.008 0.002 0.010 0.006 
PDGFR-β 0.028 0.005 0.027 0.003 
PYK2 0.020 0.005 0.028 0.001 
RET 0.033 0.004 0.033 0.012 
ROR1 0.003 0.001 0.002 0.001 
ROR2 0.045 0.004 0.043 0.005 
ROS 0.037 0.004 0.039 0.001 
RYK 0.016 0.005 0.014 0.004 
SCFR 0.037 0.004 0.033 0.002 
SRMS 0.305 0.005 0.291 0.043 
SYK 0.029 0.003 0.020 0.003 
Tec 0.030 0.020 0.018 0.004 
Tie-1 0.033 0.014 0.023 0.000 
Tie-2 0.102 0.002 0.073 0.002 
TNK1 0.184 0.005 0.196 0.001 
TRKB 0.082 0.013 0.068 0.016 
TXK 0.644 0.012 0.527 0.035 
Tyk2 0.042 0.001 0.029 0.006 
TYRO10 0.011 0.004 0.001 0.002 
VEGFR2 0.025 0.001 0.020 0.004 
VEGFR3 0.046 0.000 0.039 0.004 
ZAP70 0.109 0.005 0.068 0.015 
Note: RTKs highlighted in pink indicate those who were censored from the results due to average desities being equal or lower than that of the negative control 







Total 1 2 3 4 5 
PRL-3 
score 
1 Count 0 10 6 7 3 26 
% within PRL-3 .0% 38.5% 23.1% 26.9% 11.5% 100.0% 
% within β-catenin .0% 83.3% 100.0% 58.3% 75.0% 61.9% 
2 Count 2 1 0 2 1 6 
% within PRL-3 33.3% 16.7% .0% 33.3% 16.7% 100.0% 
% within β-catenin 25.0% 8.3% .0% 16.7% 25.0% 14.3% 
3 Count 5 0 0 0 0 5 
% within PRL-3 100.0% .0% .0% .0% .0% 100.0% 
% within β-catenin 62.5% .0% .0% .0% .0% 11.9% 
4 Count 1 1 0 3 0 5 
% within PRL-3 20.0% 20.0% .0% 60.0% .0% 100.0% 
% within β-catenin 12.5% 8.3% .0% 25.0% .0% 11.9% 
Total Count 8 12 6 12 4 42 
% within PRL-3 19.0% 28.6% 14.3% 28.6% 9.5% 100.0% 





GPS2.1 Prediction of Tyr phosphorylation sites in PRL-3 
Position Code Peptide Kinase Score Cutoff 
14 Y PAPVEVSYKHMRFLI TK/VEGFR 6.105 5.947 
   
TK/JakA/JAK2 4 3.4 
   
TK/Src/Fgr 6.625 5.375 
   
TK/Src/Lyn 1.553 1.447 
   
TK/Syk/Syk 1.941 1.706 
   
TK/PDGFR/FLT3 5.5 5 
40 Y FIEDLKKYGATTVVR TK/Alk 2 1.5 
   
TK/InsR/InsR 2.044 1.667 
53 Y VRVCEVTYDKTPLEK TK/Alk 1.5 1.5 
   
TK/EGFR 1.439 1.333 
   
TK/Fak 4.538 3.308 
   
TK/Fer 5 4.667 
   
TK/Met 1.9 1.133 
   
TK/Ret 1.429 0.643 
   
TK/Tie 10.167 7.167 
   
TK/EGFR/EGFR 1.852 1.475 
   
TK/Eph/EphB2 6.857 5.286 
   
TK/Eph/EphA3 8.667 7.333 
   
TK/Fak/FAK 6.6 5.7 
   
TK/Fer/Fer 6.8 4.4 
   
TK/FGFR/FGFR1 5.478 5 
   
TK/Met/Met 2.423 2.231 
   
TK/Src/Fgr 5.875 5.375 
   
TK/Src/Fyn 2.714 2.408 
   
TK/Src/Src 0.544 0.537 
   
TK/Tec/TXK 7.8 3.6 
126 Y LIESGMKYEDAIQFI TK/Abl 1.24 1.14 
   
TK/Csk 10 9 
   
TK/Eph 4.955 2.455 
   
TK/Ret 1.214 0.643 
   
TK/VEGFR 6.579 5.947 
   
TK/Eph/EphB2 5.571 5.286 
   
TK/Eph/EphA3 10.333 7.333 
   
TK/Eph/EphB1 9 5.5 
   
TK/Fer/Fer 4.6 4.4 
   
TK/Src/HCK 3.667 2.667 
   
TK/Tec/Tec 4.5 4 
148 Y INSKQLTYLEKYRPK TK/Eph 3.227 2.455 
   
TK/Tie 8.667 7.167 
   
TK/Abl/Abl2 5.667 5.333 
   
TK/EGFR/ErbB2 1 0.6 
   
TK/Eph/EphB2 5.429 5.286 
   
TK/Eph/EphA3 10.333 7.333 
   
TK/Eph/EphB1 10.5 5.5 
   
TK/Src/Fyn 2.49 2.408 
   
TK/Src/Brk 5.75 5.5 
   
TK/Trk/TRKB 4.25 4 
   
TK/VEGFR/KDR 1.8 1.8 
   
TK/PDGFR/KIT 4 3.75 
   
TK/PDGFR/CSF1R 3.125 1.75 
152 Y QLTYLEKYRPKQRLR TK/Csk 9 9 
   
TK/FGFR 1.6 1.533 
   
TK/Src 0.569 0.483 
   





GPS2.1 Prediction of Ser/Thr phosphorylation sites in PRL-3 
Position Code Peptide Kinase Score Cutoff 
13 S RPAPVEVSYKHMRFL AGC/PKC/Alpha/PKCa 2.567 2.455 
   AGC/PKC/Eta 4.692 3.769 
   TKL/MLK/ILK 4.444 2 22 T KHMRFLITHNPTNAT CAMK/CAMKL/LKB 2.294 1.471 
   Other/IKK/IKKb 1.125 0.75 
   Other/NEK/NEK2 4.667 3.667 
   STE/STE7/MAP2K1 7 4 
   STE/STE7/MAP2K2 3 2 
   TKL/MLK/TAK1 5.25 3.5 26 T FLITHNPTNATLSTF CK1/CK1/CK1e 0.929 0.429 
   TKL/MLK 1 1 29 T THNPTNATLSTFIED AGC/GRK/GRK/GRK-4 3.333 2.333 
   AGC/PKB/PDK1 2.059 0.794 
   CAMK/DAPK 2.167 1.5 
   CK1/CK1/CK1e 1 0.429 
   Other/PEK 1.938 1.75 
   Other/PEK/PKR 2.062 1.812 
   TKL 0.75 0.528 
   TKL/IRAK 3.75 3 
   TKL/MLK 1.25 1 31 S NPTNATLSTFIEDLK CAMK/CAMK1 2.471 1.471 
   STE/STE20/PAKA/PAK2 2.706 2.059 
   STE/STE7 1.35 0.8 
   STE/STE7/MAP2K1 4 4 
   STE/STE7/MAP2K2 8 2 
   STE/STE7/MAP2K6 2.667 2.333 
   TKL/MLK/MLK/MAP3K11 3.333 3.333 32 T PTNATLSTFIEDLKK AGC/PKB 1.971 0.853 
   AGC/PKB/PDK1 2.118 0.794 
   CAMK/CAMK1 1.647 1.471 
   CAMK/CAMK1/CAMK1a 4.5 3 
   CAMK/CAMKL/LKB 8.294 1.471 
   Other/Wnk 3.333 2.667 
   STE/STE11 1.7 1.7 
   STE/STE20/PAKA/PAK3 1 1 
   STE/STE7 1.25 0.8 
   STE/STE7/MAP2K3 3.25 1.25 
   STE/STE7/MAP2K7 2.2 1.2 
   TKL/RAF 2.4 2 43 T DLKKYGATTVVRVCE CAMK/DAPK/DAPK3 2.333 2.278 
   CMGC/GSK/GSK3A 2.5 2.167 
   STE/STE7/MAP2K2 5 2 
   TKL/MLK/MLK/MAP3K11 4 3.333 44 T LKKYGATTVVRVCEV CAMK/PKD/PKD1 1.889 1.667 
   Other/IKK 0.531 0.429 
   Other/NEK/NEK9 5.667 5 
   STE/STE20/PAKA/PAK2 2.412 2.059 
   TKL 0.694 0.528 
   TKL/MLK 1 1 52 T VVRVCEVTYDKTPLE AGC/AKT 1.764 1.697 
   AGC/PKB 1.118 0.853 
   CAMK/DAPK 1.542 1.5 
   Other/PLK/PLK1 0.915 0.872 
   STE/STE11 1.9 1.7 
   STE/STE7/MAP2K1 4 4 56 T CEVTYDKTPLEKDGI Atypical/PIKK/FRAP 6.4 2.067 
   CK1/CK1/CK1e 0.571 0.429 
   CMGC 4.627 1.829 
   CMGC/CDK 2.486 0.934 
   CMGC/CDK/CDC2 1.831 0.932 
   CMGC/CDK/CDC2/CDC2 3.928 1.201 
   CMGC/CDK/CDC2/CDK2 2.216 1.027 
   CMGC/CDK/CDK4 2.615 2.308 
   CMGC/CDK/CDK4/CDK4 2.615 2.231 
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   CMGC/CDK/CDK5 6.737 2.474 56 T CEVTYDKTPLEKDGI CMGC/GSK 2.84 2.235 
   CMGC/GSK/GSK3A 3.167 2.167 
   CMGC/GSK/GSK3B 4.347 2.347 
   CMGC/MAPK 2.737 1.227 
   CMGC/MAPK/ERK 3.928 2.096 
   CMGC/MAPK/ERK/MAPK1 5.209 2.33 
   CMGC/MAPK/ERK/MAPK3 7.644 3.034 
   CMGC/MAPK/JNK 3.542 1.312 
   CMGC/MAPK/JNK/MAPK10 4.571 3.286 
   CMGC/MAPK/JNK/MAPK8 14.667 2.444 
   CMGC/MAPK/JNK/MAPK9 2.895 2 
   CMGC/MAPK/p38 2.845 2.034 
   CMGC/MAPK/p38/MAPK12 7.667 5 
   CMGC/MAPK/p38/MAPK13 7.333 4.333 
   CMGC/MAPK/p38/MAPK14 4.38 2.18 
   Other/PLK/PLK1 1.085 0.872 
   STE/STE7/MAP2K6 3.667 2.333 
   STE/STE7/MAP2K7 3.8 1.2 
   TKL/MLK/MLK/MAP3K11 5.667 3.333 64 T PLEKDGITVVDWPFD AGC/GRK/GRK/GRK-5 2.545 1.273 
   AGC/PKB/PDK1 0.794 0.794 
   CK1/CK1/CK1d 3.667 3.444 
   CMGC/GSK/GSK3A 4 2.167 
   Other/IKK/IKKa 2.333 2.222 
   STE/STE20/PAKA/PAK3 1.3 1 
   STE/STE7/MAP2K1 5 4 86 S KVVEDWLSLVKAKFC AGC/PKC/Iota 2.615 2.308 
   AGC/PKC/Iota/PKCz 2.462 2.231 
   CAMK/PKD/PKD1 2.444 1.667 
   CK1/CK1/CK1d 3.667 3.444 
   Other/NEK/NEK9 8 5 
   STE/STE7/MAP2K2 2 2 98 S KFCEAPGSCVAVHCV CMGC/CDK/CDK4 2.615 2.308 
   CMGC/CDK/CDK4/CDK4 2.615 2.231 
   CMGC/MAPK/ERK/MAPK1 2.348 2.33 
   Other/PEK 2 1.75 
   Other/PEK/PKR 2.125 1.812 
   TKL/IRAK 3.25 3 
   TKL/MLK/TAK1 5 3.5 122 S VALALIESGMKYEDA STE/STE7 0.8 0.8 
   STE/STE7/MAP2K6 2.667 2.333 
   TKL/RAF 2 2 143 S KRRGAINSKQLTYLE AGC 0.991 0.771 
   AGC/AKT 1.865 1.697 
   AGC/DMPK/ROCK/ROCK1 2.8 2 
   AGC/PKC 1.586 1.332 
   CAMK/DAPK 2.625 1.5 
   CMGC/DYRK/Dyrk1 2.571 1.714 
   CMGC/MAPK/JNK 1.917 1.312 
   Other/IKK 0.694 0.429 
   STE 1.9 1.75 
   STE/STE-Unique/COT 4.8 4.6 147 T AINSKQLTYLEKYRP AGC/DMPK 2.487 1 
   AGC/DMPK/ROCK 2.763 1.237 
   AGC/DMPK/ROCK/ROCK1 2.133 2 
   AGC/PKC 1.383 1.332 
   AGC/PKC/Iota 2.538 2.308 
   AGC/PKC/Iota/PKCz 2.385 2.231 
   AGC/RSK 1.121 1.103 
   AGC/RSK/RSK/RSK1 3.2 3 
   CAMK/CAMKL/LKB 3.176 1.471 
   CAMK/DAPK 2.792 1.5 
   CAMK/DAPK/DAPK3 3.944 2.278 
   CAMK/PKD 4.7 4 
   CAMK/PKD/PKD1 3 1.667 
   CK1/CK1/CK1e 0.714 0.429 
   STE/STE11 2 1.7 
   STE/STE20/PAKA 2.103 2 
   STE/STE20/PAKA/PAK2 3.235 2.059 
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   STE/STE7/MAP2K1 7 4 165 T LRFKDPHTHKTRCCV Atypical/PDHK 4.75 4.5 
   CMGC/CDK/CDK5 2.526 2.474 165 T LRFKDPHTHKTRCCV CMGC/MAPK/ERK/MAPK1 2.504 2.33 
   CMGC/MAPK/ERK/MAPK3 3.322 3.034 
   TKL/IRAK 3.25 3 
   TKL/MLK 3.25 1 
   TKL/MLK/TAK1 4 3.5 168 T KDPHTHKTRCCVM AGC 1 0.771 
   AGC/DMPK 2.385 1 
   AGC/DMPK/ROCK 2.526 1.237 
   AGC/DMPK/ROCK/ROCK1 2.2 2 
   AGC/GRK/GRK 1.5 1.333 
   AGC/GRK/GRK/GRK-1 3.5 2.375 
   AGC/PKB 1.912 0.853 
   AGC/PKB/PDK1 3.059 0.794 
   CAMK/CAMK1/CAMK1a 4.75 3 
   CAMK/DAPK 3.833 1.5 
   Other/NEK/NEK2 4.667 3.667 
   Other/Wnk 3.5 2.667 
   TKL 1.083 0.528 
   TKL/MLK 4.25 1 





Distribution of Tyr, Ser and Thr residues in human PRL family members* 
 Tyr Ser Thr Total 
PRL-1 6 6 8 20 
PRL-2 6 4 11 21 
PRL-3 6 6 12 24 
*Full-length PRL sequences (isoforms 1 of PTP4A1, PTP4A2 and PTP4A3) were used in the analysis. 
 
 
